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Summary
Background: Current gold standard pulmonary artery pressure measurements (PAP) are 
not accurate using a fluid filled catheter. High fidelity micromanometer tipped catheters 
are more accurate both at rest and during exercise. They have been used to examine the 
pattern of pulmonary artery pressure waveforms under various physiological conditions.
A new thoracic impedance device has been developed, the Physioflow 1 (©Manatee, 
France), which has been shown to measure cardiac output (CO) accurately in a variety 
of respiratory conditions.
It is known that PAP varies with changes in posture, sleep and exercise, and may 
sometimes appear normal at rest in early disease. Resting pressures vary daily. 
However, pressure and flow is linearly related in physiological ranges and the 
relationship is relatively constant. Changes in pressure-flow relationships may be 
missed at rest. It has been shown that response to a given treatment may be missed if 
measurements are based solely on resting PAP. For this reason the slopes of pressure- 
flow plots, are more useful than spot measures of pressure and flow. This has not 
adequately been explored in humans.
Aims: To validate the use of the physioflow 1 cardiac output device, for use in subjects 
with pulmonary hypertension, and to develop a method of combining its data with high 
fidelity pulmonary artery catheter measurements, to produce pressure flow plots in a 
clinical context. The use of exercise or dobutamine, will be explored to achieve this, to 
then examine the effects on pressure-flow plots of the following:
1. The inhalation of oxygen or a nitric oxide/oxygen combination
2. Changing exercise posture
3. The response of different causes of pulmonaiy hypertension to the 
former two investigations
4. The response of pressure-flow curves to oxygen or nitric 
oxide/oxygen combination on vasodilator responders and non- 
responders (at rest).
Recruitment. Ethics and Methods Ethical approval was granted for all studies. All 
subjects who attended the Scottish Pulmonary Vascular Unit between April 2001 and 
August 2003, for invasive investigations, were offered to participate in the pressure- 
flow and other studies.
Whilst the subjects underwent routine right heart catheter investigations, measurement 
of cardiac output derived from the physioflow-1 cardiac output device was compared 
against thermodilutional derived cardiac output measurements concurrently measured 
during rest or during any physiological or pharmacological manoeuvres.
Those who agreed to the study had the micromanometer tipped catheter, inserted into 
their main pulmonary artery, and measurements were taken concurrently with thoracic 
impedance derived cardiac output measurements, during exercise or a dobutamine 
infusion under varying experimental conditions.
Results: We found that the physioflow 1 device, overestimated the cardiac output, 
compared to thermodilutional measurements 1.21 (± 1.85) L min"\ The percentage
change from baseline however was similar between the two methods, and the 
physioflow 1 gave an overestimation of only 2.08 % (± 12,5), making it reliable in 
following the trends of changes in cardiac output in individuals.
In the reliable production of pressure- flow plots, both studies failed. The straight leg 
raising exercise studies, had a 20% equipment failure rate, and only achieved 
statistically linear plots in 45% of studies. The slope and intercepts had wide confidence 
intervals making them unsuitable for clinical comparisons (the 95% confidence interval 
< 20% baseline in 27% of studies). The dobutamine studies were unsuccessful, as the 
PAP seemed to plateau, as cardiac output continued to increase.
Pooled data of vasodilator responders and non-responders, demonstrated that when 
given air or nitric oxide/oxygen, the non-vasodilator responders slope significantly 
decreased from 10.2 to 6.9 respectively (p < 0.001), but for responders the slope did not 
significantly change from 8.6 to 8.9, and the 95 % confidence intervals overlapped (8.2- 
8.8 versus 8.7-9.2). For individual disease groups, chronic thromboembolic pulmonary 
hypertension and noiinal subjects responded in a similar fashion (decrease in the slope 
of pressure-flow plots) to non-vasodilator responders (p = 0.004 and <0.001 
respectively), in response to oxygen and nitric oxide combined, whereas idiopathic 
pulmonary hypertensive and connective tissue disorder subjects had parallel shifts 
similar to vasodilator responders (p = 0.237 and 0.09 respectively).
Conclusion: The physioflow-1 not been shown to be accurate enough quantatively in 
general clinical practice in subjects with pulmonary hypertension when compared to
thennodilution cardiac output measurements. It does however follow trends fairly 
accurately and can thus be a useful research tool.
In conjunction with the high fidelity ambulatoiy pulmonary catheter, pressure flow plots 
can be produced with exercise. The quality of these plots in an individual, however, is 
not enough to be used to compare pressine-flows clinically. The data when pooled 
however is sufficient enough to discover other findings like the difference in response to 
vasodilators of so called vasodilator responders and non responders. It would seem that 
responders have a parallel shift and non-responders alter their pressure-flow gradient.
The use of straight leg raising exercise or dobutamine infusions does not lead to linear 
pressure flow plots of sufficient quality to be used in individuals clinically but pooled 
results may be a useful research tool.
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Chapter 1
Introduction
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1.1 A Brief History of the Science of the Pulmonary Vasculature & Pulmonary 
Hypertension
In ancient times there were numerous explanations of the working of the human body. 
Between 138 and 201 AD Galen summarised these ideas. It was thought that blood was 
formed in the liver and distributed around the body by the venous system, where it was 
consumed, whilst nourishing the body (Grover, R. F. et al 1983). It was thought that 
some of the blood flowed through the right side of the heart in order to nourish the 
lungs. Most of the blood it was thought passed into the left side of the heart via invisible 
pores. Galen believed that the lungs conveyed air to the left ventricle, where it became 
“Vital Spirit.” (Fleming, D. 1955; Grover, R. F. et al 1983). ‘SooF produced by the 
ventricle was then transported back to the lungs and exlialed. This became church 
doctrine for 1400 years. It took William Harvey, a student of Fadau, during the if^  
centuiy, to establish the idea in mainstream science, that blood follows a circuit, both 
through the systemic and pulmonary systems. (Grover, R. F. et al 1983).
Stephen Hales in the 17*^  ^ and early 18^  ^ Centuries performed the first quantitative 
measures of the systemic circulation, where he measured the carotid pressure and the 
cardiac output of a goose. He also deduced that pulmonary artery resistance was likely 
to be less than systemic vascular resistance, due to the corresponding thickness of the 
vessel walls, and that the blood velocity must be greater through the lungs then the rest 
of the body. He estimated the capillary cross diameter, and total lung capillary volume 
(Grover, R. F. et al 1983).
In 1870, Fick described the measurement of cardiac output (CO) in animals and 
estimated that in man it was likely to be 4.6 L/min. The first direct measurements of
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pulmonary arterial pressure was performed by Auguste Chauveau and Etienne Jules 
Marey (Grover, R. F. et al 1983). During the 19^  ^ and early 20^  ^ centuiy, Otto Frank 
measured the outflow pressures allowing the calculation of pulmonaiy resistance, and 
Ernest Henry Starling heart-lung preparations allowed the experimental analysis of 
mechanical and physiological properties of the heart and lung (Fishman, A. P. 2004). In 
the early part of the 20^  ^Century, Forssmann showed that right heart catheterisation was 
possible via a peripheral vein. (The experiments were performed on himself) (Fishman, 
A. P. 2004). This was taken up by Cournand and Richards, at the Bellevue laboratories. 
It was here moved from the laboratory to the bedside (Fishman, A. P. 2004). In 1953, 
Hermann Rahn used this catheter with a balloon tip to measure outflow pressure 
(Fishman, A. P. 2004). In 1970 William Ganz and Harold J. C. Swan introduced a 
balloon tipped catheter that could be advanced into the pulmonary artery under 
haemodynamic monitoring (Swan, H. J. et al 1970).
The first physiological studies into pulmonary hypertension were preceded by 
histopathological studies. In 1891, the first case report was published by Ernst von 
Romberg, calling the disease “pulmonary vascular sclerosis” (Fishman, A. P. 2004). 
Following this several other case series were published. In 1901, during a lecture Abel 
Ayerza described a syndrome categorised by pulmonary hypertension and right 
ventricular dilatation (Fishman, A. P. 2004). Until the 1940’s, it was believed that the 
cause of primary pulmonary hypertension was syphilis, but Oscar Brenner in 
Birmingham reviewed 100 case reports and autopsy files of patients with pulmonary 
hypertension and found that through histological examination syphilis was not the cause 
(Fishman, A. P. 2004).
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In 1951, Dresdale and his co-workers discovered that pulmonaiy vasoconstriction was 
involved in the pathogenesis of primary pulmonary hypertension (Dresdale, D. T. et al 
1954). Since then there has interest in the scientific investigation of pulmonary 
hypertension, but the majority has been in the pathophysiology of the disease.
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1.2 Clinical Pulmonary Hypertension
1.2.1 Definition & Epidemiology
Pulmonary arterial hypertension (PAH) accompanies nearly all heart and lung disease. 
Because of the difficulty of making measurements of pulmonary arterial pressure and 
flow, the morbidity associated with pulmonary hypertension is poorly understood. 
Pulmonary hypertension is said to exist if the mean pulmonary artery pressure is greater 
than 25mmHg at rest or 30mmHg with exercise (Rubin, L. J. 1993). A list of causes of 
pulmonary hypertension is shown in Table 1.1 (Simonneau, G. et al 2004).
1. Pulmonary Arterial Hypertension (PAH)
1.1 Idiopathic PAH
1.2 Familial PAH
1.3 Associated with (APAH)
1.3.1 Collagen Vascular Disease
1.3.2. Congenital systemic-to-pulmonar> shunts
1.3.3. Portal Hypertension
1.3.4. HIV infection
1.3.5. Drugs & Toxins
1.3.6. Other
1.4 Associated with significant venous or capillary involvement
1.5 Persistent pulmonary hypertension of the newborn
2. Pulmonary Venous Hypertension
Left sided atrial, ventricular or valvular heart disease
3. Pulmonary hypertension associated with disorders of the respiratory system
3.1 Chronic obstructive pulmonar>' disease
3.2 Interstitial lung disease
3.3 Sleep disordered breathing
3.4 Exposure to high altitude
3.5 Alveolar hypoventilation
3.6 Developmental abnormalities
4.Pulmonary hypertension due to chronic thromboembolic disease
5. Miscellaneous
Table 1.1: WHO Classification of pulmonary hypertension
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Severity varies between different causes, however the histological changes seen in the 
vessels are similar and also there also appears to be similarity in responses to treatment, 
suggesting a common link that leads to vascular changes. Changes are seen in all three 
layers of the blood vessels, the intima, the media and the adventitia. It is now clear that 
the factors leading to pulmonary vasoconstriction also leads to remodelling of 
pulmonaiy vessels, (vasomotor cell growth coupling) (Barer, G. R. et al 1989; Cutaia, 
M. et al 1990; Peacock, A. J. 1999).
The incidence of idiopathic pulmonary arterial hypertension is 1-2 per million per 
annum (Rich, S. et al 1987). It causes disabling symptoms and left untreated leads to an 
early death. The incidence of other causes of pulmonary hypertension apart from COPD 
equal another 1-2 per million per annum (Gaine, S. P. et al 1998; Sanchez, O. et al 
1999). The incidence of pulmonary hypertension amongst COPD patients has been 
calculated to be between 5-40% (Behnka, R. H. et al 1971; Fishman, A. P. 1978; Flint, 
F. J. 1954; Report of an expert committee 1970). This may give prevalence amongst the 
general population of 0.3%. In the U.S. it has been estimated that up to 30% of hospital 
admissions with ‘congestive cardiac failure’ actually have fluid retention secondary to 
hypoxic lung disease (Flint, F. J. 1954; Report of an expert committee 1970; 
Weitzenblum, B. et al 1996).
1.2.2 Pathophysiology
It is likely that pulmonary hypertension develops as a consequence of a nmnber of 
genetic and environmental influences (Humbert, M. et al 2004)which ultimately, at the 
level of the pulmonary arterioles and capillaries, can be divided into 3 
pathophysiological facets.
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As mentioned earlier, hypoxic vasoconstriction is one of the mechanisms behind 
pulmonary hypertension. The other two are destruction of the vascular bed and 
remodelling.
Over the past decade, the PPHl gene has been mapped to the locus 2q31-32 (Deng, Z. 
et al 2000; Lane, K. B. et al 2000; Nichols, W. C. et al 1997).In idiopathic pulmonary 
arterial hypertension. This gene encodes for bone morphogenetic protein-II (BMPR-2) 
receptor, Carriers have a 10-20% chance of developing pulmonary
hypertension(Newman, J. H. et al 2001), but the mutation is only found in 26% of 
sporadic pulmonary arterial hypertension(Thomson, J. R. et al 2000). A further gene the 
activin receptor-like kinase (ALK)-l has been found to be associated with pulmonary 
hypertension in patients with hereditary hemorrhagic telangiectasia (Trembath, R. C. 
2001). Bone morphogenetic protein is part of the TGF-p superfamily and may either 
promote or inhibit cell growth(Loscalzo, J. 2001). Other patients, who do not have the 
PPHl mutation, may have other abnormalities which interfere with BMPR-2 function. 
Angiopoietin-1 protein is involved in smooth muscle recruitment and vascular 
development is overexpressed in patients with pulmonary hypertension and down 
regulates BMPR2 mRNA. Angiopoietin-1 protein also is correlated with pulmonary 
vascular resistance (Du, L. et al 2003; Sullivan, C. C. et al 2003). The inability to 
regulate the proliferative response to injury may be the reason for endothelial cell 
proliferation foimd in plexiform lesions.
In pulmonary hypertensive subjects, there is often found an imbalance in many 
circulatoiy and tissue coagulation and other factors, and this may lead to in-situ 
thrombi. These factors include raised thromboxane A2 levels, reduced prostacyclin
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levels, reduced nitric oxide synthase and raised endothelin-1 lung tissue levels, elevated 
serotonin and serotonin transporter levels (Presberg, K. W. et al 2003b).
Hypoxic pulmonary vasoconstriction has been known to exist since 1946 (von Euler, U. 
S. et al 1946) but is not yet fully understood. It will be further discussed in chapter
1.3.2.1. Destruction of the pulmonaiy vascular bed is often due to diseases which result 
in a loss of lung parenchyma but it take up to 50-75% of the vascular bed to be 
destroyed before the pulmonary artery pressure rises at rest. In addition to short-term 
autoregulatory changes in vascular tone, vessels can undergo profound fibrocellular 
changes, in various clinical conditions (Ryland, D. et al 1975; Semmens, M. et al 1974), 
termed vascular remodelling. Pulmonary vascular remodelling is important clinically 
because it renders the vessels relatively non-distensible to vasodilators.
The process of pulmonaiy vascular remodelling, adventitial changes, medial smooth 
muscle hypertrophy, distal smooth muscle hypertrophy, intimai proliferation, 
endothelial cell proliferation, in-situ thrombus and plexiform lesions (Presberg, K. W. et 
al 2003a).
As pulmonary hypertension develops, the thin walled right ventricle of the heart tends 
to slowly thicken, in response to an increase in afterload. As the right ventricle dilates, 
this causes a fall in CO as the right ventricle competes for space with the left ventricle 
in the pericardial sac. This in turn may lead to right ventricular ischaemia and a diop in 
right ventricle contractility, further reducing the CO (Carlson, E. B. et al 1985; 
Franciosi, R. A. et al 1968; Gold, F. L. et al 1982; Horan, M. et al 1981; Milnor, W. R. 
et al 1978).
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1.2.3 Investigations
Following initial clinical assessment of pulmonary hypertension a multitude of 
investigations are arranged; however there is no single ideal investigation for diagnosis. 
The problems with less invasive tests are inaccuracy, and they measure surrogate 
markers of pulmonaiy hypertension and so cannot be relied apon to make a diagnosis. 
The most important investigation is right heart catheterisation. Right heart 
catheterisation is the diagnostic gold standard measuring mean pulmonary artery 
pressure (PAP) and cardiac output (CO) with the patient at rest and supine while 
performing a vasodilator challenge test. Even though this test is the gold standard it has 
its limitations as will be discussed later. There are several vasodilator substances used in 
this testing, and one of the most useful is nitric oxide (NO) (Pepke-Zaba, J. et al 1991; 
Ricciardi, M. J. et al 1998; Roberts, J. D., Jr. et al 2000). A positive vasodilator 
response is defined as a fall of 20% in either mean pulmonary artery pressure or 
pulmonary vascular resistance (Chemla, D. et al 2002).
1.2.4 Treatment
Treatment should be aimed at the underlying cause of pulmonary hypertension. 
Conventional treatments include oxygen therapy and anticoagulation.
In secondary pulmonary hypertension, hypoxia is a precipitating factor. There is 
evidence that oxygen improves symptoms in children with pulmonaiy arterial 
hypertension (1985; Kanemoto, N. et al 1989; Krai, H. et al 1993; Nagasaka, Y. et al 
1978; Stark, R. D. et al 1973; Weitzenblum, E. et al 1985; Wuertemberger, G. et al 
1990).
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The other mainstay of treatment is vasodilator therapy. The theory behind the use of 
vasodilators in pulmonaiy hypertension is based on the importance of vasoconstriction 
in the development of pulmonaiy hypertension. These can be subdivided into calcium 
channel blockers and disease directed therapy. Disease Targeted Therapies (DTT) 
includes prostacyclin, endothelial antagonists and phosphodiestease 5 antagonists. Apart 
from vasodilatation, these agents may have other beneficial effects in pulmonary 
hypertension.
Calcium channel blockers are used in those deemed to be vasodilator responders (Rich, 
S. et al 1991; Rich, S. et al 1992), and disease targeted therapy in those who are not. 
Disease target therapy may double five year survival rates (Rubin, L. J. et al 1990). 
These beneficial effects may persist up to 10 years (Bush, A. et al 1987; Ewert, R. et al 
2000; Galie, N. et al 2002; Hoeper, M. M. et al 2000; Jones, IC. et al 1989; Machhemdl, 
S. et al 2001; Olschewski, H. et al 2000; Olschewski, H. et al 2002; Oudiz, R. J. et al 
2004; Rubin, L. J. 1997; Rubin, L. J. et al 2002; Simonneau, G. et al 2002). 
Combination therapy of disease targeted therapy may also be useful (Ghofrani, H. A. et 
al 2003; Hoeper, M. M. et al 2004; Lunze, K. et al 2006).
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1.3 Introduction to Haemodynamics
1.3.1 Introduction
Optimal condition for exchange of mixed venous blood and inspired air is a low 
pressure high flow system with very little distance separating the air from the blood. 
The pulmonary circulation is a low pressure system and this prevents fluid from moving 
out of the vessels into the interstitial space and also allows the right ventricle to operate 
at a minimal energy cost. The pulmonary circulation operates at approximately 20 % of 
systemic pressures at rest. This means that the pressure-flow (P-Q) relationship is very 
sensitive to mechanical influences. The heart and pulmonary vasculature are situated in 
a pressuie chamber -  the thorax. Pressure measurements have to be interpreted relative 
to surrounding pressure as breathing effort can generate changes that override nonnal 
pulmonary vascular pressures.
Resistance can be described as the opposing force to a given constant flow. Pulmonary 
vascular resistance, (PVR), is used to evaluate the forces that oppose right ventricular 
ejection but can be misleading. PVR is calculated by 
MPAP- LAPPVR = --------—--------- , and is the ratio of the mean pressure drop across the lung to
cardiac output, where Q is blood flow per unit time (or cardiac output, CO, measured in 
L min^), MPAP is mean pulmonary artery pressure and LAP is left atrial pressure.
Pulmonary Artery Occlusion Pressure (PAOP) is the pressure measured when a balloon 
is inflated within the pulmonary artery and it gives an estimation of LAP under normal 
circumstances if the tip of the catheter is placed below the level of the left atrium. The
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pulmonary circulation is affected by passive and active mechanisms and is altered by 
varying physiological activity.
1.3.2 Passive Regulation
The pulmonary circulation can be affected by lung volume, interstitial pressure or left 
atrial pressure (LAP). Blood vessels in the lung can be divided into alveolar vessels and 
extra-alveolar vessels. As lung volume increases (during inspiration), it has different 
affects on the different groups of pulmonary vessels (Graham, R. et al 1982), The 
transmural pressures of intra-alveolar vessels and extra-alveolar vessels also depend on 
changes in alveolar and interstitial pressure produced by changes in lung volume. 
(Fishman 1985; Naeije 1996)
It has been observed in experimental models of pulmonary hypertension with positive 
extrapolated intercepts of pulmonaiy artery pressure-flow (P-Q) plots, that LAP can be 
increased up to a certain point above normal without affecting pulmonary artery 
pressure (PAP). The exact level at which increases in LAP leads to an increased PAP 
varies from model to model of pulmonary hypertension. This shows that LAP can 
seldom be taken as the effective outflow pressure to calculate resistance of a 
hypothetical Poiseuillian flow within the pulmonary circulation (Naeije, R. 1996).
1.3.3. Active Regulation
1.3.3.1 Hypoxic Pulmonary Vasoconstriction (HPV)
Hypoxic pulmonary vasoconstriction (HPV) was first demonstrated in 1946 (von Euler, 
U. S. et al 1946). Describing the effects on the pulmonaiy circulation of acute (hours) or 
chronic (days-weeks) hypoxia is complicated, in view of the great amount of inter &
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intra species variability. This can be demonstrated by the variable response of animals 
to changes in altitude. As altitude increases, the partial pressure of oxygen in the 
atmosphere decreases. Some animals, like the cow or cat, show a large increase in 
pulmonary arterial pressure to decreases in the partial pressure of oxygen, whereas 
others, like the rabbit or guinea pig show only a little response to decreases in Partial 
pressure in arterial blood (Pa02). Most animals, including man, fall in the mid category 
(Reeves, J. T. et al 1979b)
Intra species variation also occurs. In adult humans. Reeves and Grover found that there 
was a large variation in pulmonary artery pressure in those living at high altitude, with a 
lesser degree of variation or range in those living at sea level (Reeves, J. T. et al 1979a). 
The variation in the pulmonary artery pressures noted in individuals at high altitude 
appears to be due to variations in arterial oxygen levels (Grover, R. F. et al 1983).
Hypoxic pulmonary vasoconstriction is intrinsic to the lung and does not require 
external neural or humoral stimulation. As the airway oxygen tension reduces below 
lOOmmHg, the arterial pressure increases, until the response fails (Barer, G. R. et al 
1970; Hauge, A. 1968). The onset of vasoconstriction is gradual over minutes, but the 
offset is rapid (McMurtry, I. F. et al 1976). The response can be affected by other 
factors, such as cardiac output, left atrial pressure, autonomic nerve stimulation and 
circulating vasoactive substances (Naeije, R. 1996). The exact biochemical mechanism 
of HPV is unknown (Fishman, A. P. 1985; Grover, R. F. et al 1983). Giving oxygen 
may reverse the effects of hypoxic vasoconstriction.
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1.3.3.2. Nervous Control o f  Pulmonary Vascular Tone
The pulmonary Vasculature has both sympathetic & cholinergic innervation, a- 
adrenergic receptors produce vasoconstriction and P-adrenergic receptors vasodilation 
(Grover, Wagner et al. 1983; Fishman 1985). However, an increase or a change in 
sympathetic stimulation does not lead to HPV. Thus the a- adrenergic effects are either 
greater than or balanced with the p-adrenergic effects.
Studies have shown that in total autonomic block by chemical sympathectomy, 
pressure-flow plots in dogs move to a higher pressure (Murray, P. A. et al 1986; Naeije, 
R. et al 1989). This suggests that under certain circumstances the sympathetic system 
may produce a net vasodilatory response.
1.3.3.3 Humoral Control o f the Pulmonary Vascular Tone
Many mediators have been proposed to modulate pulmonary vascular tone (Naeije, R. 
1996), but only prostacyclin and nitric oxide have been shown to reduce normal 
vascular tone in experimental models.
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1.4. Effects of Various Physiological Conditions on the Pulmonary Circulation
1.4.1. Hyperoxia
Pulmonary arteries have been shown to dilate in response to hyperoxia (Madden, J. A. 
et al 1985; Peake, M. D. et al 1981). During ventilation in the normal lung, the 
pulmonary vasculature is kept in a relatively relaxed state. Hyperoxia may lead to an 
acute fall in calculated pulmonary vascular resistance and pulmonary arterial pressure, 
but with no significant effect on the systemic circulation or cardiac output (Tucker, A. et 
al 1975). Hyperoxia selectively decreases the pulmonaiy vasoconstrictive response of 
prostaglandin p2a (Lonigro, A. J. et al 1975) but does not affect the response to 
serotonin and noradrenaline (Archer, S. L. et al 1989).
1.4.2. Posture
When a human stands up, the intravascular pressure increases due to the force of 
gravity, leading to increased transmural pressure and dilation of the venous system. This 
leads to less venous return and reduced heart filling. Normally 400-500ml is shifted 
through the leg veins. Although the reservoir of pulmonary blood is decreased, the left 
heart can still be filled out of this reduced reserve for 10 beats. This is followed by an 
increased vascular resistance in the skeletal muscle and a reflex tachycardia, 
augmentation of the contractility of the ventricles, and a catecholamine release. In 
humans at rest, cardiac output may be up to 25% lower, stroke volume 40% lower and 
heart rate 30% higher when erect as compared to supine. The distribution of blood in 
the lungs can be split into 4 zones with regards to the source of pressures that alter flow, 
and these are partially gravity dependant, (Permutt, S. et al 1962; West, J. B. et al 1964). 
In the upright position, the blood volume is redistributed to the dependant parts of the 
body and lung, and thus cardiac return and filling is reduced (Bevegard, S. et al 1960;
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Reeves, J. T. et al 1961b). In the lung, the blood distributes, preferentially perfusing the 
lower segments (Harf, A. et al 1978; West, J. B. 1999).
In the supine human lung, the whole lung is perfused (Reeves, J. T. et al 1988a). 
Pulmonary venous pressure is important for vascular recruitment, thus a higher LAP 
would allow more recruitment (Permutt, S. et al 1962; Wagner, W. W., Jr. et al 1979). 
In the erect lung at rest, there is higher pulmonary vascular resistance as there is a 
smaller lung vascular bed being perfused, and at rest PAP is too low to allow even 
distribution of blood (West, J. B. 1999). However, even moderate exercise is enough to 
reverse this and allows the recruitment of upper lobe vessels (Harf, A. et al 1978). An 
increase in the cardiac output is likely to be the major factor behind this but increasing 
ventilation may be a contributing factor (Bake, B. et al 1974).
1.4.3. Exercise
Reeves, Grover and Dempsey extensively reviewed the literature and reanalysed 
combined data with regards to exercise and the pulmonary circulation in normal humans 
(Reeves, J. T. et al 1988a). For supine exercise they analysed data on 91 subjects, (28 
females), with 196 measurements from several studies (Bevegard, S. et al 1960; 
Bevegard, S. et al 1963; Bevegard, S. 1963; Dexter, L. et al 1951; Gurtner, H. P. et al 
1975; Holmgren, A. et al 1960; Varnauskas, E. 1955). In erect subjects they analysed 
data on 24 subjects (1 female), with 104 measurements (Bevegard, S. et al 1963; 
Groves, B. M. et al 1987; Reeves, J. T. et al 1987). In the supine subjects, the workload 
was up to 1600 kg m min"\ In mild exercise there was a two to three times increase in 
oxygen uptake, but there was no change in pulmonary vascular resistance. However
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more significant amounts of exercise resulted in a slight decrease in pulmonary vascular 
resistance (Bevegard, S. A. et al 1963; Holmgren, A. et al 1960). When reviewing the 
paired data in individuals, there was a ImmHg rise in PAP for every IL rise in cardiac 
output (Reeves, J. T. et al 1988a). It was assumed that the outflow pressure was 
pulmonary artery wedge pressure (Pawp), and that the net driving force through the 
lungs was the difference between PAP and Pawp. Both the regression lines for PAP and 
Pawp, when paired with Q, had similar intercepts across the y-axis, and thus when the 
PAP-Pawp vs Q plot was produced, the intercept appeared to got though the origin 
(Reeves, J. T. et al 1988a). This would suggest that there is only a little change in the 
pulmonary vascular resistance.
In upright subjects, during mild exercise, they found a significant rise in Pawp from 5 ± 
3 mmlig, to 9 ±2 mmHg. They also found that PVR also fell significantly, from 1.5 ±
0.5 to 0.8 ± 0.3 units. With heavier exercise, they found that PVR was only reduced 
slightly when compared to mild exercise, with values in these individuals of 2.1 ±0.6 
imits at rest, to 0.8 ± 0.2 during mild exercise, and 0.5 ±0.1 units during heavy exercise. 
They also found that in individuals, the PAP- Q relationship was linear, and the Pawp-Q 
relationship was linear, but the PAP-Pawp & flow relationship was not. This suggested 
that when changing from mild to moderate exercise, there is no increase in the pressure 
gradient, but the calculated PVR decreases (Reeves, J. T. et al 1988a). When the data 
for resting pressures whilst erect were removed from the linear regression calculations, 
the line went through the origin, and gave a PVR value of 0.63, which is close to the 
value of 0.61 obtained for the PVR during exercise at rest. This would suggest that the
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main affect of posture is during rest, and even mild exercise takes away the influence of 
posture (Bevegard, S. A. et al 1960; Reeves, J. T. et al 1961a; Reeves, J. T. et al 1988a).
It is felt in general that lung vascular resistance acts passively during exercise, but 
during prolonged exercise there may be a drop in pulmonary vascular resistance 
(Bkelund, L. G. 1967).
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1.5. Pulmonary Vascular Resistance
Since the Swan-Ganz catheter was introduced in 1970, pulmonary vascular resistance 
(PVR) has been measured worldwide. The catheter allows measurement of pulmonary 
arterial occlusion pressure (PAOP), However as it is a fluid filled catheter, it is 
inaccurate in the measurements of instantaneous pressures, due to inadequate frequency 
response, motion artefacts, errors in zero levelling and altered signal quality due to 
regular debubbling and frequent flushing. However, it is assumed that the measurement 
of mean vascular pressures is reliable. Thermodilutional flow measurements require 
several cycles (and are not simultaneous), thus this catheter imposes a simplification in 
which is the pulsatile nature of the pulmonary circulation is ignored.
In steady state flow haemodynamics, resistance is calculated as a pressure drop from an 
upstream point (inflow pressure, Pi„) to a downstream point (outflow pressure, Pom) 
divided by the flow. In smooth-walled thin, non-distensible tubes, with a laminar flow 
of a Newtonian fluid, Poiseuille’s law states that: R = (?,„ -  Pout)/Q ” n .r ‘^
Where 1 is the length of the tube, p is the coefficient of viscosity, and r is the radius. In 
most clinical circumstances PAOP gives an estimation of LAP, provided the catheter tip 
is placed below the level of the left atrium. If pulmonary venous resistance is increased 
then PAOP is less then pulmonary arterial wedge pressure (PAWP), and PAWP will 
overestimate LAP. Poiseuille’s law assumes that in the pulmonary circulation (PAP- 
LAP)/Q plots are both linear and cross the origin. Accordingly the PVR, the slope of 
(PAP-LAP)/Q is constant.
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1.6 The Pressiire-Flow Relationship & Limitations of PVR Calculations
There are several limitations to the use of PVR calculations. Pulmonary vessels are 
compliant and thus PVR should decrease as MPAP increases (by virtue of the effect of 
pressure on vessel calibre). Also, the pulmonary vessels may collapse as a result of 
outside forces at low PAP. These outside forces may include alveolar pressure on 
capillaries or elastic or muscular recoil of the vessel.
These limitations in PVR measurement or the (PAP-LAP)/Q relationship mean that, 
although the relationship may be linear at a physiological range, it may have a positive 
intercept (extrapolated) and in some subjects PVR decreases as blood flow increases.
Theoretically (PAP-LAP)/Q should not follow Poisseuille’s law as pulmonary blood 
flow has a branching pattern and is not laminar as it is not a simple Newtonian fluid. 
However physiological experiments suggest that the relationship is linear with a 
positive intercept, both in animals and humans (Naeije, R. 1996). This is a constant 
observation in isolated lung preparations.
In well recmited, well oxygenated subjects who are healthy, the plots may intercept the 
origin. In hypoxia, increased alveolar pressure, vasoconstrictor drugs and a variety of 
pulmonary and cardiac diseases may shift the curves to a higher slopes and higher 
intercepts. (Fishman, A. P. 1985; McGregor, M. et al 1985a; Mitzner, W. et al 1989; 
Naeije, R  1996).
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1.6.1. Explanation for Higher Intercepts in Pressure Flow Plots
Linear curve shifts towards higher pressures with an increase in pressure intercepts have 
been explained by the vascular waterfall model (Penmitt, S. et al 1962). According to 
this model, the pulmonary circulation is made up of parallel collapsible vessels, with 
different closing pressures. At low flow (and pressure) these vessels are derecruited. At 
higher flows within the normal physiological range, the P~Q curves are linear, and their 
extrapolated pressure intercept represents the mean of the individual vascular closing 
pressures. This mean closing pressure is the effective downstream pressure of the 
pulmonary circulation. The slope of the linear portion of the P-Q curves reflects the 
cross-sectional area of the perfused vessels and is interpreted as an incremental 
resistance upstream from the site of vascular closure.
There is however an alternative explanation based on the ‘distensible vesseP model 
(Zhuang, F. Y. et al 1983). According to this model, the diameter of the pulmonary 
vessels increase, as their transmural pressure increases. This pressure/diameter ratio 
flattens progressively until a limiting diameter is attained. The resulting P-Q curves are 
markedly affected by small changes in compliance. Interestingly a parallel shift of P-Q 
cui’ves is predicted by the model if both resistance and the compliance increases in small 
order arterioles (Mitzner, W. et al 1989)
1.6.2. Interpretation and Problems with Pressure-Flow plots
Interpretation of pulmonary vascular P-Q curves in intact animals must take into 
account major methodological difficulties. PAP can be affected at both the highest and 
lowest flows by changes in the mixed venous PO2, neurohumoral activity and LAP 
(Fishman, A. P. 1985; McGregor, M. et al 1985a; Mitzner, W. et al 1989; Naeije, R.
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1996). In addition, very low flows are impossible to study in intact animals. A slight 
overestimation of PAP at the highest Q leads to an increased slope and decrease the 
extrapolated pressure intercept of a P-Q plot. This can be avoided by limiting the 
analysis of data points to comparisons at a given level flow.
The ideal way to describe pulmonaiy vascular function is as a P-Q curve generated from 
as many points as possible. If the analysis is restricted to the effect of a pharmacological 
intervention at one single point, one may be mislead into believing that the intervention 
has improved the PVR, as seen in figure 1.1 (ie C to A), but all that has happened is the 
flow has decreased. Correspondingly, an improvement might be missed by single 
measurements (figure 1.1 : B to A) but the pharmaceutical agent has decreased the P-Q 
plot. Thus, the use of a P-Q diagram allows a more reliable identification of changes in 
pulmonary vascular tone at different cardiac outputs.
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PAP-LAP
PVR
Q
Figure L I: Pulmonary arterial and flow relationships and the mis~representation o f  
resistance changes o f  the pulmonary vasculature from point A, when measuring 
classical pulmonary vascular resistance changes in respect o f to two possible 
coordinate values, B & C.
The relationship of (PAP-LAP)/Q or PVR is only meaningful if LAP is the relevant 
downstream or outlet pressure (McGregor, M. et al 1985b; McGregor, M. et al 1985a; 
Snidennan, A. D. et al 1988). For instance in normal subjects the pressure flow ratio 
(PVR) decreases as blood flow increases using LAP as the outlet pressure, and this has 
been assumed to be secondary to flow induced dilatation or recruitment of new parallel 
vessels. Snidennan et al, (1984, 1988) found in animal studies that the mean pulmonary 
artery pressure to flow relationship is constant over a large range of flows (Snidennan, 
A. et al 1984; Snidennan, A. D. et al 1988), but they also found that the pressure flow 
relationship intercept was always positive. Its minimum intercept represents the critical
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closing pressure (the pressure at which blood vessels collapse) (Burton, A. C. 1951; 
West, J. B. et al 1964), which was usually related to alveolar pressure rather then left 
atrial pressure. This slope represents resistance, but becomes misleading if LAP is less 
than the critical closing pressure, because LAP is no longer the appropriate downstream 
pressure, but critical closing pressure is. The critical closing pressure in normal man is 
lOmmHg (Brofman, B. H. et al 1957) but in subjects with COPD may as great as 30 
ininHg (Channs, Brofman et al. 1958). To date no measurements have been made in 
pulmonary hypertension.
It is known that if a vasodilator is given in pulmonary hypertension, stroke volume will 
increase, but PAP changes little. Thus the PVR apparently decreases, as calculated from 
/Q. Figure 1.2 helps demonstrate the possible explanations for a change in PAP and CO 
to an pharmacological agent, where pressure-flow coordinates change from A to B. 
From the pressure-flow model there may be one or a combination of both of two 
alternative explanations.
1. It may be that critical closing pressure increases, but real PVR remains constant, (the 
vessels have the same cross sectional area as normal subjects). If critical closing 
pressure increases, PAP would be higher for any given level of flow.
Also, if critical closing pressure was reduced by vasodilator drug, and real resistance 
left unchanged, Q would increase without an increase in the apparent driving pressure, 
leading to an apparent decrease in calculated PVR
2. Increases in real PVR (the vessels have a reduced cross sectional area) associated 
with no change in critical closing pressure (Snidennan, A. D. et al 1988).
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PAP- LAP
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Change in 
critical ► 
closing ▼ 
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PVR
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resistance
Figure 1.2: Possible explanations for change in pressure and flow in an individual 
subject
1.6.3. Pulmonary Vascular Pressure-Flow Relationships: Evidence from animal studies 
The plots seen in animals vary. Hypoxia increases the slope of pressure-flow plots in 
both dogs and pigs, but with a greater increase in pigs (Maggiorini, M. et al 1998). Dogs 
MPAP have variable response to hypoxia (up to 50% non-hypoxia responders) 
(Lejeune, P. et al 1988). Minipigs & dogs have reduction in P-Q slopes to both hypoxia 
and hyperoxia when given nitric oxide. The shift of the slope up, to hypoxia, was 
reversed. Minipigs have a greater reduction in downstream resistance (as calculated by 
PaOP) (Maggiorini, M. et al 1998). Other chemicals and pharmacaeutical agents, in 
both normoxia and hypoxia were found to have variable effects on both the gradient and 
intercept (Lejeune, P. et al 1988).
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1,6.4. Pulmonaiy Vascular Pressure-Flow Relationships: Human studies
1.6.4,1. Normal Values at Rest
The haemodynamic values in humans at rest are PAP 13mmHg (8-20), PAOP 9 mmHg 
(5-14), RAP 5mmHg (2-9). Q 6.5 1 min'^ (4-8.3), Heart rate 69 bpm (40-100) (Naeije, 
R. 1996).
1.6.4.2 Methods o f measuring P-Q
Pressure flovy curves can be produced by several methods. Currently using exercise is 
the main method in use. In the past, unilateral pulmonary arterial occlusion and 
extracorporeal circulation were used to produce P-Q curves.
Unilateral pulmonary arterial occlusion relies on the assumption that flow is divided 
equally between the two lungs. If the artery of one lung is obstructed, then all the blood 
flows through the other lung. From the changes pre and post occlusion the P-Q can be 
plotted for the obstructed lung. Using this method, the average intercept pressure in 
normals is -lOmmHg (slightly higher than LAP), and the slope of the P-Q curve is 0.9- 
1 mmHg/l/min (Evans, P. et al 1971; McGregor, M. et al 1985a; Reeves, J. T. et al 
1988a).
Physical exercise can be used for P-Q plots, but as discussed below, it is not ideal. 
However, so long as LAP, pleural and alveolar pressures are monitored, and excessive 
changes between different levels of flow are avoided, physical exercise is acceptable. 
An infusion of dobutamine at lOng/kg/min may be an alternative method of studying 
passive P-Q relationships (Naeije, R. et al 1994).
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1.6.4.3. Physical Exercise <& Posture
All increase in cardiac output during exercise does not normally affect pulmonary 
vascular pressures (Fishman, A. P. 1985; Reeves, J. T. et al 1988a). In healthy supine 
young adults the P-Q plots during moderate exercise does not exceed 1 mmHg/l/min, 
corresponding to a PAP of 25mmHg, for a Q of about 20 1/min (Reeves, J. T. et al 
1988a) Exercise -induced PAP greater than 30 mmHg is considered diagnostic of 
pulmonary hypertension.
The P-Q plots during exercise may also be influenced by exercise induced changes in 
pleural pressure, alveolar pressure and left atrial pressure. PAOP increases to 12-15 
mmHg during moderate exercise, but during strenuous exercise may increase to as 
much as 30-35 mmHg (i.e. in triathletes) (Naeije, R et al 1993; Reeves, J. T. et al 
1988a). Interestingly these changes in PAOP does not seem to affect the slope of PAP- 
Q plots during exercise, probably because of vascular distension at high levels of Q and 
PAOP.
P-Q slopes have been reported to decrease when exercise is performed standing or 
sitting, as opposed to supine. This can be explained by vascular derecuitment at rest 
(Reeves, J. T. et al 1988a).
1.6.4.4. Age & Negative Intercept
In older subjects, exercise is associated with greater increases in PAP and PAOP at 
lower CO. In patients with cardiac and/or pulmonaiy disease, pulmonaiy hypertension 
at low levels is explained by early increases in LAP and intrathoracic pressure, and also 
by mixed venous blood hypoxemia which enhances hypoxic pulmonary
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vasoconstriction (Naeije, R. 1996). AU these changes account for the negative 
extrapolated pressure intercepts for P-Q plots produced by physical exercise in patients 
with pulmonary vascular disease of various origins (Janicki, J. S. et al 1985; Naeije, R. 
et al 1994).
These changes thus may make exercise not the ideal method to generate multipoint 
pulmonary vascular P-Q plots, which are only influenced by flow.
1.6.4.5. Hypoxia
Using the unilateral pulmonary arterial occlusion method, it has been shown that 
inspiratoiy hypoxia ( ? %  9-12%) in normal subjects shifts P-Q plots in parallel towards 
higher pressures (Evans, P. et al 1971; McGregor, M. et al 1985a).
1.6.4.6. Pulmonary hypertension
It has been shown that improvements by treatment with prostacyclin may be missed by 
PVR alone but detected by P-Q changes (Castelain, V. et al 2002; Janicki, J. S. et al 
1985). Depending on the underlying cause of pulmonary hypertension the P-Q 
relationship have varying slopes or intercepts (Evans, P. et al 1971; Janicki, J. S. et al 
1985; Leeman, M. et al 1990; McGregor, M. et al 1985a; Naeije, R. et al 1994).
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1.7. General Haemodynamics
The importance of impedance and hydraulic energy in the subject of pulmonary 
hypertension can be taken from the fact that even when vasodilators reduced PVR, it is 
the total right ventricular load (which includes a pulsatile component) and not changes 
inflow or resistance that will influence clinical outcome. Resistance would be more apt 
with constant flow (using an electrical analogy-D.C. current) whereas impedance is 
more apt for pulsatile flow (AC current).
1.7.1 Pulmonary Vascular Impedance
It is possible to measure PAP & Q instantaneously. Pulmonary Vascular Impedance 
(PVZ) is basically the instantaneous pulmonary artery P/Q changes, separated into 
separate harmonics. Each hannonic has its own modulis (amplitude) and phase delay. 
PVZ is calculated after comparing the instantaneous harmonic frequencies of PAP & Q. 
Pulmonary vascular impedance is the ratio of pressure oscillations to flow oscillations. 
It is most often measured in the main pulmonaiy artery (‘input impedence’). It is 
expressed as two components : the ratio of pressure and flow moduli and a phase 
angle (whether the pressure changes come before or after flow changes, negative 
indicates flow before pressure wave. Both of these are compared against frequency 
(multiples of HR) (Milnor, W. R. 1982). Pulmonary vascular impedance at 0 hz (Zo), is 
equivalent to pulmonary vascular resistance as calculated from PAP/Q.
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Figure 1.3: Example of graphical representation of first 6 harmonics of pulmonary 
vascular impedance in a normal human subject, with pulmonary artery input impedance 
and phase.
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Pulmonary vascular impedance at 0 hz (Zo), is equivalent to pulmonary vascular 
resistance as calculated from PAP/Q.
The impedance decreases from this maximum to a minimum at 2-3 hz. Then increase to 
a smaller secondary maximum at 5-6 hz
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At low frequencies, the phase angle is negative and this means that blood flow changes 
lead pressure flow changes (Naeije, R. 1996).
1.7.2. Models of the Pulmonary Circulation
Various attempts have been made to tiy and mimic and explain the observed behaviour 
of the pulmonary vascular bed, and input impedance including early attempts by 
Engelberg and Dubois, the Fisimian's transmission line theory and the Pollack's 
transmission line theory model (Engelberg, J. et al 1959; Pollack, G. H. et al 1968; 
Weiner, F. et al 1966). These models emphasise the differences compared to the 
systemic circulation in that; wave reflection is less in the pulmonary circulation and 
pulse transmission is decreased pulse wave velocity and differences of wave 
amplification.
1.7.3. Wave Reflection
In the systemic circulation, from the relationship of resistance to the minimum and the 
subsequent impedance modulii, we can deduce the coefficient of reflection in peripheral 
arteries. This is approximately 0.8 (ie the wave reflected from peripheral bed has an 
amplitude of 80% of incident wave) (O'Rourke, M. F. 1971). The point of reflection is 
equivalent to the point of minimums in frequency. Thus, the distance to point reflection 
= À./4 = (v/f)/4,
where, A.=wavelength, v = wave velocity, f  =harmonic frequency & v=l. (figure 1.4)
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f'igure 1.4: Example of single reflected wave, where only when the reflection point is % 
of the wavelength, or a multiple of a wavelength and a %, will it register at the receiver.
receiver
wavelength
Reflection point
A high frequency suggests a small wavelength. There are multiple waves of same 
frequency, but at different phases. Different phased waves have the ability to cancel 
each other out, especially if the wavelength is smaller than distance to receiver 
(catheter). A wave with wavelengths larger than the distance to the receiver have no 
opportunity to cancel each other out. Thus the higher the frequency found at the 
receiver, the smaller the wave’s wavelength, and the more proximal the reflection point 
of the wave must be, as demonstrated in figure 1.5 (Westerhof, N. et al 1972).
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Figure 1.5A <& B: waves produced at two different reflection points. Wave 1 & 2 are in 
black, and combined wave produced is in red. A. Two high frequency waves, which 
when combined, cancel each other out B. Low frequency waves, which may be additive
A. High frequency waves
Wave 1
Wave 2
4B. Low frequency wavj Receiver point
Reflection point 1, Combined waves
Recdver
point
Wave 2
Combined waves2
In hypertension, the reflected wave velocity is faster than in normal subjects and thus 
the modulus and phase curves are shifted to right. This may be secondary to decreased 
vessel distensibility. Increased in PVR may change PVZ little (O'Rourke 1970) and vice 
a versa, decreases in PVZ may not be noted by measuring PVR.
Systemic central pulse pressure increases if there is an increased resistance and 
decreased distensibility of the blood vessels (O'Rourke 1970)
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1.7.4. Aortic pressure waves
1.7.4.1. Contour o f  ascending aortic pressure wave
Hypertension leads to changes in pulmonary impedance, which increases in lower, as 
compared to higher, pressure harmonics. It also leads to changes in phase. This 
combination leads to increased amplitude of aortic pressure wave and alteration in its 
shape.
At low pressure there is a simultaneous peak flow and pressure wave. With increasing 
mean pressure the first peak of pressure wave becomes less prominent (becoming either 
a hump or change in slope of upstroke. The diastolic wave moves from diastole into late 
systole and contributes to late systolic pump. The diastolic wave falls in smooth and 
exponential fashion (O'Rourke 1970)
Figure 1.6: Changes in normal aortic pressure wave contour in rabbits subject to 
alteration in mean pressure
~  150
100
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L 7.4.2. Synthesised aortic pressure waves
Normally diastolic wave is not apparent in the proximal aorta or brachiocephalic 
arteries. However if there is a reduction in pulse wave velocity, the diastolic wave 
becomes apparent. This is due to the late return of reflected wave before aortic valve 
closure compared to normal early return. As the pulse wave velocity increased the 
diastolic wave becomes less apparent and the amplitude of pressure wave increases in 
late systole (O'Rourke, M. F. et al 1980).
Ejection wave shortening leads to the diastolic wave becoming apparent due to the 
lower body reflection wave returning after aortic closure. (O'Rourke, M. F. et al 1980). 
This is found in hypertension, arterial degenerative disease, and aortic coarctation 
(O'Rourke, M. F. 1970). The mechanism is completely explicable from change in 
vascular bed and not the pattern of ventricular ejection.
In children and animals, pressure wave contour in different systemic arteries can be 
explained from wave reflection (at upper and lower body) leading to a prominent 
diastolic wave. As age increases this disappears. It is attributable to a high wave 
velocity leading to reflected waves from the upper and lower body both fusing together 
and combining with the initial wave generation, from the ventricle. They become 
prominent when wave velocity falls or duration of ejection shortens, (ie shock or 
hypotension).
1.7.5. Pulmonary artery wave reflection
The oscillations in pulmonaiy vascular impedance result from wave reflection in animal 
studies (Bergel, D. H. et al 1965; Caro, C. G. et al 1961). Pressure wave reflections
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originate from the pulmonary microcirculation but also from branch points in the large 
vessels (Piene, H. et al 1982). The timing of these reflections to the entrance of the 
pulmonary bed depends on the distance of the reflecting site and also the wave 
transmission velocity Distance of the reflecting site is much shorter in the pulmonary 
circulation compared to systemic circulation. The low pressure / high compliance nature 
of the pulmonary vasculature leads to a slower velocity compared to systemic 
circulation (O'Rourke, M. 1982; Westerhof, N. et al 1972). The matching of wave 
transmission velocity and arterial length results in the same pronounced impedance 
minimum seen in both circulations. Maximum flow amplitude occurs at the same 
frequencies where impedance is lowest.
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Figure 1.7; Graphical example of matched pulmonary and aortic impedance and blood 
flow harmonics. (Matched for transmission velocity and arterial length)
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Maximal flow amplitude with minimum impedance leads minimum expenditure of 
pulsatile power and thus optimal vascular-ventricular coupling. This relationship is
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adjusted by the phase relationship between pressure and flow, power being proportional 
to the cosine of this angle (Kuusmaul, Noordergraaf et al. 1992). It is worth noting that 
the flow patterns at vascular junction are more affected compared to pressure from 
reflected waves as reflected waves subtract from flow in one direction of the branch and 
adds to it in the other but reflected waves add to pressure waves in all branches of the 
junction.
In pulmonary hypertension, lower compliance leads to a faster wave reflection velocity, 
which in turn leads means reflections occur earlier during systole and enhance the 
systolic pressure load on the right ventricle. This occurs in the systemic circulation but 
can be reduced by nitroglycerin (Fitchett, D. H. et al 1988). Effects of vasodilators on 
the pulmonary vascular impedance in hypertension, has not been adequately 
investigated.
Computer models of the pulmonaiy circulation suggest that, if large vessel compliance 
is unchanged, the usual vasodilator response, (increase flow and decreased ejection 
time) leads to a small decrease in mean pressure and little change in SPAP, and 
consequently pulse pressure increases and DPAP decreases. However, if vasodilators 
result in the opens previously closed vascular channels closed by pathological 
vasoconstriction they would reduce PVR and diminishes the contribution of reflected 
waves on the SPAP. Unless pulmonary artery compliance decreases or pulmonary 
artery resistance declines more than systemic vascular resistance there will not be a 
decrease in SPAP (Sniderman, A. D. et al 1988).
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In summary, pressure generated by the right ventricle is determined by the flow output 
from the ventricle and the hydraulic arterial load.
Figure L8: Venn diagrams o f relative contributions o f elastance, reflections and 
resistance & critical closing pressures to hydraulic load on the right ventricle in normal 
humans and pulmonary hypotension
HYDRAULIC ARTERIAL LOAD ON THE RIGHT VENTRICLE
ELASL
RESISTANCE
REFLECTI0NSCRITICAL CLOSIING 
PRESSURE
ELASTANCE
RESISTANCE
CRITICAL CLOSIING 
PRESSURE
[U3FLECTIONS
NORMAL CIRCULATION PULMONARY HYPERENSION
In the pulmonary circulation, elastance (compliance) and wave reflections may become 
more important to the overall hydraulic load compared to the normal pulmonary 
circulation. Thus PVR only describes part of the load on the heart.
Increasing CO is beneficial to the circulation as an increased SV reaching the systemic 
circulation will lead to a diuresis, less fatigue and more well being. But increasing CO 
could result in increase load on the right ventricle and lead to heart failure and death. 
The reason for the increased load on the right ventricle can be seen when considering 
the end-systolic pressure-volume relationship (Sagawa, K. 1978; Sagawa, K. 1981). If a 
vasodilator results in an increase in CO, this consequently leads to an effect on the right 
ventricle. The increased venous return leads to a right ventricular pressure change. If
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SPAP & contractility do not change, an increased SV requires increased right 
ventricular end diastolic (RVED) volume. RVED volume increases result in an 
increased ejection fraction and increasing diastolic and systolic wall tensions. If RV 
already generating excessive power, this will be hanuful.
If SPAP are reduced, an increase in SV can be achieved by a decrease in RVSD 
volumes and perhaps RVED volumes leading to reduced systolic and diastolic wall 
tensions and thus beneficial to the overworked RV.
Thus only if pulmonary pressures are reduced can the vasodilator be beneficial to RV 
performance. This occurs rarely (Rich, S. et al 1983).Calcium blockers can sometimes 
do this (Rich, S. et al 1985).
Figure 1.9: The pulmonary vasodilator effect on pressure volume relationship in the 
right ventricle, with increased CO.
A. When PAP unchanged, increased SV achieved by increased EDV
B. When decresed PAP, systolic volume and wall stress decrease, and if  RV  
function improve, EDV and stress will decrease
ESPVR = end-systlic pressure-volume relationship 
DPVR= diastolic pressure volume relationship
A
ESVR
DPVR
B
ESVR
DPVR
Ventricular volume Ventricular volume
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1.7.6 Animal Studies of Impedance and Hydraulics
Several studies have been performed in rabbits (Caro, C. G. et al 1961; Engelberg, J. et 
al 1959) and dogs (Bergel, D. H. et al 1965; Elkins, R. C. et al 1971; Pace, J. B. 1971; 
Patel, D. J. et al 1963; Reuben, S. R. et al 1971b), studying impedance and hydraulics in 
the pulmonary circulation. These had many differences in methodology, but similarity 
in results.
These studies showed that there was an overall similarity of the pulmonary input 
impedance pattern to that of the ascending aorta. Impedance moduli decreased rapidly 
from a high level at 0 hz (Zo), to significantly lower levels at higher frequencies.
However there are several differences between the pulmonaiy and aortic impedances 
including an increased distensibility of pulmonary artery (slope of the decline related to 
pulmonary artery compliance). There are many differences in the pulmonary input 
impedance spectrum as compared to the systemic circulation which suggest diminished 
wave reflection in comparison to the systemic circulation. In some subjects, a clear 
early impedance minimum and secondary rise at twice its frequency point to a relatively 
discrete and symmetric effective reflection site. This may correspond to the major 
division of the main pulmonary artery into two branches (Kuusmaul, W. G. et al 1992). 
In hypoxia, it has been found that the impedance first minimum changes from 3.5 to 5.6, 
and with serotonin to 6.6 in dogs (Reuben, S. R. et al 1971b). With sympathetic nerve 
stimulation this moved to 7.5. This indicates a major change in the site of wave 
reflection, so the site was more proximal. Thus the site of vascular resistance moves 
more proximal.
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1.7.8. Hydraulic Energy
One of the consequences of the pulsatile nature of blood nature of blood flow is that 
more energy is used to move blood per minute than if the heart somehow generated 
non-pulsatile flow.
The hydraulic energy associated with blood flow of two types, potential energy which is 
the product of flow and pressure, (Ep = Q.P) and kinetic energy which is calculated as 
the physical mass of blood and square of its velocity, (Er = 14 m.v^).
Both types of energy depend on instantaneous flow and velocities, and are 
underestimated when calculated from mean pressure, cardiac output or SV. The 
difference in estimated energy to actual energy can be regarded as a kind of ‘extra’ 
energy due to pulsations.
This pulsatile component nonnally makes up about one third of the total hydraulic 
power output of right ventricle and one tenth of left ventricular output (but can increase 
to approxhnately one third of left ventricular output in aortic coarctation) (Milnor, W. 
R. et al 1969).
Right ventricular pulsatile power is affected by a change in heart rate, the compliance of 
the branches of the large pulmonary arteries and by wave reflection (Milnor 1983). The 
System is most efficient when flow occurs during low impedance. As proximal portion 
of vasculature contains most pulse wave energy, it is most efficient to have low 
impedance here.
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In normal humans PAPP is approximately 50% of PAP. Thus the pulsatile arterial 
power generated by the RV is an important proportion of total external power (30-40%).
An important issue is, do vasodilators reduce pulsatile pressure & thus power 
requirements.
An important component of pulsatile hydraulic load is the elasticity of the large and 
medium size arteries. Normal pulmonary arteries are thinner walled compared their 
systemic counterparts and the more distensible elastic vessels extend to arteries of 1mm 
in size (Sniderman, A. D. et al 1988). Consequently the pulsatile load in the pulmonary 
circulation is less (although a bigger proportion of total) compared to the systemic 
circulation. As pulmonary hypertension develops the distensibility (or compliance) of 
the elastic arteries decreases (Reuben, S. R. et al 1971a), partially due to structural 
changes in the pulmonary circulation, and also in part due to the higher pressures the 
arteries operating in the steeper portion of their pressure-volume relationship. Thus a 
larger amount of right ventricular energy must be expended to distend the stiff 
pulmonary arteries.
If vasodilators were able to decrease the PAP, it could be assumed that compliance 
would increase as the arteries move down their pressure-volume relationship. Were this 
to occur, we would find a disproportionate fall in the systolic pressure compared to 
mean pressure.
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1.7.9. Right Ventricular Haemodynamics
Compared to the systemic circulation, pulmonary circulation is unique in its ability to 
transport an equivalent amount of flow with substantially lower pressures. In addition, 
the pulsatile nature of ventricular ejection and the homeostatic requirements for an 
equivalent amount of blood ejected per beat from each ventricle, place unique 
constraints upon the right ventricle and the opposition to forward flow in the 
pulmonaiy circulation (Kuusmaul, W. G. et al 1992).
There are several differences between normal right and left ventricles. The right 
ventricle is thin walled, with one third of the muscle is in continuity with the left 
ventricle. It has a bellow shape and inertial forces dominate the development of 
intracavity pressure (result in sufficient pressure for ejection).
The presence of low pulmonary vascular resistance minimises load on right ventricle by 
matching output impedance of pump with input impedance of pulmonary vascular 
system (Milnor, W. R. 1982).
1.7.10. Characteristics of the Pulmonary Artery
The external hydraulic components of opposition to forward flow in the pulmonary 
circulation must be different its systemic counterpart, in order to produce the same flow 
at such a reduced pressure. At the steady state, the tenn of opposition (resistive, PVR) 
to flow must be substantially less than systemic vascular resistance. The vascular 
distensibility in the pulmonary circulation must be greater than the systemic circulation. 
The intrapulmonary course of the vasculature has a radial distribution of perivascular
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and interstitial pressure. It is subject to gravitational (postural) affects and has a distinct 
pattern of vascular division
But there are also similarities with the systemic circulation. The amount of blood 
ejected per beat and the size of the proximal vessels are similar in both the systemic and 
pulmonary vasculature.
The differences in the pulmonary circulation lead to certain features. There is increased 
distensibility and decreased resistance and thus a low PAP. If PAP was equal the 
systemic pressure then there would be transudation across the alveolar membrane and 
pulmonary oedema.
The proximal portions of the right and left circulation are both within the intrathoracic 
cavity. But only the pulmonary circulation has the rest of its vasculature in the 
intrathoracic cavity. This leaves it subject to variations in the intrathoracic pressure.
The remarkable pattern of vascular division in the pulmonary circulation leaves a rather 
short proximal elastic pulmonary artery and a complex pattern of distal brandling and 
tapering. This has important implications for wave reflections and transmission 
(Kuusmaul, W. G. et al 1992).
1.7.10.1 Compliance
Decreased arterial compliance is unlikely to cause major impairment of large pulmonary 
and systemic arteries. For instance, aging decreases compliance but does not cause heart 
disease (Gonza, E. R et al 1974).
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1.7.10.2. Resistance
Increased pulmonary vascular resistance leads to impaired right heart function. This 
causes increased pressure, causes decreased vascular compliance and increased load on 
the right ventricle This is associated with symptoms and death (Reeves, J. T. et al 
1988b).
1.7.10.3. Pulmonary artery, resistance, compliance and the right ventricle
Reduced compliance of pulmonaiy arteries is associated with increased mortality (Gan,
C. T. et al 2007). Pulmonaiy vascular resistance increases alone lead to PAP becoming 
narrow (animal studies). This is not seen in pulmonary hypertensive patients. They have 
an increase in PAPP as chronic increases in pulmonary vascular resistance leads to 
increases in the turgidity and the thickness of the walls of large pulmonary arteries. 
Both lead to decreases in the compliance in large Pulmonary artery (Milnor, W. R. et al 
1978). A decrease in compliance affects the right ventricular load in the following way. 
If the changes that occur with decreased compliance and increased pulmonaiy vascular 
resistance in animals resemble those of patients, with decreased flow, right ventricular 
hypertrophy and increased pulmonary arterial pulse pressure then reduced compliance 
and increased pulmonary vascular resistance lead to a decrease in flow. This implies 
that low compliance imposed an additional load to the right ventricle.
Decreased lung vessel compliance by up to sixteen fold, with an unchanged pulmonary 
resistance leads to a reduction of blood flow but the reduction in flow is less than that 
caused by a fourfold increase in pulmonaiy vascular resistance. This leads to an increase 
in right ventricular systolic pressure. Pulmonaiy arterial diastolic pressure remains low 
but with an increase in PAPP. Thus decreased compliance of large pulmonary vessels
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contributes to loading of the Ventricle & may be responsible for large PAPP in 
pulmonary hypertension. Even in mild pulmonary hypertension, where there is an 
absence of gross abnormalities in the right ventricle, the mechanical function of the 
right ventricle may be affected, leading to dyssynchiony (Lopez-Candales, A. et al 
2007).
In the systemic circulation, there is an increased in systemic systolic and pulse pressures 
with increasing population age due to stiffened vessels and hypertension. The pressure 
wave has an increased amplitude, late peak and absence of norm diastolic wave 
(O'Rourke, M. F 1985).
The degiee of Left ventricular hypertrophy is related to systemic systolic arterial 
pressure and to arterial pulse velocity, even at a constant systemic diastolic pressure, 
and thus decreased compliance, independent to left ventricular systolic load (Bothier, B. 
N. et al 1985).
In the isolated heart, reduced pulmonary artery compliance affects the right ventricular 
pressure, leading to a change shape of the pressure cuiwe.
In normal subjects, the pressure contour resembles a square wave (high fidelity 
catheters). In pulmonary hypertension, the normal right ventricular pressure contour is 
followed by a secondary pressure rise. This is not seen in pulmonary valvular stenosis, 
but only when the obstruction to flow is distal (Reeves, J. T. et al 1988b). This suggests 
that a load that is imposed in late systole leads to a right ventricular response and
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increasing pressure. Late pressure rises account for 30-40% of the total systolic 
pressure.
Hori et al (Hori, M. et al 1981) confirmed that a load suddenly imposed during ejection 
leads to a change in the pressui*e contour within a beat.
Imposing impedance on the left ventricle early in systole leads to an early increase in 
left ventricular pressure, similar to that seen in with that seen in the late introduction of 
impedance. Thus during a single contraction, the left ventricle can perceive a change in 
load and respond. No change in power is required if flow decreases and pressure 
increases.
Extrapolating to the pulmonary circulation, we can speculate that a late systolic load is 
behind the increases in pressure seen in pulmonary hypertension. We can also state that 
the pressure contour arises from an abnormal circulation, as obstruction at the outlet 
valve does not lead to a change in contoiu (Reeves, J. T. et al 1988b) and also Decreases 
in compliance lead to a late load rise (Elzinga, G. et al 1980).Thus, decreased 
Compliance lead to a late load rise, increased right ventricular pressure and pulmonary 
hypertension. In vitro flow and pressure contours are similar in normals but dissimilar if 
there is an increases in pulmonary vascular resistance and decreases in compliance.
In animal models flow is maximal during early systole and pressure maximal 
during late systole. This suggests that a late load leads to impaired output (especially 
when the load is maximum). Data from isolated heart model resembles humans as 
measured by echo. In normals, maximal flow is during mid systole. In pulmonary
78
hypertension, maximal flow is during early systole. Doppler measurements confirm that 
as pulmonary vascular resistance increases, maximal flow becomes earlier (Kitabatake,
A. et al 1983). Thus the pressiue maximum occurs after the flow maximum in 
pulmonary hypertension and pressure rises as flow falls (later in systole). Increased 
pulmonary vascular resistance and decreased compliance, lead to a late load, and late 
systolic augmentation occurs by early return of reflected wave (O'Rourke, M. F 1985).
In dogs with congenital pulmonary stenosis and raised right ventricular pressure, in 
response to occlusive hypereamia, the normal increase in systolic coronary artery blood 
flow is decreased (and is less than diastole). Total flow is approximately 100% of the 
normal, but a higher work load is required by the right ventricle due, to increased 
pulmonaiy vascular resistance, and thus flow not adequate. This leads to right 
Ventricular ischaemia (Franciosi, R. A. et al 1968; Gold, F. L. et al 1982). At post 
mortem right venticular infarcts are reported in pulmonary hypertension with nonnal 
coronary arteries (Carlson, E. B. et al 1985; Horan, M. et al 1981).
It is observed -  RV adepts variably to similar severities of pulmonary hypertension as 
assessed by PAP and PVR. Improved evaluation would come from using pulsatile 
haemodynamics and would allow a better understanding of right ventriculovascular 
coupling (Kuusmaul, W. G. et al 1992). The use of pulsatile haemodynamics could also 
explain the disappointing clinical results of vasodilators selected exclusively on the 
basis of PVR in patients with pulmonary hypertension (Sniderman, A. D. et al 1988).
79
1.8. Pharmacological Agents
1.8.1. Nitric Oxide
Following the identification of nitric oxide (NO) in 1986 as a factor known to be a 
mediator in the relaxation of blood vessels, there has been an exponential increase in the 
understanding if its biological role (Murad, F et al 1995; Murad, F. 2006). NO is an 
unstable radical, with a molecular weight of 30g/mol, and with a low blood-gas partition 
coefficient.
The affinity of haemoglobin for oxygen is 10  ^times less than that for NO (Borland, C. 
1991). In the lungs, nitric oxide combines with oxygen and water and leads to 
methaemoglobin and nitrate entering the systemic circulation. This reactivity with 
oxygen and methaemoglobin, leads to a short half life and limits the effect of NO on the 
pulmonary circulation (Carlsen E & Comroe JH Jr 1958). The half life of NO has been 
estimated at between 0.05 to 1.8 milliseconds (Celermajer, D. S. et al 1994; Stamler, J. 
S. et al 1994) Because of this NO must be continuously produced.
1.8. LI. Physiological Effects
Stamler et al (1994) & Celeimajer (1994), demonstrated that there must be a continuous 
release of NO even at rest in normoxia, as when they infused a NO antagonist into the 
pulmonary circulation in both adults and infants respectively, they increased pulmonary 
vascular resistance and decreased pulmonary blood flow velocity. (Fagan, K. A. et al
1999). During hypoxia, it is likely that NO production is increased as with the 
endothelial NOS knockout mice, which develop pulmonary hypertension in hypoxia 
(Isaacson, T. C. et al 1994; Zhao, L. et al 1993). Experiments have also demonstrated 
that even in chronic hypoxia, there must be continuous production of NO. When NO is
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inhibited under these conditions, there is an increase in basal vascular tone (Ignarro, L. 
J. et al 1987; Ignarro, L. J. et al 1999; Singh, S. et al 1997).
NO inhibits platelet aggregation and is also a potent inhibitor of smooth muscle cell 
migration and proliferation, and both of which would oppose the development of 
pulmonary hypertension, by reducing in-situ thrombi and remodelling (Borland, C. 
1991).
1.8.1.3. Toxicity
At the levels of NO used clinically, less than 80ppm, if used for only a few hours, NO 
has very few side effects.
1.8.1.4. Therapeutic Use
Compared to systemic agents, NO has several potential advantages in both the 
investigation and treatment of pulmonary hypertension. It has few of the systemic side 
effects (Pepke-Zaba, J. et al 1991) due to its short half life, and it is a potent and 
selective pulmonaiy vasodilator (Clark, R. H. et al 2000; Clark, R. H. et al 2003; 
Davidson, D. et al 1998; Joumois, D. et al 1994). As mentioned earlier in this chapter, it 
is an ideal agent for the vasodilator test required in the assessment of pulmonary 
hypertension. Its is now routinely used in the treatment of persistent pulmonary 
hypertension of newborns and has been found to improve the outcome in this condition 
(Leier, C. V. et al 1983).
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1.8.2, Dobutamine
Dobutamine was originally developed as a synthetic catecholamine for short term 
parenteral administration and became clinically available in 1978 (Leier, C. V. et al 
1983). It is a powerful ionotrope, with relatively mild chronotropic and vascular effects. 
The predominant mechanism of action, augmentation of myocardial activity, is 
mediated thi’ough predominantly betai adrenergic receptor stimulation. However, at 
standard doses, it also has betaz and alphai agonist activity. The effects of these 
additional activities are normally balanced, and so have very little effect on the systemic 
vasculature (Leier, C. V. et al 1979).
The plasma concentration of dobutamine seems to be directly related to its 
haemodynamic effects (Kates, R. E. et al 1978) In clinical practice, dobutamine 
infusions use are commenced at 2-3 pg kg'  ^ min'^ increments every 10-30 minutes until 
the desired effects are obtained. Usually at doses gieater than 15 pg kg"^  min'^ side 
effects such as headaches, tachycardias, arrythmias, headaches, anxiety, tremors and 
blood pressure changes may occur. The onset of action of a continuous infusion of 
dobutamine, usually occurs within 2 minutes, with maximal effects occurring after 10 or 
more minutes. Due to the short plasma half life of 2.37 ± 0.70 minutes (in cardiac heart 
failure) means that most of the drug will be metabolised within 10-12 minutes of the 
infusion being stopped.(Loeb, H. S. et al 1977; Stoner, J. D., Ill et al 1977). Its major 
metabolites are pharmacologically inactive. Unlike some other clinically used 
catecholamines, dobutamine does not alter ventricular pressures (Mishra, M. B. et al 
1997).
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In many cardiology departments, dobutamine is often used as a surrogate to exercise, in 
order to perform a cardiac stress test. A standard protocol for this, uses 3 minute stages, 
with incremental doses, and with the range of infusion being given, ranging from 5 to 
40pg/kg/min (Mishra, M. B. et al 1997). Mishra et al, (1997) investigated the 
haemodynamic effects of dobutamine in 69 human subjects being investigated for 
ischaemic heart disease, and found that in these subjects mean stroke volume rose from 
67.5ml pre test, to 82 ml on 20 pg kg'^ miiT  ^ dobutamine and 85ml on 40 pg kg'  ^ m in'\ 
Only 26% of subjects reached their maximal stroke volume, by using 10 pg kg'^ min'^ 
of dobutamine (Vatner, S. F. et al 1972; Vatner, S. F. et al 1974). Studies in animals 
have shown that the prime action of dobutamine is on contractility, with myocardial 
contractility increasing by 82% in exercise compared with 125% with dobutamine 
(Cohen, J. L. et al 1993).
Another study, comparing dobutamine to exercise, found when using the standard 
dobutamine stress testing protocol, (with dobutamine used up to doses of 40 pg kg'  ^
min'^), that none of the subjects investigated had any fatigue, versus 58% in the exercise 
group (p<0,001). 29% of patients had arrhythmias in the dobutamine group versus 8% 
in the cardiac group (p<0.05), the majority were clinically non-significant arrhythmias, 
like premature beats, but 4% of subjects had a supraventricular tachycardia. Only 4% 
had non-sustained ventricular tachycardias (Bradford, K. K. et al 2000; Jenkins, I. R. et 
al 1997; Murali, S. et al 1991; Schneider, A. J. et al 1987).
The effects of dobutamine on the pulmonary circulation are more difficult to ascertain. 
Studies suggest dobutamine reduces PVR. (Ducas, J. et al 1992; Furman, W. R. et al
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1982; Hyman, A. L, et al 1985; Lejeune, P. et al 1987b; Light, R. B. et al 1988) 
However, these studies do not take account to flow affects on PVR. Where flow 
conditions have been controlled, pulmonary vascular resistance, as ascertained from the 
gradient of the difference of pulmonary arterial inflow and outflow pressure against 
flow, has been found to either remain static, increase or decrease.(Pagnamenta, A. et al 
2003).
A study by Pagnamenta et al, of experimentally induced pulmonary hypertension in 10 
anaesthetised and ventilated dogs, found that dobutamine up to a concentration of 10 pg 
kg'  ^ min'^ had no effect the pressure flow gradients produced in these animals 
(Pagnamenta, A. et al 2003). However, at higher doses, the effect is dependant on the 
existing tone. If the existing tone is high, dobutamine may reduce the pressure flow 
plots, and if the basal tone is low, it may increase the pressure flow gradient (Lejeune, 
P. et al 1987a). Previously, the same team demonstrated that in dogs, dobutamine at 10 
pg kg'  ^ min'^ did not affect the pressure flow plots during hypoxia or hyperoxia. 20 pg 
kg“^ min"  ^ led to an increase in the difference between pulmonaiy arterial pressure and 
occlusion pressui’e at the lowest flows in hyperoxia, but in hypoxia decreased it at all 
levels (Lejeune, P. et al 1987a).
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1.9. Pulmonary Artery Pressure: Methods of Measurements
1.9.1 Swan-Gantz Catheterisation: Brief overview
Right heart catheterisation is the most useful investigation in pulmonary hypertension as 
it allows the measurements of a number of important variables. The swan-gantz catheter 
allows the right atrial and ventricular pressures to be measured before it is placed in the 
pulmonary artery and an indirect measiuement of the left atrial pressure can be made, 
by obstructing a branch of the pulmonary arteiy using a balloon. The catheter can also 
be used to measure pulmonary artery pressure and using the thermodilutional method, 
an indication of cardiac output can be made.
1.9.1.2. Measurements & Accuracy
Using a swan ganz catheter allows various measurements to be made but the accuracy 
of these is variable. As the pressure is measured using a fluid filled catheter, they are 
limited in accuracy as they are liable to artefacts such as overshooting and over 
dampening. An accurate estimation of the zero point is also required.
1.9.1.3. Disadvantages & Problems
Apart from the risk from an invasive intervention, the measurements can only be made 
in a supine position and that real life daily haemodynamic changes cannot be 
determined.
1.9.2. Ambulatory Pulmonary Artery Catheter: A Brief Overview 
Attempts have been made to measure continuous pulmonaiy artery pressures by fluid 
filled catheters in a partially ambulatory subject (Levy, R. D. et al 1986). Although they 
managed to get a limited amount of data on ten patients, this method was fraught with
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problems. There was a difficulty of localising the zero reference point, there was a 
requirement for anticoagulation, and there was a need for filtering for data retrieval. In 
addition Levy et al (1986) (Levy, R. D. et al 1986), found that a change in posture 
altered the zero reference point by 4 mm and that there were often substandard 
recordings due to repeated clotting of the catheter tip and dampening of the sine 
pressure wave. They were also problems with the equipment and a liability to artefacts. 
They were satisfactoiy in measuring stationary pressure, but have limitations in fidelity 
when they are used with varying pressure.
In order to measure it during daily activities of living and during exercise tests another 
method of measurement was required. Micro-manometer tipped pressure catheters were 
ideal. Levy et al (1986), validated these catheters against fluid filled catheters (Levy, R.
D. et al 1986). The amplitude response, the method of measuring pressure, was constant 
over a selected band of frequencies and fell off at frequencies above and below this. If 
high frequency response was severely limited then the fastest moving components, the 
upstroke (systolic pressure) may have been underestimated. This was the case with fluid 
filled catheters which underestimate the systolic pressure by up to 20 % compared with 
the micromanometer tipped catheter.
7.9.2./. Measurements, Accuracy & Risk
As mentioned earlier, the micromanometer tipped catheter has been validated by Levy 
et al, (1986) as well as Gibbs et al (1989,1992), when compared with fluid filled 
catheters (Gibbs, J. S. et al 1989; Gibbs, J. S. et al 1992). There are however a number 
of problems associated with these catheters. One problem with the micromanometer 
tipped catheters was zero drift. This has been overcome in the newer catheters, by
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zeroing it during the in vivo measurements on several occasions and then using a 
computer program to readjust all the measurements to correct for this (Raeside, D. A. et 
al 1998; Raeside, D. A. et al 2000; Richards, A. M. et al 1990). In addition, the pressure 
transducer was placed at the catheter tip, making the tip its own zero reference point.
1.9.2.2. Use in Pulmonaiy hypertension
The micromanometer tipped catheter has been used to measure pulmonary artery 
pressure while lying flat, sitting, while asleep and during exercise. Raeside et al (1998,
2000) and Richards et al (1990), performed several studies using these catheters 
successfully (Donald, K. W. et al 1953; Fagard, R. et al 1990; Grenvik, A. 1966; Hillis, 
L. D. et al 1985; Reddy, P. S. et al 1976; Reeves, J. T. et al 1961a; Sekelj, P. et al 1958; 
Vissher, M. B. et al 1953; Warburton, D. E. et al 1999a).
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1.10. Measurement of Cardiac Output
There are various methods of measurement cardiac output. These range from non- 
invasive methods like Doppler echocardiography, thoracic bio-impedance cardiography, 
semi invasive techniques like LIDDCO, and PICCO, (both of which have not been 
validated for exercise) and invasive techniques like thermodilutional cardiac output or 
Pick method. They have various problems including, accuracy, difficulty of 
implementation during exercise, reproducibility and risks. There may also be some 
difficulty in performing them during exercise.
1.10.1. Invasive
L I 0.1.1. Gold Standard
Invasive techniques, namely the direct Pick and dye-dilutional methods, are still 
currently the gold standard methods for measuring cardiac output. A number of studies 
have been performed comparing these two methods, performed in the 1940’s to 60’s, 
showing that they give reliable and valid detenuinations of cardiac output at rest and 
submaximal exercise to an accuracy of within 5-10% (Doyle, J. T. et al 1953; Eliasch, 
H. et al 1920; Friedlich, A. et al 1950; Miller, D. E. et al 1962; Thomasson, B. 1957; 
Warburton, D. E. et al 1999a). The measurement of cardiac output via the Pick method 
relies on the measurement of oxygen from an arteiy and on mixed venous blood 
sampled centrally (pulmonary artery), along with a measure of oxygen consumption, by 
the body (lungs), during a steady state condition (Warbruton, Haykowsky et al. 1999). 
This requires a pulmonary artery catheter to be inserted centrally, and then cardiac 
output, Q is calculated by the Pick equation,
CaO 2 — Ev O2
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This gives an accurate measurement of cardiac output (Kopelman, H et aJ 1951; 
MacCanon, DM et al 1955; Warburton, D. E. et al 1999a), at rest or submaximal 
exercise, but becomes a problem in maximal exercise when a steady state of exercise for 
2-3 minutes is not achievable. It also requires highly trained personnel to perfonn 
precisely and meticulously, and without this becomes more inaccurate (Clausen, J. P. et 
al 1970; Grenvik, A. 1966; Hillis, L. D. et al 1985; Mohammed, M. M. et al 1981; 
Warburton, D. E. et al 1999a). In addition there may be problems with cardiac 
catheterisation, including arrhythmias, and perforation of the artery or right ventricle 
(Ekblom, B. et al 1968; Strand, P. O. et al 1964).
L 10.1.2. Thermodilutional
The thennodilutional technique can be used to measure Q at both rest and exercise. It is 
based on the same technique as the dye-dilutional test, but replaces the dye with cold 
saline (or 5% dextrose) injected through a proximal port of a pulmonaiy arteiy catheter. 
This cools the blood and this blood is measiued at the tip of the catheter by a thermistor. 
The amount of cooling is inversely proportional to Q (Nishikawa, T. et al 1993).
The advantages of thermodilution compared to the dye-dilutional method is that it 
produces no changes in the indicator baseline, allows numerous measurements to be 
made and recirculation is of little concern (Nishikawa, T. et al 1993).
Its disadvantage is that as heat is used as a marker, a proportion of it may be lost during 
handling of the syringes and in the catheter before it enters the circulation (Mackenzie, 
J. D. et al 1986; Russell, A. E. et al 1990). The error due to the temperature of the
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injected water not being ice cold is that Q is approximately 2.86% overestimated for 
every 1°C that the injectate temperature is warmer (Nishikawa, T. et al 1982; 
Nishikawa, T. et al 1988; Nishikawa, T. et al 1990; Nishikawa, T. et al 1992). For every 
13 seconds a glass filled syringe is held in a hand at 36°C, the 10ml of iced water will 
increase in temperature by 1°C, (Evonuk, E. et al 1961). Further more, physiological 
variations occur in blood temperature as a result of phasic heat exchange of air in the 
lungs (Kohanna, F. H. et al 1977; Nishikawa, T. et al 1993). Using iced fluid may also 
lead to a transient slowing of the heart and alterations in systemic and pulmonary 
arterial pressures, right atrial pressure, and right ventricular pressure (Cigarroa, R. G. et 
al 1989; Hillis, L. D. et al 1985; Nishikawa, T. et al 1993; Ohteki, H. et al 1981; Olsson,
B. et al 1970; Rahimtoola, S. H. et al 1965; Samet, P. et al 1966a; Samet, P. et al 
1966b),. These effects are gieater the cooler the fluid is and the larger the volume 
(Cigarroa, R. G. et al 1989). In subjects with a low cardiac output, it may overestimate 
cardiac output due to recirculation of the indicator before analysis is complete (Konishi, 
T. et al 1992).
In patients with valvular heart disease, it has been found that thermo dilution cardiac 
output is often unreliable (Hamilton, M. A. et al 1989). In tricuspid regurgitation, this 
may lead to an imderestimate of cardiac output (Hoeper, M. M. et al 1999). Konishi et 
al (1992) found that a combination of a low cardiac output state and tricuspid 
regurgitation have opposing errors which may cancel out and lead to a more accurate 
result (r = 0.98, slope = 0.86). Similar results have been found in other studies 
(Branthwaite, M. A. et al 1968; Espersen, K. et al 1995; Mackenzie, J. D. et al 1986; 
Russell, A. E. et al 1990; van, Grondelle A. et al 1983). Hamilton et al (1989) also
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reported little difference between Pick measurements and thermodilution measurements 
in subjects with heart failure and tricuspid regurgitation (r =0.8). Similar findings have 
been found by others (Hsia, C. C. et al 1995; van, Grondelle A. et al 1983).
In patients with pulmonary hypertension, Hoeper et al (1992) found an acceptable 
agieement between Pick and thermodilutional cardiac output measurements (mean 
±95%, +0.01±l.lL/min), but with a large splay of single results of approximately 
±l.lL/min (±30%). Similar findings have been found by others (Becklake, M. R. et al 
1962; Chapman, C. B. et al 1950; Werko L et al 2006; Zeidifard, E. et al 1976)
The accuracy of the thermodilutional technique is debatable, and certainly it is not a 
gold standard method, but it has found widespread use in clinical practice. Many studies 
have reported that this measurement may overestimate the value of Q compared to 
Doppler echocardiography, CO2 rebreathing, and direct Pick methods, during supine or 
upright rest and light exercise of up to 40% (Warburton, D. E. et al 1999a) and this error 
may be even greater during vigorous exercise (Clausen, J. P. et al 1970; Espersen, K. et 
al 1995).
1.10.2 Non-In vasive
Other methods of measuring cardiac output include the foreign gas method, indirect 
Pick method and Doppler echocardiography. The foreign gas method has been found to 
be less accurate during resting conditions and in subjects with pulmonary conditions 
(Clausen, J. P. et al 1970; Farhi, L. E. et al 1976).
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The results of the indirect Pick method may vary from direct Pick by 0 to 31% at rest 
(Espersen, K. et al 1995; Gardin, J. M. et al 1984; Shaw, J. G. et al 1985) and 2 to 19% 
during exercise (Christie, J. et al 1987; Shaw, J. G. et al 1985).
Doppler echocardiography has several possible areas in which errors can be introduced 
resulting in a lot of inter and intra operator variability (Kubicek, W, G. et al 1966), and 
in studies, Doppler echocardiography has been found to often underestimate Q when 
compared to other methods of measuring cardiac output, by up to 21% (Sraraek, B. et al 
1983) or may overestimate in the supine posture (Bernstein, D. P. 1986).
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1.11. Thoracic Bio-impedance
In 1966 Kubicek et al (Kubicek, W. G. et al 1966) described a method of calculating 
stroke volume, i.e. cardiac output (Q ) , from thoracic impedance signal. However 
obtaining the results required special electrodes, a specific configuration, vigorous skin 
cleansing, and measurements of distances between electrodes were required. It was also 
assumed the thorax was like a cylinder. All these factors may lead to the introduction of 
errors into the assessment. Later, Sramek et al (1983)(Osypka, M. J. et al 1999) 
suggested an alternative equation likening the thorax to a truncated cone. This equation 
has been further modified by Benstein et al (1986) (Osypka, M. J. et al 1999) to 
improve accuracy. There are now a number of commercially available instruments 
available for the measurement of bioimpedance, incorporating these equations.
One of the more recent devices is the Physioflow® (Manatee Biomechanical, 
Macheren, Paris). This had further modified the equation to allow ease of use and a 
more accurate result.
1.11.1. Basic Principles & Theory
In electricity an analogous relationship exists to the biological
relationship between cardiac output (q ) , pressure gradient (MAP -  CVP, where 
MAP is the mean arterial pressure and CVP is central venous pressure) and peripheral 
vascular resistance (R),
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MAP -  CVPwhere Q ~ ----------------- . This is Ohm's law where the flow of a direct current. 1, isR
analogous to Q , is equal to the voltage drop, E, between the two ends of circuit with 
resistance, R, giving us
ER = y ,  where R is measured in ohms (Cl).
If the current. I, remains constant then any change in resistance, AR, is proportional to 
any change in voltage AE, i.e.
AR « AE, so any voltage drop would be due to a drop in resistance.
The resistance of an electrical object is dependent on the size, shape and resistivity of a 
material. For an alternating current, resistance is known as impedance, Z, and is 
frequency dependent. We would then obtain the equation.
Following the logic for the direct current, we get
AZ « AE. I remains constant then any change in resistance, AZg is proportional to any 
change in voltage AE.
The impedance of a simple cylindrical circuit, is equal to the specific resistance of the 
material, (p), times its length (L), divided by its cross sectional area, (A),
z  = P YA
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Thus if both L and p remain constant, then Z is inversely proportional to the cross 
sectional area.
If like Kubicek et al(Kubicek, W. G. et al 1966) we assume that the thorax can be 
modelled like a cylindrical conductor, with length L, and which has embedded, within 
itself and in parallel with itself, a second smaller cylindrical conductor, the great vessels 
(Figure 1.10) (Osypka, M. J. et al 1999).
Figure J. 10. Cylindrical conductor as a simple model o f  the human thorax. In this model, the great 
vessels (aorta, pulmonary artery) are considered as a .smaller cylindrical conductor o f cross- 
.sectional area (Ay), length (L), and specific resistance (ps) o f hlood, and the remaining thoracic 
volume is characterized by cross-sectional area Aj, length L, and .specific resistance pr (Pb < <  Pr)- 
©(Osypka, M. J. et a l 1999)
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It is assume that with each beat-to-beat pulsation, the cross sectional area of the great 
vessels will alter, giving us an area. If ventilation is suspended, then it can be assumed 
that change in Z, (AZ), with each heartbeat, is caused mainly by changes in the cross 
sectional area of the great vessels.
By using all these assumptions and synthesising them with the theoiy of Ohm’s law, the 
changes in the cross sectional area of the gieat vessels, in turn must lead to an inverse 
change in thoracic impedance. The impedance changes are directly proportional to the 
voltage and can be measured (Osypka, M. J. et al 1999) and varies directly and 
proportionally in time with changes in the pulmonary and aortic blood volume, (Khan, 
M. R. et al 1977), giving the following equation.
A V ( t ) = P B ~ - A Z ( t )  ”  S V  =  p „ - - U . d Z / d t - T  
%
where Zo, is the measured non pulsatile baseline impedance. This is the basis for 
thoracic bioimpedance and directly leads to the Kubicek equation (Osypka, M. J. et al 
19991^ where SV is stroke volume in ml, p is the resistivity of blood (1350 cm), L is the 
measured distance between the neck and thoracic leads, Zo is baseline thoracic 
impedance (Q) dZ/dt is the, maximum rate of change of impedance during systole 
(Q/sec) and T is left ventricular ejection time (s).
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Thus in practice a constant current is introduced across the chest and the voltage drop 
measured. This voltage measured is proportional to impedance across the chest The 
major part of Zo does not change during beat to beat, only a small component due to the 
air to liquid ratio during breathing (Wang L. et al 1995).
In healthy adults Zo has a mean value of 300 (Bernstein, D. P. 1986; Kubicek, W. G. et 
al 1966; Sramek, B. et al 1983; Sramek, B. B et al 1983). Superimposed on this baseline 
impedance is change in impedance, AZ, which is due to both changes due to ventilation 
and due to blood flow, giving the following equation,
Z(t) = Z„ + AZ(t)
à i
Expiration Inspiration
max. Inspiration max. Expiration max Inspiration
Time
Figure 1.11. Variation of thoracic impedance Z(t) = Zo * [DELTA ]Z(t) with a 
ventilation cycle and with each heart heat. The electrocardiogram on top is a 
reference for the impedance changes related to the cardiac cycle. © (Osypka, 
M. J. et al 1999)
97
The overall variations in impedance due to respiration are greater then the variation in 
impedance due to blood flow (Figure 1.11) (Appel, P. L. et al 1986; Goldstein, D. S. et 
al 1986).
If ventilation is suppressed or corrected for, only the cardiac component of thoracic 
impedance is left. This is usual about 0.1 to 0.2 O, (about 0.3% to 0.5% of total thoracic 
impedance). It was found in a theoretical model developed by Wang and Patterson 
(1995) (Gotshall, R. W. et al 1989), that blood vessel structural changes only 
contributed 4% to thoracic impedance.
1.11.2. Non-physioflow bio-impedance devices
Both the Kubicek, and the Sramek & Bernstein (Yakimets, J. et al 1995) methods of 
analysing bio-impedance derived cardiac output relies on sitting a set of two electrodes 
on the neck and two on the lower thorax, to inject and sense current, and four electrodes 
to sense an ECG.
These equations have been tested against each other and against invasive measurements 
on many occasions. In some diseases both these equations have performed adequately 
against thermodilutional measurements (Jensen, L. et al 1995).
Gotshall et al (1989) (Jensen, L. et al 1995) also compared the equations, using different 
equipment, against critically ill patients, (with additional thermodilutional 
measurements) and in normal subjects. They found in critical care patients there was no 
significant difference between either the equations or the thermodilutional
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measurements. However the values in normals where found to be divergent. The 
Smarek-Bernstein equation was found to have higher values than the Kubriek equation, 
the latter being more compatible with previously published values of cardiac output in 
supine normal patients at rest. An extensive review by Jensen et al (1995) (Bernstein, D. 
P. 1986; Jensen, L. et al 1995; Kubicek, W, G. et al 1966; Penney, B. C. 1986; Sramek, 
B. B et al 1983), foimd that the Kubricek method when compared to the direct Pick 
method, had correlation values of between 0.63 -  0.93 and the modified Sramek- 
Bernstein equation method had correlation values ranging from 0.41 to 0.99 (Charloux, 
A. et al 2000; Jensen, L. et al 1995), when compared with thermodilutional methods. 
Analysis of AZ may also be problematic in subjects who are fluid overloaded, as this 
reduces baseline impedance to 200 or less (Warbuiton, D. E. et al 1999b). This 
suggests the value obtained for cardiac output may vary depending on the equation used 
and the equipment as well as the type of subject the measurements are taken on.
1.11.3. Physioflow Cardiac Output Monitoring Device: Theory
The physioflow (Physioflow, Type PF05L1, Manatee, France) bio-impedance cardiac 
monitoring device was developed after technical improvements occurred in the 
available hardware (a new generation of analog technology allows the Physio Flow to 
improve signal filtering and stability and provide better data processing), and the basic 
equation has been adjusted. The equation has been modified in order to overcome the 
difficulties in evaluating blood resistivity (p), the distance between recording electrodes 
(L) and Zo used in the Kubicek and Sramek-Bernstein equations.
Previously getting a precise measurement of Zq, the distance between electrodes and a 
measurement of left ventricular ejections time was needed for measuring cardiac output
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by thoracic impedance (Charloux, A. et al 2000; Hsu, A. et al 2006), but the physioflow 
avoids the need to know these values. The Physioflow equation was developed by the 
analysis of an extensive database. Impedance cardiography is based on the analysis of 
signal wavefonn and its variations. The database was collected on patients with a 
variety of cardiovascular conditions ranging from severe heart failure to 
hyperthyroidism, and taken at rest and exercise using the physioflow prototype. The 
haemodynamic status was assessed using echocardiography and angiography.
This equation has allowed the discarding of Zo, thorax height, distance between sensing 
electrodes and blood resistivity in the calculation of SV (Charloux, A. et al 2000).
It uses the following formula:
Q, = fcxSV ixB SA
where is cardiac output (1/min)), /c is the heart rate (beats/min); [based on R-R
interval measurement, determined on ECG first derivative, dECG/dt, (providing a more 
stable signal)], BSA (m^) is body sinface area, calculated according to Haycocks 
formula (BSA = 0.24265 x x where BM is body mass in kg and H is
height in cm), and SVi is SV index (SV divided by BSA).
An evaluation of SVi is derived from SVicai which can be calculated by the following 
equation:
SVicai = k X [(dZ/dti„ax)/(Z,„ax”Z,„i„)] X W(TFITcai), where W(TFITcai) is the weighted 
thoracic flow inversion time. The explanation for the production of this equation is
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given in Charloux et al (2000) (Charloux, A. et al 2000)SVicai represents the baseline 
reference. During the data acquisition phase, the variations of the parameters described 
above are analysed and compared to those obtained during the calibration phase.
SVi = SVicai X 3 V C T I  /  C T IcaixT F IT cai /  T F I T  where CTI is dZ/dt, or the 
contractility index
Charloux et al (Charloux, Lonsdorfer-Wolf et al. 2000) suggested that the physioflow 
thoracic impedance cardiac output device had several apparent advantages over other 
methods of non-invasive thoracic impedance cardiac output devices are, which were:
1. Multiple electrodes are not needed (only 4 impedance electrodes and two ECG 
electrodes) to obtain good quality signals
2. The SV results may have better reproducibility even under non-optimal 
conditions (different electrode positions, types or perspiration)
3. A greater range of applications (e.g. cyclo -  ergometer)
4. No need to measure thorax morphology
5. Increased reliability of the whole acquisition procedure by introducing a 
calibration phase.
1.11.4. Physioflow Cardiac Output Monitoring Device: Validation & Reproducibility 
There have only been a few studies examining the accuracy and reproducibility of the 
physioflow (Physioflow, Type PF05L1, Manatee, France) device. The reproducibility of 
the test was performed as part of a thesis submitted to the University Hospital in 
Angers, France by Dr R Trouve in his thesis (Trouve, R. 1997).
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Two tests of reproducibility were performed. The first involved 25 haemodialysis 
patients, over 3 sessions providing 75 measurements of stroke volume. The results were 
a reproducibility correlation of, r = 0.98 p < 0.0001.
Similar results were obtained during another test of 7 patients, supine at rest, using 3 
separate operators and with 3 consecutive measurements being made by each operator. 
The purpose was to evaluate reproducibility of stroke volume measurements under 
various measurement conditions and operators. The results were inter and intra-operator 
reproducibility of r > 0.96, p<0.0001. These results also demonstrated a remarkable 
reproducibility during cyclo-ergometer exercise, and imder non-optimal measurement 
conditions (important modifications of electrode positions).
Hsu et al (Hsu, A. R. et al 2006) quoted unpublished results from their own laboratories, 
that in 20 young men (age 27 + 4 years) the coefficient for variation for SV and Q at 
peak exercise using the Physio Flow during repeat exercise ergometer tests, spaced 
more than 2 days apart were 3.6% and 3.4% respectively.
There have only been three published studies comparing cardiac output results using the 
physioflow (Physioflow, Type PF05L1, Manatee, France) with invasive methods. 
Charloux et al (2000) (Charloux, A. et al 2000)evaluated the reliability and accuracy of 
the Physio Flow, at rest and during a mild constant effort performed in the supine 
position on 40 patients with either sleep apnoea syndrome or chronic obstructive 
pulmonary disease. The cardiac output was compared with results obtained by 
simultaneous direct Fick cardiac output measurements. Thirty-two patients were able to 
perform exercise, ranging from 10 to 50 watts. 72 cardiac outputs measurements were
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taken at rest and during exercise, and ranged from 4.34 to 14.84 L/min for Physio Flow 
and from 3.60 to 15.03 L/min for "direct" Fick. Under linear regression analysis, a 
correlation coefficient of 0.89 (p<0.001) was obtained for resting values and of 0.85 
(p<0.001) for exercising values of physioflow versus Fick cardiac output.
Comparison of the two techniques with the Bland and Altman method was also 
performed. At rest, the mean difference (Q Fick -QPF) was 0.07 L/min (95% 
confidence interval: -0.23, +0.27 L/min), which represents 0.29% of the mean resting 
cardiac output. The (QFick - QPF) difference did not vary significantly with the mean 
of (QFick, QPF). The limits of agreement were (-1.18, +1.32 L/min) at rest. Thus, in 
95% of paired measurements, the difference between Q Fick and Q PF was within a (- 
19%, +19%) interval. During a mild effort, the mean of the (QFick - QPF) difference 
was 0.26 L/min (2.44% of mean exercising cardiac output) with a (-0.17, +0.69 L/min) 
95% confidence interval. The limits of agreement during exercise were -2.16 and +2.68 
L/min (-21%, +26% of cardiac output).
In the second study, Richard et al. (2001)(Richard, R. et al 2001) performed a study 
during which a 1-minute step incremental exercise test was performed from rest to 
maximal peak effort by a group of 12 subjects. Each subject performed two comparable 
tests while their Q was measured by impedance cardiography using the new device ( Q 
Impl, QImp2). In a subgroup of seven subjects Q was also determined by the direct 
Fick method (QFick) during the second test. The mean difference between the values 
obtained by impedance (i.e. QIm pl-QIm p2) was -0.009 l.min"  ^ (95% confidence
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interval: -4.2 l.min \  4.2 l.min \  and Q ranged from 3.55 l.min'^ to 26.75 l.min"  ^ (n = 
146). When expressed as a percentage, the difference (Qlmpl -Q Imp2) did not vary 
with increasing cardiac output. The mean difference between the results obtained using 
direct Fick and the impedance method was not significant at rest (0.07 L-min'\ i.e., 1%) 
and during steady state exercise [0.26 L-min'\ i.e., 2.78% (95% confidence interval: - 
27.44%, 21.78%]. In addition, they also reported that the direct Fick method was highly 
correlated with the impedance method during steady state exercise (r  ^= 0.79, P < 0.05, 
N = 40 and during incremental testing (r == 0.94, P < 0.01, N = 50).
In a third study, Bougault et al (2006) examined whether the Physio Flow would still be 
reliable measuring cardiac output at maximal exercise in patients with COPD when 
compared to the direct Fick method. The difference found between Physioflow and 
direct Fick measurements were found to be 3.2 L/min ± 2.9 L/min (31 ± 21%) for 
maximal incremental exercise and 2.5 ± 2.1 L/min (25 ± 20%) for the strenuous 
intermittent work exercise test measurements, when analysed by the Bland Altman 
method (Bland, JM. et al 1986a)
Mourea et al (2001) presented data at an international meeting which analysed the 
results of measurements by the thermodilutional method and taken by the physioflow on 
107 ITU patient. They found that the results had a linear regression factor of r = 0.88 
(p<0,001), with an equation of Q physioflow =0.75 « Q t h e r m  +L33. The Bland 
Altman analysis found a bias o f-0.014 L/min.
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1.11.5. Cardiac Output Conclusion
In essence, the most reliable method for measuring cardiac output in human subjects is 
the invasive method of Direct Fick cardiac output. The Fick method is more reliable at 
rest then exercise. It requires a steady state of exercise and is quite invasive and 
intensive, Thermodilutional cardiac output measurements are less intensive, but under 
several circmnstances may be inaccurate when compared to the Fick method.
Non- invasive tests also have problems. Doppler echocardiography is hard to perform 
during exercise and the reliability of the Indirect Fick method is questionable.
Thoracic Bioimpedance may be an easy alternative non-invasive method of measuring 
cardiac output at both rest and exercise. It however requires several assumptions to 
made about the physiology of the thorax. The accuracy and reproducibility of the results 
obtained seem to depend on the equation and types of device used as well as any other 
pathological conditions the patient may have, and each impedance device has to be 
validated under varying physiological and pathological conditions.
The physioflow device has been validated under a few pathophysiological conditions. 
Under sub-maximal exercise it seems to perform well, but in certain patient groups may 
not be accurate. It has not yet been validated in patients with pulmonary hypertension at 
either rest or exercise but results in other patient groups suggest that it may be a useful 
device for the measuring of cardiac output, non-invasively.
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1.12. Aims
The work relayed to this thesis was undertaken as a review of the literature found that 
pulmonary hypertensive subjects have important changes in their pressure- flow 
relationships when exposed to various pharmacological agents or physiological 
manoeuvres, which are not demonstrated at rest (as per PVR).
Performing exercise may be difficult in patients with respiratory conditions, hence 
dobutamine is routinely used as a substitute for exercise in order to increase cardiac 
output in patients with cardiac disease. There have been no investigations as to whether 
in the diseased pulmonary vasculature, the response of the pulmonary circulation to 
dobutamine follows a similar pattern to exercise and whether dobutamine could be a 
reasonable substitute for exercise.
The main aim of this thesis was, by using a combination of high fidelity 
micromanometer tipped catheters to measure pulmonary artery pressures (PAP), and 
non-invasive cardiac output (CO) derived from impedance plethsmography in subjects 
with pulmonary hypertension (PHT), to investigate the pulmonaiy circulation.
There has been a paucity of infonnation relating to the pulmonaiy circulation under 
dynamic stress, in humans. This research would demonstrate the importance of 
investigating the pulmonary circulation under dynamic conditions and also the 
advantages of simultaneously measuring PAP and CO. It would also open further 
avenues of research, into whether subjects with different pressure-flow responses had 
differing prognoses and response to treatments.
106
This project aimed to:
1. Validate the use of the Physioflow 1 for measuring cardiac output in 
subjects with pulmonary hypertension.
2. Examine the viability of the production of pressure-flow plots by this 
method, for general clinical practice
3. Examine if in the subjects studied, whether there was any difference 
in pressure flow plots with respect to disease type or vasodilatory 
response
4. Examine if with cardiopulmonary exercise testing, we can discover a 
non-invasive surrogate of pressure-flow plots
5. Examine dobutamine as an alternative to exercise for pressure flow 
plots
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Chapter 2
Methods
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2. METHODS
2.1. Ambulatory Pulmonary Artery Pressure Monitoring
2.1.1. Equipment
The catheter was a 7 F micromanometer tipped catheter supplied by Gaeltec Ltd 
(Dunvegan, Isle of Skye) (Figure 2.1). This catheter is designed for multiple use and 
was gas sterilised in ethylene oxide. The data was recorded by a portable battery 
powered recorder, (Type MPR/2, Gaeltec Ltd, Dunvegan, Isle of Skye), (Figure 2.2.), 
before being downloaded into a Toshiba satellite 21 OCS laptop. Patients were supplied 
with a diary.
Figure 2.1: Gaeltec Pulmonary Artery 7F 
catheter
I #
Gaelté^
1—
t t
i - *  %
Figure 2.2. Gaeltec MPR2 
Portable Battery powered 
recorder
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2.1.2. The Software
The ambulatory pulmonary artery pressure monitoring programme was supplied by 
Gaeltec Ltd (Dunvegan, Isle of Skye), and required a computer running a DOS and 
windows 3.1 operating systems
2.1.3. Making a Prolonged Pulmonary Artery Pressure Recording
The portable recording box had new batteries for every recording and catheters was sent 
to TSSU for ethylene glycol gas sterilisation a minimum of 10 days before the planned 
date of catheterisation. On the morning of the catheterisation, the patient had a 8G 
French sheath inserted in the right internal jugular vein in the cardiac pacing room.
The computer, catheter and recording box were taken to the catheterisation laboratory. 
Following completion of the routine right heart catheterisation on the subject, the 
ambulatory Gaeltec catheter was removed from its sterile packaging, coiled, and placed 
in sterile saline for a minimum of two minutes. 0.4mls of air was injected into the port 
using an insulin syringe with the needle removed and end of the catheter was obseiwed 
under the sterile saline to check that there was no air leakage. The catheter was kept 
under the saline for a minimum of 2 minutes as the coating absorbed some fluid. The 
catheter was then connected to the recorder box that was then switched on and the 
programme started. On the monitor, the set up menu was entered and the legend 
'^‘calibrate pressure transducers’^ selected.
This offered a positive or negative pressure calibration. A ‘negative’ pressure 
calibration was always be used. Wlien this was selected, the menu required the recorder 
to be stopped. At this stage the non-sterile rubber tubing, stored with the computer, was
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connected to the port on the catheter and via a 3-way tap, to the port on the rear of the 
recording box. The 3-way tap was opened to air and return pressed. The system was 
then opened to air before the pressure calibration was continued. Return was then 
pressured again and 0 mmHg was established. The programme required a negative 
pressure calibration to be performed in which the 20 ml syringe is connected to the 3- 
way tap in communication with the recording box and the catheter, and the syringe was 
gently sucked until the programme read “calibration complete” and the recording box 
likewise. At this stage the catheter was ready for insertion into the patient.
2.1.4. Cardiac Catheterisation using the Ambulatory Gaeltec Catheter 
This was placed in the usual way in the proximal pulmonary artery. Care was taken not 
to advance the tip too far into the pulmonary circulation as wedging led to loss of trace 
as well as to complications. The tip of the ambulatory was placed no further distal than 
the transverse processes, preferably on the right.
Once the catheter was satisfactorily in place it was re-connected to the recording box 
then on the computer screen the “record” menu was selected and “start new real time 
recording” option selected. This showed a real time pressure tracing. There was no need 
to record at this stage. 0.4 mis of air was again injected into the port in the catheter to 
see if the preset 0 was satisfactory. So long as the value lay between plus or minus 32 
the error was suitable to be corrected later.
The catheter was now in a satisfactory position making an adequate recording, and the 
sheath was pulled back over the catheter to its end and left in position. This tended to 
displace the catheter further into the pulmonary circulation, therefore the catheter
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position was screened again before finally being secured with a suture at the point of 
insertion.
2.1.5. Starting a New Recording
The computer and recording box was required in order to start a new recording. The 
computer and the recording box were taken to the subject and were connected to the 
catheter. From the computer programme, “start real time recording” was selected from 
the “record” menu to check that the catheter continued to record satisfactorily. The 
recorder battery voltage was checked again at this stage using the selection from the 
same menu and if this was adequate, a new recording was started. The 4 megabyte 
RAM card was inserted in slot in the base of the recording box and “ start recorder” 
selected from the record menu. This cleared the memory card for a new recording and 
gave the time on the liquid crystal display that the new recording was started. At this 
point, this recording was being recorded both on the memory card and on the hard disc 
of the computer.
It was possible to view the actual trace at any time during this on screen using the “start 
new real time” record option in the record display and during the early period of the 
trace this was done on a number of occasions to check that 0 calibrations are adequate.
2.1.6. Troubleshooting
When 0 calibrations were not accurate i.e. injection of 0.4 mis of air results in the trace 
reading a figure different from 0, an “in vivo” calibration was performed. To carry this 
out, under the ‘record’ menu, the recorder was stopped, the balloon on the catheter was 
inflated and kept inflated with 0.4 mis of air. The “enter terminal mode” selection was
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then made from the record menu. At C prompt the instruction PZERO in continuous 
upper case was entered and return pressed. The programme instructed the user when the 
new 0 had been inserted into the catheter and at this stage the ambulatoiy PAP 
programme was re-entered. “Start new real time recording” was selected from the 
record menu and 0 rechecked viewing the screen trace. If this procedure was successful, 
the 0 calibration resulted in an adequate trace which records close to the actual 0 line 
when calibrated.
If the tracing was still not satisfactory, the above procedure was repeated (several times 
if necessary).
0 calibration was performed several times at beginning and end of the trace and 
intermittently throughout the recording.
The liquid Crystal display on the recording box indicated the time and the percentage of 
memory that had been used.
2.1.7. Event button
If the patient was put through a series of experiments, standing etc., the “event” button 
on the recording box was pressed at the beginning and end of these manoeuvres.
2.1.8. Completing a Trace
At the end of a ambulatory recording from the record menu the "stop recorder" option was 
selected and this selection confirmed using the mouse as requested by the program. 
The 4 megabyte RAM card was then removed from the recording box and inserted in the
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card reader device which was connected to the computer via the printer port.
On the "record" menu the "read data from PC card slot" was then selected and the patient 
file was transferred from the RAM card to the hard disc of the PC. This was then 
saved to the hard drive and patient details entered as appropriate. Under "comments", 
the catheter used was recorded as subsequent problems that could have occurred 
during recordings, and which may have been specific to individual catheters, 
could have been identified.
At no time during transfer of data from the PC card to the hard disc of the computer was the 
bottom option on the menu entitled "Initialise Card in PC slot" selected, as this would have 
wiped the data from the RAM cai'd. This data was backed up on floppy disc.
A section of the visible recorded tracing was highlighted on the screen, on the time scale 
covering a few hours. The program was then told to save the data first as a beat file, then as 
an average file and then finally the average file was saved as a comma delimited asc text file.
Windows 3.1 was started by typing in WIN and using excel the asc text file was 
imported as a delimited file. The comma delimits were selected when importing the 
file, and then the file was resaved as an excel file.
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2.1.9. Ending the Catheterisation
The ambulatoiy catheter was removed and hand washed in wann soapy water. The balloon 
was re-checked by it being placed under water again, 0.4 ml of air was injected into 
the catheter port and the balloon at the end of the catheter was checked for the 
escape of any air bubbles. The catheter was then be dried and re-connected to the 
recording box and a "new real time recording" was started luider the Record menu.
The end of the catheter was then placed in the grey top pressure chamber, the plastic 
tubing connected to the end of this chamber and, via a 3-way tap, to the 
sphygmomanometer. A syringe was then connected to the 3-way tap and a pressure 
(measured by the sphygmomanometer) was applied to the pressure chamber and hence 
the catheter. This pressure appeared on screen as a square wave trace with a given value 
at the side of the screen for the pressure being measured by the catheter. Thus for an 
applied pressure of 50 mmHg ideally the pressure wave on screen also recorded 50 
mm.
2.1.10. Analyzing a Trace
The original pressine trace was viewed on screen. This was accomplished by entering 
the Amb.PAP. program and the "review"' option was selected.
"Review" menu - "list load recordings", "list load from Disc C" commands were 
entered in sequence, and the patient trace selected and loaded. At this point the 
trace required to be corrected for any 0 drift.
Using the "Select page" option at the foot of the screen, the cursor was dragged to the 
beginning of the trace and the time corresponding with that was noted as the start time
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of the manoeuvre.
At this point, the trace was opened out to 1.03 min per page and using the page up/page 
down facilities the first of the 0 calibrations was brought onto the screen. The cursor was 
then placed on the middle of the 0 calibration and the value to the right of the screen was 
read, the actual measurement which was made at that time. At this stage, if there was 
any error inherent in the catheters calibration, revealed against the true pressure 
applied in the pressure chamber with the sphygmomanometer, then this was corrected.
2.1.10.1. Y axis change
The CTRL F9 keys were pressed simultaneously and a window appeared on screen, 
showing "Channel normalizing procedure". The carriage return was then pressed, and 
when "Enter value at cursor" appeared, 0 was entered. Return was then pressed and 
the computer would request, "Enter the output observed output observed for a 
thousand unit step". The eiror noted against the measured pressure of 50 was calculated 
for a unit step of 1000 (e.g. a reading of 40 mm against a measured pressure of 50 
would require 800 to be entered). Carriage return was then pressed and the 
"continue" option on the bottom line selected and the channel normalized. The trace 
was then re-checked at the first and last 0 points to check that these were on the 0 line.
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Figure 2.3: Example o f Zero calibration points, on raw data 
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If this was not the case, then in addition to the correction being inserted, the trace 
was also required to be levelled. The cursor should once again be placed on the first 
0 calibration, and the F9 key pressed. The box on screen indicated that the channel 
leveling procedure was being used and that the cursor indicated the first point to be 
included. Carriage return was then pressed and the cursor moved to the next 0 point, 
F9 was pressed again and so on until the end of the trace. Once the last 0 had been
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selected using F9, Shift F9 was pressed and the entire trace was levelled. At this stage 
the trace had been corrected and levelled and was ready for further analysis.
2.1.11. Further Analysis
The "analyse" option was selected and from the review menu make "beat by beat" file 
selected. The programme analysed the entire trace beat by beat removing any 
artefacts. At the end of this procedure the beat file had been created and this was stored 
on the hard drive using the patient's name followed by the suffix BT.
Once the beat-by-beat file had been created, the next option "Start new average file" was 
selected and the procedure was repeated. The prograimne selected every 16 beats of 
information and created a new average file. This again was stored on the hard disc 
with the patient's name and suffix AV. To analyse the trace further the "use average 
data file" option was selected.
2.1.1 LL Creating an ASCII File
The "use average data" file was selected and the average data appeared on screen. The 
trace was opened out to, 1.4 minutes per page and using the select page option the cursor 
dragged to the beginning of the trace. Using the mouse the trace was then marked as 
close to the beginning as possible. The screen then read that the trace has been marked 
for analysis and a 2nd point was selected. Using the select page option the cursor was 
dragged to the end of the file and the 2nd point marked at the end of the trace. Under the 
"analyse" option Create ASCII file appeared and was selected. The programme created 
an ASCII file for the entire average trace and this was stored again to the hard drive 
with the patient's name and suffix ASC.
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For statistical analysis the ASCII files were imported into an Excel file, as a delimited 
file, and comma’s selected as the delimiter.
On Excel, The first column was time (1.0= 24hours), 2"  ^DPAP, 3^  ^MPAP, 4* SPAP,
5^ Heart rate, 6^  ^ SaOi, 7^ '^ HR from SaOi monitor, and the 8^ was an ECG and 9^ ^
EVENTS.
Time was converted to hrs min secs by changing cell format on excel.
Each set of data was a 16 sec average. The time was as a decimal fraction of a day but 
was converted to hours, minutes and seconds by changing the format of the cell to 
00 :00:00.
2.L I 1.2. Backup
This data was backed up using the Windows 3.1.
Windows 3.1 was started by typing in WIN. A back up of the excel, ASCII and the !
raw data files was made. The raw data was found in the subdirectories in the |
ildirectory PAPECGO |
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2.2. Physioflow
2.2.1. Physioflow Set-up and Use
The following is a very brief summary of the manual and details from correspondence 
with the designer of the physioflow 1, with regards to the calibration phase, assessing 
adequacy of signal acquisition and trouble shooting to improve results.
Device: Physio Flow PF-05 Labi, Manatee, France
Software: software version PF-1.05 for Windows 95/98/Me/XP/2000 (32-bits)
Laptop: Sony HEP R600P Pentium IV 850MHz
Figure 2.4a & h: (a) Physioflow device, connected to computer and leads
Figure 2.4a & b: (b)Device alone
g-WB!
0/06 '20 )3
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The Physio Flow 1 is a non-invasive cardiac output measurement device that can be 
used in patients at rest or under exercise.
The user manual is available to download form the World Wide Web at 
http://www.physioflow.com/download/free/enmanlG4.zip.
2.2.2. Connections, Device & Subject
The subject was connected, using pre-gelled ECG electrodes. The ambu Blue sensor SP 
(Ambu, Copenhagen, Denmark), was an Ag/Al wet gel electrode, ideal for medium term 
stress testing.
The electrodes were placed on the thorax in the shown figure 2.5. Two electrodes are 
used to monitor ECG in order to measure the heart rate. Four electrodes were used to 
monitor the impedance signal.
WHITE
BLUE
RED
GREEN
BLACK
(neutral)
ORANGE
Figure 2.5: Electrode positions for Physioflow 1 
device
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The exact position of the impedance electrodes was not supposed to be critical provided 
that one pair is on neck base, and one on thorax base. Adjustments, as mentioned later, 
were often found to be useful.
During bicycle exercise, VI ECG electrode was positioned on the manubrium sterna, 
the upper impedance electrodes were not placed on the sternocleidomastoid muscle 
(neck basis), and the lower electrodes were not placed over the over abdominal muscle. 
Cable wires were fixed on patient’s skin with adhesive tape.
2.2.3. Pre calibration requirements
Pre calibration is described in detail in the manual.
2.2.4. Calibration Phase
Instructions appeared on the Calibration Wizard screen, which were followed. 
Calibration was particularly important as reliability and reproducibility depended on it. 
After the best signal stability possible was achieved, it was performed on 60 cycles (the 
standard profile is 30 cycles). The subject was requested to remain still and to breath 
normally. A simultaneous blood pressure reading was taken for basal reference values.
122
Wudid
PabcM Boyiuÿ sti. not speaidnjt. 
■id biTNtbmy nonualy
CMtrM I
Figure 2.6: Calibration Phase
ECG and impedance metric signals were displayed on the screen from the start of this 
phase and it was important to ensure that they are reproducible, stable, and without 
artefacts or interference (figure 2.6).
It was also vitally important that the heart rate results were accurate, by reviewing the 
cycle beat by beat on the dE/dt signal (light blue digits corresponding to heart rate and a 
dark blue signal waveform). Similarly, it was important that verification that the 
characteristic points of the dZ/dt (green) signal were correctly detected, represented by 
the presence of red and yellow squares on the signal, the red at the maximal peak and 
the yellow a little time after the maximal trough in the waveform. The yellow square in 
dZ/dt was also checked to ensure that it did not appear at the end of the heart cycle.
If signal was satisfactory, then “ Calibration ” was clicked in order to proceed
123
When calibration was completed (60 heartbeats), systolic and diastolic blood pressure 
was entered. Once the calibration results were verified, they were accepted and 
monitoring was started.
If the calibration looked wrong (bad quality of signal, aberrant values), calibration was 
restarted by entering (« Retry »).
In order to improve calibration and signal, other adjustments were possible. It was 
possible to increase the calibration cycle to include a larger number of cycles, by 
entering the profile menu, and entering calibration window. By using this menu, it was 
also possible to adjust the acquisition signal from a default of 20 cycles before 
acquisition of data, to 1 cycle (which was required for the pressure-flow experiments). 
When necessary, entering the analysis menu and entering the signal setup submenu 
allowed the increase or decrease of sensitivity of both the analysis of the ECG and the 
impedance (Z) signals.
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2.2.5. Monitoring/Recording Phase
Figure 2.7: An example of the 'Monitoring Screen \ with the current values for heart 
rate (HR, bpm), stroke volume (SV, ml), cardiac output (CO, L/min) and cardiac 
index (Cl, UminW), as well as graphical representations of these values on the y  
axis against time on the x axis. Also on this monitoring screen is dE dt (differential 
of the ECG signal versus time) and dZ/'dt (differential of impedance signal versus 
time)
The default monitoring screen (HR = Heart Rate, SV = Stroke Volume, CO Cl = 
Cardiac Output/Index (cardiac index is cardiac output divided by body surface area), 
SAP, MAP, DAP (systolic/mean/diastolic arterial blood pressure)) was left for the 
studies as in figure 2.7.
During the monitoring, events were marked by pressing SPACEBAR. A window 
appeared in which details of commencement or discontinuation of an experimental
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protocol were noted. Pressing “enter” validated this event and a vertical line appears on 
the screen. The recording was completed by clicking on “ End of acquisition ” .
The colour squares on the dZ/dt signal (red to yellow) were checked to see if one could 
draw a curve oriented downwards (during systolic phase), as shown in figures 2.8 a, b & 
c.
Figure 2.8a Figure 2.8b
Figure 2.8b
Figures 2.8 a, b &c: Examples of acceptable signal for physioflow cardiac 
output measurements, showing dE/dt (differential of the ECG signal versus 
time) and dZ/dt (differential of impedance signal versus time).
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2.2.7. Poor Signal & Possible solutions
Despite the measures taken, often the acquisition signals were of poor quality. The 
following are examples, with the solutions used.
In figure 2.9a, there was no systolic curve during dZ/dt and the colour squares were not 
regularly plotted. The possible solutions were to clean and shave the skin again, replace 
impedance electrodes, and reposition impedance electrodes (on the same horizontal 
level).
Figure 2.9a:Poor quality signal received by physioflow device
In figure 2.9b, there was an artefact on dZ/dt curve occurring during QRS. The possible 
solution to this was to clean and shave the skin again was to replace impedance 
electrodes, and reposition impedance electrodes (on the same horizontal level).
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Figure2.9b: Another example of a poor quality signal received by the physioflow device
Figure 2.9c demonstrated a trace which had electrical interference with static electricity 
on the ECG.
The solution to this was if possible turn off source of static electricity. In addition, it 
was important to check that no physioflow wires were crossing other wires (e.g. the 
micromanometer catheter).
In figure 2.9d, the majority of QRS were no properly detected and heart rate was wrong. This 
problem could often occurs in case of bundle branch block or pacemaker patients (QRS large 
and of low dynamic, and in this case the solution was to increase ECG sensitivity as 
previously mentioned. An alternate solution would have been to reverse the ECG leads.
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Figure 2.9c: third example ofpoor quality signal from physioflow device
Figure 2.9d: Final example of poor quality signal
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2.2.8. Other tips and signal ways of improving signal quality 
During the studies, one came across other problems and solutions
1. It was found that the use of Q & SP blue sensor electrodes or other short & 
medium term electrodes, were inadequate for the study. We switched to using 
long term silver oxide gel electrodes.
2. Avoiding pressing down on gel part of electrode during placement
3. When the ECG downward peak was HIGH the ECG electrodes were inverted
4. When ECG recognised too many points, the threshold was DECREASED, & if 
too few it was INCREASED.
5. The most important points was to review waveform were the red and yellow 
boxes on the dZ /dt. These should have been in systole ie after QRS ( as shown 
in figure 7) with the curves of the dZ/dt falling after the red box, before going up 
to the yellow box.
6. To improve signal occasionally electrode placement on the back of the neck was 
tried (less skin folds).
7. Occasionally the electrodes were placed onto the lower rib cage (esp during 
exercise as less muscle interferance).
8. The blood pressure measured during calibration was as accurate as possible, as 
any error here would have been square rooted for cardiac output, (ie error blood 
pressure error 5%, cardiac output error will be 10% error (1.05 x 1.05) in cardiac 
output.
9. Entering the analysis menu and entering the signal setup submenu allows the 
increased or decreased of sensitivity of both the analysis of the ECG and the 
impedance (Z) signals.
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10. We improved initial calibration by calibrating over more cycles, as mentioned 
previously (60 compared to 30).
11. And finally if due to time constraints it was not possible to adjust analysis for 
reliable analysis (red and yellow box placements), but the dE/dt & dZ/dt signals 
were reliable, it was possible to run the physioflow simulator as described later 
and an adjust analysis parameters at a later time.
P o i n t  o f  s t a r t  o f s y s t o l e ,  
c o r r e s p o n d i n g  t o  d o w n w a r d  
i n f l e c t i o n  o f  d E / d t  c u r v e  
( b l u e  l ine)
Figure 2.10:Point o f start o f  systole o f  dZ dt signal, corresponding to the maximum point o f  the 
negative inflection o f dE/dt signal
Also note if right ventricular hyperterophy, this may lead to changes in the Z curve with 
the systolic wave being smaller then the diastolic wave (figure 2.11)
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Small systole high diastole
Figure 2.11: Change in Z curve seen with right ventricular hypertrophy, with small systole and large 
diastole peaks.
2.2.9 Reviewing acquisition
Instructions are as per the manual available on 
http://www.physioflow.com/download/free/enmanl04.zip.
2.2.10. Physioflow Simulator Operation
If the impedance wave analysis had been sub optimal due to difficulties in adjusting the 
wave form analysis parameters during the experiment the entire recording could have be 
reanalysed under different settings by using two computers, one playing the recorded 
information and the other analysing it. However there were two problems with this, the 
computers would analyse this as a continuing loop and the initial calibration data was 
not recorded, so calibration had to be performed on the actual previously recorded data 
and thus making it difficult to ascertain what time periods in the new analysis 
correspond to the old analysis. This process was not undertaken during this study. 
Instructions on how to perform this were obtained at the time this additional software 
was obtained.
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2.3. Pressure-Flow Experiments
The experiment was explained to the patient. As previously described the APAP 
catheter was inserted into the right (or left if not possible) pulmonary artery via a main 
central vein.
The ambulatory catheter was attached to the ambulatoiy box and this to the laptop 
computer. The computer is APAP progiamme was switched to real time mode, in which 
the pulmonary artery wave fonn can be monitored. Several zero calibration manoeuvres 
were performed (as described previously). The physioflow electrodes were then 
attached and the machine underwent a calibration period (as described previously). The 
machine’s parameters were adjusted to save data for each cardiac cycle and were 
adjusted in order to optimise the impedance waveform
Then several readings of the time on the physioflow computer, the laptop for APAP and 
the APAP box were taken in order to later match the data from the APAP and 
physioflow devices.
The subject was placed the gas inhalation mouthpiece in their mouth. The gas delivery 
system was as described in chapter 2.5. The subject was given time to become 
comfortable with the device, whilst on air. Once comfortable, the experiment began, 
•with the patient inhaling a gas whilst at rest, either air, Oxygen at 15 l/min or a 
combination of NO at 40ppm and oxygen at 15 l/min.
After 5 minutes of acclimatization, the patient was asked to start raising their legs 
alternately, at a rate of 1 leg rise per second, and for a total of 3 minutes or until they
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tired out. Then prior to the next exercise test, the subject rested whilst inhaling air or 
oxygen as desired for 3 minutes, before repeating the entire procedure again, until all 
three sets of gases were given. The order in which the gases were given was selected at 
random prior to the experiment.
The data was then analysed as described in chapter 2.7.
Subject
Blood pressure 
monitor
NOxBOx
MPR/3 pulmonary 
artery catheter
Physioflow 1
&
9
Figure 2.12:Pressure~Flow experiments. Patient inhaling experimental gas, whilst 
attached to the physioflow cardiac output monitor, a blood pressure monitor and the 
micromanometer tipped pulmonary artery catheter and recorder.
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2.4. Gas Delivery System
2.4.1. Materials
Magill-Mapelson A 1.6m with 2L reservoir bag (Intersugical Ltd, Berkshire, UK). 
Assorted Male to female connectors of 22 & 30 sizes, with T junctions and adaptors 
from Nitric oxide monitoring kit (Intersugical Ltd, Berkshire, UK).
Flextube (Elephant tubing) 22mm (Intersugical Ltd, Berkshire, UK).
Oxygen bubble tubing (UN 881) 3mm, (UHS, Enfield, UK)
NoxBOx 11 (Bedfont Scientific, Kent, UK).
Nitric oxide gas cylinder (LindeGas, UK Ltd)
Air gas cylinder (LindeGas, UK Ltd)
Oxygen via piped hospital oxygen supply, (BAG Ltd)
Adjustabk flow 
VB.1^  fbr nitric 
oxide ibw
NOxBOx
Oxygen
siçpty
Air
cylinder
Nititc
oxide
cylinder
Figure 2.13a: Gas delivery system, used to deliver nitric oxide & air. Or air 
alone, or when attached to hospital oxygen supply, oxygen or nitric oxide and 
oxygen
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Figure!. ISb: Gas delivery system. The entire supply piping
S2 *
k'SXMJê&i:
Figure 2.13c: Gas delivery system. The supply piping
Magill-Meçielson A 1.6m with2L reservoir bag
___________________ A ____________________
Nitric Oxide 
supply tubing
Sampling 
tubing to 
NOxBOx
Standard 2 4F 
Elephant tubing V alve
Air/Oxygen 
simply—15LAnin
Gas supply to 
subjects mouth 
(via mouthpiece)
2L reservoir bag
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The gas delivery system, was the same system used clinically at the Scottish Pulmonary 
Vascular Unit between 2001 & 2004, and was made up of a basic Magill-Mapelson A 
1.6m with 2L reservoir bag system, attached to a further 22mm flextube, via a nitric 
oxide adaptor kit (Figure 2.14 a-c). Air or oxygen was supplied at the tail end of the 
system, at 15 L min"\ Nitric oxide was also supplied here. The mixture of gases was 
thoroughly mixed when it reaches the middle section, with the 2L reservoir bag. The 
concentration of NO is sampled here. A further 1.6m downstream, the subject inhaled 
the mixture. They also exhaled through the system, and the gas escaped through the 
escape port of the APT 60cni^ relief valve. The valve was set at mid pressure in order to 
cause some back flow through the system, and mixing of gases at the reservoir bag 
point.
The sampled gas was tested by the NoxBOx II, and after a few minutes of calibration 
time, the flow of NO was adjusted by the adjustable flow valve, in order to obtain the 
desired NO concentration (figure 2.14a-c). The Patient inhaled the gases, via a rubber 
reusable mouthpiece (sterilised by Milton sterilisation solution). This mouthpiece fitted 
tightly in the mouth, between the teeth and the lips, to form a seciue seal, whilst nasal 
breathing was prevented by the use of standard nasal prongs. Between the mouth piece 
and the main delivery system was a standard microbial filter.
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2.5 Matching APAP and Physioflow data
During an experiment, on at least three occasions the corresponding time points for the 
APAP machine and the physioflow machines were noted.
Using this information of equivalent time points noted down during the experiment, the 
difference between the times were calculated, and the average of this was then used to 
allow conversion of APAP times to physioflow times.
For instance if 09:33:22 (Hours:minutes:seconds) was the APAP time, and 00:01:02 
was the physioflow time, the difference would have been 09:33:22 - 00:01:02 giving 
09:32:20. This would then be used to convert all other APAP times to physioflow times 
(ie APAP = 09:33:38 the equivalent physioflow time would be = 09:33:38- 09:32:20 
giving 00:01:18.
Then the time periods corresponding to the APAP data was marked on the physioflow 
data, and the averages from this time period until the next time period were calculated 
for the physioflow data (as previously mentioned the APAP data time period correspond 
to the average data over the preceding 16 seconds). For instance data over the time 
period 00:01:02 to 00:01:18 would be averaged.
This data would be then added to the corresponding APAP data and would allow further 
analysis to be undertaken.
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2.6 Study groups, Recruitment and Data gathering
Subjects were recruited from all patients attending the Scottish Pulmonary Vascular 
Unit, (Western Infirmary, Glasgow, UK), between October 2001 and July 2003, all of 
which were due to undergo invasive investigations for suspected pulmonary 
hypertension. Bioimepedance data (n=30, for chapters 3-9) and those with combined 
bioimpedance data and micromanometer tipped data (n=24, from 2001-2003, for 
chapters 4-8). Figiues 2.14a & b demonstrate the recruitment pool for the studies, and 
the other studies patients were being recruited for simultaneously.
The inclusion and exclusion criteria were as follows.
Inclusion criteria
1) Primary or secondary pulmonary hypertension at echocardiography 
and/or right heart catheterisation
2) Listed for right heart catheterisation for purposes other than this study
3) Age 18-80
4) Informed consent
Exclusion criteria
1) Exercise capacity limited by disease other than pulmonary 
hypertension
(e.g. musculoskeletal disorder)
2) Prostacyclin infusion via Hickman line.
3) Left-sided heart disease including significant aortic or mitral valve 
disease, cardiomyopathy, left ventricular failure or coronary artery 
disease limiting exercise tolerance.
4) Nursing or pregnant women.
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The ‘normal’ patients recruited, were all symptomatic, and initial investigations at 
referring hospitals were suggestive of pulmonary hypertension but after investigating at 
the unit, they were found to have no obvious disease pathology.
All studies, as well as routine clinical tests were performed over a period of a week, as 
demonstrated in figure 2.15. Spirometry, CT scanning, echocardiography and 6-minute 
walk test were all performed by the regular NHS staff. The right heart catheterisation 
and routine haemodynamic measurements were performed either by Dr R. Syyed, 
Professor A.J. Peacock or Dr H. Mortimer. The simultaneous thoracic bioimpedance 
and thennodilutional cardiac output data were noted by either. Dr R. Syyed, Dr H. 
Mortimer or Sister A. Crozier. The thoracic bioimpedance device setup and the insertion 
of the ambulatory pulmonary artery catheter were perfonned by Dr R Syyed. The 
thoracic bioimpedance device was left to run during the routine haemodynamic tests. If 
Dr Syyed was performing the routine haemodynamic investigations, and the thoracic 
bio-impedance signal was lost, it was not possible to re-set this device. All other 
experiments were performed by Dr R. Syyed. All data processing and analysis was 
performed by Dr R. Syyed.
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MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY
AM Admission from any part of 
Scotland
Blood tests 
Pulmonary 
function tests 
6-minute walk 
test
Further discussion 
of research +/- 
consent 
MRl scan 
Oenetic bloixi tests
Insertion of 
catheter sheath 
into right internal 
jugular
Test set up o f 
cardiac output 
measurements
Pressure-Flow
Study/
Dobutamine
pressure-flow
study/ other
studies*
(Removal of
catheter)
Commencement
of treatment
PM Clerk in /  /  first discussion of 
research
HR-CT & CT-PA 
Further 
discussion of 
research +/- 
consent
Echocardiography Routine 
haemodynamic 
measurements & 
vasLxlilator study 
Non-invasive 
cardiac output 
measurements
(Cardiopulmonary 
Exercise Test)/ 
erect pressure- 
flow study 
(removal of 
catheter)
HOME
Discussion o f 
results with 
patient
Pressure-Flow
Study/
l>>butamme
pressure-flow
study/ other
studies*
Overnight
ambulator)
catheter study
Figure 2.15: Timetable ofprocedures for subjects during their 1 
week admission. Routine clinical tests are labelled in black, and 
research in red
2.7 Data analysis
Data are expressed as mean ± S.D. The tests used varied between experiments. The 
student t-test was used for chapter 3. using SPSS-Vs 14.0, Bland Altman analysis 
(Bland, JM. et al 1986b) for Chapter 4. Multivariate analysis was performed in chapter 
3, but due to heterogeneity and small number of subjects recruited, and the interrelated 
variables like pressure variables, the analysis may not be statistically robust.
For chapters 5-8, the Poon test to combine data was used (Poon, C. S. 1988) and this 
data was further analysed by general linear regression analysis (SPSS vs 14.0). Linear
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regression analysis was used to produce histograms and normality plots, as well as the 
values and confidence intervals of the slopes and intercepts of the lines obtained. Initial 
assessment of the probability of the linearity of the plots was done by visually 
reviewing the scattergrams of the plots and the histogram and normality plots of the 
residuals. Further assessment of the whether the likelihood of the linearity of the plots 
of paired data was by the ANOVA test of linearity where possible. A test of the 
usefulness of the plots was attempted by performing the ANCOVA test, a test of 
likelihood of parallelism, on the data, comparing air with nitric oxide / oxygen 
combination, air with oxygen and oxygen with the nitric oxide / oxygen combination.
2.8 Ethics
Ethical approval was provided by the West Ethics committee. North Glasgow NHS 
University Trust. All subjects gave informed consent for thoracic bioimpedance cardiac 
output measuiements as part of their clinical evaluation for suspected pulmonary 
hypertension.
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Chapter 3
A Comparison of Cardiac Qptput Measured by Thermodilutional Methods & by 
the Physioflow 1 Thoracic Bioimpedance Device in subjects being investigated for
Pulmonary Hypertension
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3.1 Introduction
For years, the clinical gold standard test for measming cardiac output has been by the 
thennodilutional method. This has been widely validated against gold standard 
experimental methods.
With regards to the use of the thennodilutional method in subjects with pulmonary 
hypertension, its accuracy has been questioned, but it is now in routine use. In a number 
of studies, it has been shown to overestimate cardiac output as compared to Pick and 
dye dilutional methods, the experimental gold standards (Branthwaite, M. A. et al 1968; 
Hsia, C. C. et al 1995; Mackenzie, J. D. et al 1986; Russell, A. E. et al 1990; van, 
Grondelle A. et al 1983) at rest and during exercise.
Since 1966, (Kubicek, W. G. et al 1966) cardiac output has been monitored 
experimentally by measuring the electrical impedance changes across the thorax. There 
have been several equations and devices developed over the past 30 years to measure 
this, with varying but improving accuracy (Bernstein, D. P. 1986; Sramek, B. B et al 
1983). The accuracy, reliability and reproducibility of these devices in clinical practice, 
however have not been good enough to contemplate their use either as a replacement or 
an adjunct to current clinical gold standard methods (Warburton, D. E. et al 1999).
Recently a new device, the Physioflow 1 (Physioflow, Type PF05L1, Manatee, France) 
bioimpedance device, was developed after technical improvements occurred in the 
hardware (a new generation of analog technology allows the Physio Flow to improve 
signal filtering and stability and provide better data processing), and the basic equation 
has been adjusted. The equation has been modified in order to overcome the difficulties
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in evaluating blood resistivity (p), the distance between recording electrodes (L) and 
baseline impedance (Zo) used in the Kubicek and Sramek-Bernstein equations. There 
have been several studies investigating the accuracy and reproducibility of the 
physioflow in clinical practice. Charloux et al (2000), investigated a number of subjects 
with respiratory conditions (COPD, n=^ 26, sleep apnoea, n=14) at rest and during 
exercise, and found that a strong correlation was obtained between the physioflow 
determined cardiac output and the Pick derived cardiac output values, of 0.89 (p<0.001) 
at rest and of 0.85 (p<0.001) during exercise. Similar results have been found by both 
Bougauit et al (2005) and Richards et al (2001). The physioflow seems to be more 
accurate in a clinical practice when used in a number of clinical conditions and 
situations compared to older devices.
This device has not been validated for use in subjects with pulmonary hypertension, and 
a study to investigate its usefulness in this was undertaken.
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3.2 Methods
3.2.1. Data Subjects
All the subjects were patients at the Scottish Pulmonary Vascular Unit between October 
2001 and July 2003, who had been admitted for routine investigations, which included 
measurement of thennodilutional cardiac output, of their suspected pulmonary 
hypertension. There were 30 subjects examined on 33 occasions, and with 32 sets of 3 
cardiac output measurements undertaken whilst breathing air, (table 3.1, n^-33), 7 whilst 
breathing oxygen, 12 breathing a nitric oxide and oxygen combination (NO/O2) and 7 
whilst exercising (table 3.2). There were 13 males & 17 females. The mean (±S.D.) age 
was 58.2 (± 13.8) years. The general demographics are seen in table 3.1 & 3.4.
4 subjects were normals without pulmonary hypertension and the other 26 had 
pulmonaiy hypertension due to the following causes, 3 with COPD, 6 with Connective 
tissue disease (CTD), 1 due to portopulmonary (portopulm.) hypertension, 7 due to 
idiopathic pulmonary arterial hypertension (IPAH), 6 due to chronic thromboembolic 
pulmonary hypertension (CTEPH) and in one subject, at the time of the study the exact 
cause of pulmonary hypertension was still to be established. The demographics for the 
disease groups, and for the activity undertaken are given in tables, 3.1 and 3.4a & b.
Pulmonary and right heart haemodynamic data obtained via the right heart 
catheterisation, was available for all the subjects (table 3.4a), and spirometry data 
available in 14 patients (table 3.4b)
148
Table 3.1
Subject
Number
Initials Age Sex Cardiac Output on Air 
Thermodilutional 
(L*min
Cardiac Output on Air 
Bioimpedance 
(L*min’’^)
Diagnosis
1 M,C 55 F 8.1 7.6 normal
2 i,c 40 F 3.7 5 normal
3 B,R 37 F 5.6 5.8 normal
4 L,G 52 F 5.8 6.5 normal
5 G,C 49 M 5.5 10.2 EPAH
5 G,C 50 M 4.6 4.9 IPAH
5 G,C 50 M 4.2 5.1 IPAH
6 W,F 67 M 3.3 3.8 IPAH
7 E,M 73 F 3.7 8.7 IPAH
9 S,S 45 F 4.5 8.1 IPAH
10 D,H 64 F 3.3 3.5 IPAH
11 H,C 37 F 4.3 4.6 IPAH
12 M,Y 37 F 3.4 4.3 IPAH
13 R,C 54 F 3.6 3.6 CTD
15 I,P 46 F 4.4 5.1 CTD
16 J,P 59 M 2.4 3.8 CTD
17 K,S 62 F 3.9 4.1 CTD
18 J,R 74 F 2.6 4.4 CTD
19 E,K 73 F 2.6 2.7 CTD
20 J,F 71 M 3.7 5.1 CTEPH
21 S,0 74 M 5 9.1 CTEPH
22 A,C 62 M 4.8 4.4 CTEPH
23 A J 35 F 5.3 &25 CTEPH
24 C,A 46 M 4.4 5.5 CTEPH
25 E,R 67 F 3.6 4.3 CTEPH
28 W,F 71 M 2.6 4.1 ILD
29 D,B 72 M 5.1 6.4 ILD
31 R,McD 60 M 2.2 5.1 COPD
32 M,T 81 F 4.1 5.2 COPD
33 H,J 77 M 2.6 4.4 COPD
34 S,C 48 F 10.7 5.1 portopiilm
35 M,E 76 F 3.6 2.7 unknown
Mean 58.2 4.3 5.3
S.D. 13.8 1.7 1.8
Table 3.1: Details o f subjects studied concurrently with both the thoracic impedance 
cardiac output Physioflow 1 (Mantanec, France) device and a standard swan-gantz 
thermodilutional pulmonary arteiy catheter (n^30). All subjects for the thesis have 
been allocated an individual number, 1 to 37. Details o f age, sex and underlying cause 
o f pulmonary hypertension, as well as cardiac output measurements (Lmin^) for both 
methods measurements o f subjects at rest, supine inhaling air are listed
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Cardiac Output on Cardiac Output on Cardiac Output on 
Exercise
Oxygen Nitric Oxide (L rain’^ )
(L min"^ ) (L min ')
Number
Thermo­
dilutional
Bio­
impedance
Thermo­
dilutional
Bio­
impedance
Thermo­
dilutional
Bio­
impedance
1 9 9.9
3 11.3 11.6
4 10.8 11
6 4.5 4.5
7 4.1 8.1
9 4.8 8.9
10 3.2 3.3
13 3.8 4
15 4.8 6.8
16 2.4 4.1
17 3.3 4.3 4 4.5
19 2.7 3
20 3.5 4.8 3.4 4.8
21 7.5 16.4
22 4.5 4.6
23 5.7 7.1 6.7 7.6
24 4.6 5.7 4.5 5.5
28 3.1 4.1
29 4.7 6 5.1 6.5
32 3.7 3.8
33 3.1 5.3
Mean 4.72 4.74 4.16 5.56 7.54 9.47
S.D. 0.66 1.00 0.90 1.69 3.12 4.23
Table 3.2: Details o f cardiac output measurements (L»min^) studied concurrently whilst 
inhaling oxygen, nitric oxide and during exercise, from both the thoracic impedance 
cardiac output Physioflow 1 (Mantanec, France) device and a standard swan-gantz 
thermodilutional pulmonary artery catheter. All subjects were supine. Subject numbers 
corresponds M>ith subjects in table 3.1.
Table 3.3a
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Number Initials
Ox’
Thermo­
dilutional
Change
(Basf
/gen
BiO“
impedance
in Cardiac ( 
sline is Care 
(L‘ii
Nitric
Thermo­
dilutional
Dutput from E 
iac Output 01 
iin-i)
Oxide
Bio­
impedance
iaseline 
1 air)
Exe
Thermo­
dilutional
rcise
Bio­
impedance
1 M,C 0.9 2.3
3 B,R 5.7 5.8
4 L,G 5 4.5
6 W,F 1.2 0.7
7 E,M 0.4 -0.6
9 S,S 0.3 0.8
10 D,H -0.1 -0.2
13 R,C 0.2 0.4
15 I,P 0.4 1.7
16 J,P 0 0.3
17 K,S -0.6 0.2 0.1 0.4
19 EJK 0.1 0.3
20 J,F -0.2 -0.3 -0.3 -0.3
21 s ,o 2.5 7.3
22 A,C -0.3 0.2
23 A,T 0.4 0.85 1.4 1.35
24 C,A 0.2 0.2 0.1 0
28 W,F 0.5 0
29 D,B -0.4 -0.4 0 0.1
32 M,T -0.4 -1.4
33 H,J 0.5 0.9
Mean -0.14 -0.14 0.22 023 2.29 332
S.D. 0.38 0.70 0.40 0.43 2.24 238
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Table 3.3b
Number Initials
Pe
Oxy
Thermo­
dilutional
;rcentage oh 
(Base
gen
Bio­
impedance
ange in Care 
line is Card 
(“/
Nitric
Thermo­
dilutional
iiac Output 
ac Output 0  
6)
Oxide
Bio­
impedance
from Baselii 
n air)
Exei
Thermo­
dilutional
le
•cise
Bio­
impedance
1 M,C 11 30.3
3 B,R 101.7 100
4 L,G 87 693
6 W,F 317 4.5
7 E,M 9.9 -6.9
9 S,S 6.7 8.9
10 D,H -4.8 -5.7
13 R,C 6.7 11
15 I,P 9.9 333
16 J,P 0 7.9
17 K,S -15.5 4.9 2.9 9.7
19 E,K 2.3 11.1
20 J,F “6.1 -5.9 -8.1 4.8
21 S,0 51 80.2
22 A,C -4.9 4.6
23 A,T 6.3 7.1 25 21.6
24 C,A 4.5 3.6 3 0
28 W,F 17.3 0
29 D,B -8.4 -6.3 -0.7 1.6
32 M,T -9.8 -26.9
33 H,J 19.2 20.5
Mean -Z99 -Z26 6.07 4.43 41.12 4938
S.D. 11.50 14.44 10.99 5 09 3933 3157
Table 3.3a & b: Details o f change (a) and percentage change (b) in cardiac output 
measurements studied concurrently whilst inhaling oxygen, nitric oxide and during 
exercise, from both the thoracic impedance cardiac output Physioflow 1 (Mantanec, 
France) device and a standard swan-gantz thermodilutional pulmonary artery catheter 
as compared to baseline values at rest, supine, breathing room air. Actual cardiac 
values are listed in tables 3.1 and 3,2. Subject numbers corresponds with subjects in 
table 3.1.
Table 3.4a
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Number Initials MPAP
(mmHg)
SPAP
(mmHg)
DPAP
(mmHg)
PAPP
(mmHg)
RAP
(mmHg)
PVR
( i m i l - l g  / L  m i n ' )
PAWP
(mmHg)
1 M,C 17 23 11 12 47 2
2 B,R 15 24 3 21 9 0,5 12
3 L,G 14 26 3 23 5 1 7
4 i,c 8 14 2 12 14 0 1
5 G,C 57 91 37 54 6 9 7
6 W,F 79 137 48 89 11 20 14
7 E,M 63 115 23 92 14 13 15
9 s,s 60 103 60 43 10 13 3
10 D,H 46 80 23 57 5 11 9
11 H,C 33 55 17 38 2 7
12 M,Y 48 79 33 46 0 14 1
13 R,C 49 77 27 50 8 12 5
15 I,P 36 62 17 45 5 7 6
16 J,P 99 130 82 48 4 37 9
17 K,S 36 61 22 39 2 4
18 J,R 42 70 25 45 11 15
19 E,K 48 86 26 60 6 18 2
20 J,F 63 100 36 64 20 12 20
21 s ,o 46 79 27 52 8 11
22 A,G 55 90 40 50 20 8
23 A,T 60 103 36 67 8 9
24 G,A 25 40 19 21 15 3 15
25 E,R 40 66 21 45 4 9
28 W,F 39 54 28 26 18 5 12
29 D,B 33 50 20 30 1 5 7
31 R,McD 43 74 26 48 11 16 8
32 M,T 30 50 10 40 4 4 13
33 H,J 49 90 30 60 19 16 22
34 S,G 19 31 9 22 15 0.4 10
35 M,E 36 65 17 48 2 9
Mean 43.8 72,5 26.4 46.0 8.9 9.96 9.4
S.D. 19.4 30.4 16.8 18.6 6.0 7.55 5.8
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Table 3.4b
Number Initials
FEVi
(L)
%predicted
FEVi
FVC
(L)
%predicted
FVC
FEVI/FVC 
Ratio
{%)
KCO %PredictedKCO
1 M,C 2.67 119 3.25 123 103
2 B,R
3 L,G
4 i,c
5 3.57 99 4.98 112 72 1.21 81
6 W,F
7 E,M
9 s,s
10 D,H
11 H,C 3.57 99 4.98 112 72 1.21 81
12 M,Y 2.84 100 3.24 99 88 1.82 101
13 R,C 3.02 119 4.07 137 74 0.25 15
15 I,P
16 J,P
17 K,S
18 J,R
19 E,K
20 J,F 3.41 113 4.58 116 75 1.03 81
21 s ,o
22 A,C
23 A J 3.57 97 4.1 97 87 1.26 74
24 C,A 3.24 89 4.54 102 0.91 60
25 E,R
28 W,F 2.29 89 2.61 78 88 20
29 D,B
31 R,McD 2.16 64 3.9 92 55 0.34 24
32 M J 1.16 75 2.19 115 53 0.5 36
33 H,J 1.34 50 2.48 69 73 0.32 26
34 S,C
35 M,E
Mean 2.74 92.7 104.3 76.4 0.88 0.88 54.5
S.D. .84 21.2 0.97 19.0 14.8 0.52 30.8
Tables 3.4a & 3.4b: Table 3.4a is giving haemodynamic values o f the individual 
subjects in the study. The values are obtained through a standard swan-ganz fluid filled
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pulmonary artery catheter. Table 3.4b spirometic values available for individual 
subjects. Subject numbers corresponds with subjects in table 3.1.
3.2.2. Procedure
The physioflow 1, cardiac output bio-impedance device, was set up and calibrated 
before the patient connnenced right heart catheterisation. Blood pressure was initially 
inputted at this time. Thereafter, a designate operator for the physioflow-1 cardiac 
output bio-impedance device was only then allocated, if staffing levels permitted. 
Further adjustments to the device, and further blood pressure adjustments were only 
made in 10 subjects. During the clinical procedure three sets of thermodilutional cardiac 
output measurements ( C O t h e r m )  were taken when felt to be clinically relevant, and bio­
impedance cardiac output data was noted at the same time (COpp). The bio-impedance 
device was set to give measurements over a 15 second interval. Several sets of 
thermodilutional cardiac output data were made until three values matched within 10% 
or 0.5L/min of each other. This was then averaged to obtain a single value. Only the 
bioimpedance measurements taken at the same time as the selected thermodilutional 
measurements were noted and averaged.
During the right heart catheterisation, pulmonary artery pressures (Diastolic, mean and 
systolic pulmonary artery pressure, DPAP, MPAP, SPAP), right atrial pressure, (RAP), 
and pulmonary arteiy wedge pressure, (PAWP) were measured.
Spirometry results (forced expiratoiy volume in 1 second, FEVi, Forced vital capacity 
FVC, & diffusion coefficient, KCO) were obtained by a vitalograph, in 14 patients.
155
3.2.3 Ethics
Ethical approval was provided by the West Ethics committee. North Glasgow NHS 
University Trust. All subjects gave informed consent for thoracic bioimpedance cardiac 
output measurements as part of their clinical evaluation for suspected pulmonary 
hypertension.
3.2.3. Statistics
Population data was analysed to give values +/- standard deviations. Comparisons 
between the measurements obtained by both methods was initially performed by linear 
regression, and then analysed by the Bland Altman method. This was done for all the 
results, and sub-analysed for the results whilst receiving air, oxygen, nitric oxide, or 
during exercise, and also for the subjects with IPAH, CTD, & CTPEH individually.
The actual change, as well percentage change, from baseline (on air) to receiving 
oxygen, nitric oxide, or with exercise were compared between thermodilutional results 
and bio-impedance results.
These actual and percentage differences between the thermodilutional results and bio­
impedance results were compared with spirometry and right heart catheterisation data 
for the subjects in order to ascertain whether there was any underlying reason for the 
differences in cardiac output data obtained.
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3.3. Results
The correlation coefficient squared of the two techniques was r^  = 0.463 (p < 0.001) 
when all the data was analyzed, and gave a regression equation of COpf = 1.924 + 
C O t h e r m  • 0.844 (L*min'^), for all 57 sets of measurements, as shown in figure 3.1a. & 
3.1c. A comparison (by the Bland-Altman method) of the two techniques was made for 
all 57 measurements, as shown in figures 3.1b & 3.Id, and the total mean difference 
(COpF - C O t h e r m )  (± standard deviation) was found to be 1.21 (± 1.85) L*min"% (giving 
95% confidence intervals of between -2.44 and 4.86 L*min'^). The total mean 
difference (COpp - C O t h e r m )  (± standard deviation) as expressed as a percentage of 
mean of COpp and C O t it e r m  was found to be 23.35 (± 35.9) %.
If, to avoid overrepresentation of individuals, only the first result of subject 5 was taken 
as well as only measurements taken on air at rest, the correlation coefficient squared of 
the two techniques was r^  = 0.152 (p < 0.019) when all the data was analyzed, and gave 
a regression equation of COpp ^  3.38 + C O t h e r m  • 0.451 (L«min^), for the 35 sets of 
measurements. A comparison (by the Bland-Altman method) of the two techniques was 
made for the 35 measurements, and the total mean difference (COpp - C O t p e m v i)  ( ±  
standard deviation) was found to be 1.03 (± 1.93) L*min \  (giving 95% confidence 
intervals of between -2.83 and 4.89 L#miif^). The total mean difference ( C O p f  - 
C O t h e r m )  (± standard deviation) as expressed as a percentage of mean of COpp and 
C O t h e r m  was found to be 21.5 (± 40.2) %.
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Figure 3. la: Comparison o f  cardiac output (CO) obtained usitig the impedance methcxi (COpp) during all 
the physiological situations compared with that o f  the cardiac output obtained by the thermodilutional 
method (C O th e r m )  ht the 30 individuals (n=57 the line o f identity given by the continuous black line, and 
the regression line fo r  the combined paired data, by the broken purple line. Individual diseases shown in 
a, with the paired data o f  normal subjects represented by an inverse purple triangle. Idiopathic 
pulmonary arterial hypertension (IPAH) by a red hexagon. Connective tissue disorders (CTD) by a green 
square. Chronic obstructive pulmonary disease (COPD) by a dark blue circle, interstitial lung disease 
.shown with a tanned upright triangle. Chronic thromboembolic pulmonary hypertension by a light blue 
star, Portopulmonary hyperten.sion by an orange hour glass and the unknown si4bject by a green cross.
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Figure 3.1b: Comparison o f  cardiac output (CO) obtained using the impedance method (COpp) during all 
the physiological situations compared with that o f  the cardiac outptit obtained by the thermodilutional 
method (C O th e r k Ù  hi the 30 individuals (n=57) as a graphical representations o f  the differences between 
the two measurements (COpp- C O th e r m  vs. the mean o f the two measurements [(COpp+ COtherm)^^] for  
each measure, according to the Bland and Altman method. The continuous thick horizontal line 
represents the line o f origin o f the x-axis, the thin continuous line indicate the means difference or bias 
and the broken lines, the limits o f agreement (defined as mean ±  2S.D.). 7he paired data o f a normal 
subjects by an inverse purple triangle. Idiopathic pulmonary arterial hyperten.sion (IPAH) by a red 
hexagon, Connective tissue disorders (CTD) by a green square, Chronic obstructive pulmonary di.sea.se 
(COPD) by a dark blue circle, interstitial lung disease shown with a tanned upright triangle. Chronic 
thromboembolic pulmonary hypertension by a light blue star, Portopulmonary hypertension by an orange 
hour glass and the unknown subject by a green cross.
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Figure 3.1c
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figure 3. le: Comparison o f  cardiac output (CO) obtained using the impedance method (COpp) during all 
the physiological situations compared with that o f  the cardiac oiHput obtained by the thermodilutional 
method ( C O th e r m )  in the 30 individuals (n=57) the line o f identity given by the continuous black line, 
and the regression lines fo r  the combined paired data, by the broken purple line. . The paired data fo r the 
individual physiological circumstances are shown, with inhalation by air shown by a dark blue circle, 
oxygen by a green square, nitric oxide by a red upright triangle, and during exercise with a purple 
hexagon.
Figure 3. Id
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Figure 3. Id: Comparison of cardiac output (CO) obtained using the impedance method (COpp) during all 
the physiological situations compared with that o f the cardiac output obtained by the thermodilutional 
method (COtpieriO -^ 0 individuals (n=57) as a graphical representations o f the differences between 
the two measurements (COpp- COtherk-i the mean of the two measurements [(COpp+ COmEmf^V for 
each measure, according to the Bland and Altman method. The continuous thick horizontal line 
represents the line of origin of the x axis, the thin continuous line indicate the means difference or bias 
and the broken lines, the limits of agreement (defined as mean ± 2S.D.). The paired data for the 
individual physiological circumstances are shown, with inhalation by air shown by a dark blue circle, 
oxygen by a green square, nitric oxide by a red upright triangle, and during exercise with a purple 
hexagon.
When analyzed the individual subgroups of the paired data on air, oxygen, nitric 
oxide/oxygen combination and during exercise, the following results were obtained.
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The correlation coefficient squared of the two techniques whilst inhaling air was r^  = 
0.179 (p = 0.085) when all the data was analyzed, and gave a regression equation of 
C O p F  =  3.385 + C O t h e r m  •  0.447 (L*min’ )^, for all 32 sets of measurements, as shown 
in figure 3.1c. A comparison (by the Bland-Altman method) of the two techniques was 
made for the 32 measurements and the total mean difference ( C O p f  - C O t h e r m )  ( ±  
standard deviation) was found to be 1.02 (± 1.87) L#min \  (giving 95% confidence 
intervals of between -2.66 and 4.69 L*min'^). The total mean difference ( C O p f  -  
C O t h e r m )  (± standard deviation) as expressed as a percentage of mean of C O p f  and 
C O t it e r m  was found to be 22.89 (± 39.1)%.
The correlation coefficient squared of the two techniques whilst inhaling oxygen was r^  
= 0.479 (p = 0.085) when all the data was analyzed, and gave a regression equation of 
COpF = 0.92 + C O t f ie r m  • 1.032 (L#min'^), for all 7 sets of measurements, as shown in 
figure 3.1c. A comparison (by the Bland-Altman method) of the two techniques was 
made for the 7 measurements and the total mean difference ( C O p f  - C O t it e r m )  (± 
standard deviation) was foimd to be 1.04 (± 0.72) L»min"\ (giving 95% confidence 
intervals of between -0.38 and 2.45 L*min‘). The total mean difference ( C O p f  -  
C O t h e r m )  (± standard deviation) as expressed as a percentage of mean of C O p f  and 
C O t h e it m  was found to be 24.45 (± 17.09) %.
The correlation coefficient squared of the two techniques whilst inhaling nitric oxide 
was r^  = 0.347 (p = 0.044) when all the data was analyzed, and gave a regression 
equation of C O p f  = 0.969 + C O t h e r m  • 1.105 (L#min'^), for all 12 sets of 
measurements, as shown in figure 3.1c. A comparison (by the Bland-Altman method)
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of the two techniques was made for the 12 measurements and the total mean difference 
(C O pF  - C O th erm ) (± standard deviation) was found to be 1 .4 1  ( ±  1 .3 7 )  L*min'\ (giving 
9 5 %  confidence intervals of between - 1 . 2 7  and 4.08 L«mm^). The total mean 
difference (C O pf -C O th er m ) (± standard deviation) as expressed as a percentage of 
mean of C O pf and C O therm  was found to be 2 9 .0 8  ( ±  2 8 .1 6 )  % .
The correlation coefficient squared of the two techniques during straight leg raising 
exercise was P = 0.463 (p = 0.09.) when all the data was analyzed, and gave a 
regi'ession equation of C O p f  = 2.553 + C O t h e r m  • 0.919 (L*min“^ ), for all 5 sets of 
measurements, as shown in figure 3.1c. A comparison (by the Bland-Altman method) 
of the two techniques was made for the 5 measui ements and the total mean difference 
(COpF - C O t h e iîm )  (± standard deviation) was found to be 1.95 (± 3.11) L*min'\ (giving 
95% confidence intervals of between -4.16 and 8.04 L*min'^). The total mean 
difference ( C O p p  - C O t h e r m )  (± standard deviation) as expressed as a percentage of 
mean of C O p f  and C O t h e r m  was found to be 29.01 (± 28.16)%.
Several of the individual disease subgroups were sub-analysed, IPAH, CTEPH, 
normals, CTD and ILD.
The correlation coefficient squared of the two techniques in the four subjects without 
pulmonaiy hypertension, was r^  = 0.96 (p < 0.001) when all the data was analyzed, and 
gave a regression equation of C O p f  = 1.165 + C O t h e r m  • 0.909 (L*min'^), for all 7  sets 
of measurements, as shown in figure 3.2a. A comparison (by the Bland-Altman 
method, figure 3.2b) of the two techniques was made for the 7  measurements and the
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total mean difference ( C O p f  - C O t h e r m )  (± standard deviation) was found to be 0.45 (± 
0.58) L*min'\ (giving 95% confidence intervals of between-0.69 and 1.60 L#min'^). 
The total mean difference ( C O p f  - C O t h e r m )  (± standard deviation) as expressed as a 
percentage of mean of C O p f  and C O t h e r m  was found to be 5.68 (± 7.34) %.
If, to avoid overrepresentation of individuals, only the measurements taken on air at rest 
were analysed the correlation coefficient squared of the two techniques, was r^  = 0.95 (p 
= 0.02) when all the data was analyzed, and gave a regression equation of C O p f  = 2.76 
+  C O t h e r m  • 0.60 (L*min’ )^, for the 4 sets of measurements, as shown in figure 3.2a. A 
comparison (by the Bland-Altman method), of the two techniques was made for the 4 
measurements and the total mean difference ( C O p f  - C O t h e r m )  (± standard deviation) 
was found to be 0.42 (± 0.76) L#min'\ (giving 95% confidence intervals of between 
1.1 and 1.95 L*min'^). The total mean difference ( C O p f  - C O t h e r m )  (± standard 
deviation) as expressed as a percentage of mean of C O p f  and C O t h e r m  was found to be 
7.06 (± 12.70)%.
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Figure 3.2a: Comparison o f  cardiac output (CO) obtained using the impedance method (COpp) during all 
the physiological situations compared with that o f  the cardiac output obtained by the thermodilutiotml 
method (COtherkO ./or individuals with no pulmonary hypertension (normals) (n=7) are shown in a, with 
the paired data o f a normal subjects by purple inverse triangle, the line o f  identity’ given by the 
continuous black line, and the regression lines fo r  the combined ordinate, by the broken purple line.
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Figure 3.2b: Comparison o f cardiac output (CO) obtained using the impedance method (COpp) during all 
the physiological situations compared with that o f the cardiac output obtained by the thermodilutional 
method (COmEmd for individuals with no pulmonaiy hypertension (normals)(n^ 7) are shown in a, with 
the paired data of subjects by a pwple inverse triangle in figure 3.2b as a gi^aphical representations of 
the differences between the two measurements (COpp - COtherm v5. the mean of the two measurements 
[(COpp + COtherm)^V for each measure, according to the Bland and Altman method. The continuous 
thick horizontal line represents the line of origin o f the x-axis, the thin continuous line indicate the means 
difference or bias and the broken lines, the limits of agreement (defined as mean ±2S.D.).
The correlation coefficient squared of the two techniques in the 7 subjects with IPAH 
was r^  = 0.453 (p = 0.12) when all the data was analysed, and gave a regression 
equation of COpf ^  -3.273 + COtfierm • 2.269 (L«min“^ ), for all 13 sets of 
measurements, as shown in figure 3.3a. A comparison (by the Bland-Altman method.
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figure 3.3b) of the two techniques was made for the 13 measurements and the total 
mean difference ( C O p f  -C O T H E R M ) (± standard deviation) was found to be 1.19 (± 2.00) 
L*min‘^ (giving 95% confidence intervals of between -2.00 and 5.83 L#min"^). The 
total mean difference ( C O p f  - C O t f ie r m )  (± standard deviation) as expressed as a 
percentage of mean of C O p f  and C O t h e r m  was found to be 37.8 (± 39.7) %.
If, to avoid overrepresentation of individuals, only the measurements taken on air at rest 
the correlation coefficient squared of the two techniques in the 7 subjects with IPAH 
was r^  = 0.60 (p = 0.041) when all the data was analysed, and gave a regression 
equation of C O p f  = -4.201 + C O t h e r m  • 2.594 (L*mm^), for the 7 sets of 
measurements, A comparison (by the Bland-Altman method) of the two techniques was 
made for the 7 measurements and the total mean difference ( C O p f  - C O t h e r m )  ( ±  
standard deviation) was found to be 2.17 (± 2.17) L#min"\ (giving 95% confidence 
intervals of between -2.17 and 6.51 L*min"^). The total mean difference ( C O p f  -  
C O t it e r m )  (± standard deviation) as expressed as a percentage of mean of C O p f  and 
C O t h e r m  was found to be 42.7(± 42.7) %.
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Figure 3.3a: Comparison o f cardiac output (CO) obtained imng the impedance method ( C O p f )  during all 
the phy.sio!ogical situations compared with that o f  the cardiac output obtained by the thermcxJiiutional 
methcxJ (COthersO seven individuals with idiopathic pulmonary hypertension (IPAH)(n=9), the paired  
data o f a shown by a red hexagon and in six individuals with chronic thromboembolic pulmonary 
hypertension (n=l4), the paired data shown by blue stars. The line o f identity given is by the continuotts 
black line. The regression lines fo r  the combined paired data, o f IPAH and CIEPH, are given by the thin 
black line, and the broken black line respectively.
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Figure 3.3b: Comparison o f  cardiac output (CO) obtained using the impedance method (COpp) by the 
Bland and Altman method during all the physiological situations compared with that o f the cardiac 
output obtained by the thermodilutional method (COff^pp^J in seven huiividuals with idiopathic 
pulmonary hypertension (IPAH)(n=13), are .shown), the paired data o f  which are shown by a red  
hexagon. The differences between the two measurements (COpp - C O th e r m  va- the mean o f the two 
measurements [(COpp + COtherm)/^] fo r  each measure, are represented graphically. The continuous 
thick horizontal line represents the line o f  origin o f  the x-axis, the thin continuous line indicate the means 
difference or bias and the broken lines, the limits o f agreement (defined as mean ±2S.D.).
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Figure 3.3c: Compari.son o f  cardiac output (CO) obtained using the impedance method (COpp) by the 
Bland and Altman method during all the physiological situations compared with that o f  the cardiac 
output obtained by the thermodilutional method (C O th e r m )  iu six individuals with chronic 
thromboembolic pulmonary hypertension (n=14), the paired data shown by blue .stars. The differences 
between the two measurements (COpp - C O th e r m  the mean o f the two measurements [(COpp  ^
C O th e r k i) ' '^ ]  f(^f <^^ ch measure, are represented graphically. The continuous thick horizontal line 
represents the line o f  origin o f the x-axi.s, the thin continuous line indicate the means difference or bias 
and the broken lines, the limits o f agreement (defined as mean ±2S.D.).
The correlation coefficient squared of the two techniques in the 6 subjects with CTEPH 
was r^  = 0.665 (p <0.001) when all the data was analyzed, and gave a regression 
equation of C O p f  = -3.789 + C O t h e r m  • 2.446 (L*min’'), for all 14 sets of 
measurements, as shown in figure 3.3a. A comparison (by the Bland-Altman method.
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figure 3.3c) of the two techniques was made for the 13 measurements and the total mean 
difference ( C O p f  - C O t h e r m )  (± standard deviation) was found to be 3.95 (± 2.01) 
L*min'\ (giving 95% confidence intervals of between -2.76 and 6.19 L*min“^ ). The 
total mean difference (COpp - C O t it e r m )  (± standard deviation) as expressed as a 
percentage of mean of C O p f  and C O t h e r m  was found to be 30.3 (± 40.8) %.
The correlation coefficient squared of the two techniques in the 6 subjects with CTD 
was r^  = 0,522 (p = 0.008) when all the data was analyzed, and gave a regi'ession 
equation of C O p f  = 1.122 + C O t h e r m  ® 0.917 (L«min*), for all 12 sets of 
measurements, as shown in figure 3.4a. A comparison (by the Bland-Altman method, 
figure 3.4b) of the two techniques was made for the 12 measurements and the total 
mean difference ( C O p f  - C O t h e r m )  (± standard deviation) was found to be 0.84 (± 0.72) 
L#min"\ (giving 95% confidence intervals of between -0.58 and 2.26 L*mm'^). The 
total mean difference (COpp - C O t it e r m )  (± standard deviation) as expressed as a 
percentage of mean of C O p f  and C O ti-i e r m  was found to be 22.3 (± 19.2) %.
If, to avoid overrepresentation of individuals, only the measurements taken on air at rest 
the correlation coefficient squared of the two techniques in the 6 subjects with CTD was 
r^  = 0.338 (p -  0.226) when all the data was analyzed, and gave a regression equation of 
COpp = 2.10 + C O t h e it m  • 0.57(L»min'^), for the 6 sets of measurements. A comparison 
(by the Bland-Altman method), of the two techniques was made for the 6 measurements 
and the total mean difference (COpp - C O t h e r m )  (± standard deviation) was found to be 
0.70 (± 0.75) L»min"\ (giving 95% confidence intervals of between -0.80 and 2.20 
L*min'^). The total mean difference (COpp - C O t it e r m )  (± standard deviation) as
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expressed as a percentage of mean of C O p f  and C O t h e r m  was found to be 19.4 (± 20.8)
Figure S. 4a
7 -
6 - R = 0 9 3  
P  = 0  01 Line of identity
I. 5 -
4 “
3 -
2 3 54
t h e r m
Figure 3.4a: Comparison o f cardiac output (CO) obtained using the impedance method (COpp) during all 
the physiological situations compared with that o f  the cardiac output obtained by the thermodilutional 
method ( C O th e r m )  individuals with connective tissue disease (CTD)(n=12) are shown in a, with the 
paired data o f  a shown by a square and in the two individuals with interstitial lung disease (ILD)(n=5), 
the paired data shown by brown triangles. The line o f  identity given is by the continuous black line. The 
regression lines fo r the combined paired data, o f  CTD and ILD are given by the broken black line 
respectively and the broken black line differmg line and space lengths respectively.
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Figure 3.4h: Comparison of cardiac output (CO) obtained using the impedance method (COpp) by the 
Bland and Altman method during all the physiological situations compared with that of the cardiac 
output obtained by the thermodilutional method (COthebm) in the two individuals with interstitial lung 
disease (ILD)(n=5), the paired data shown by brown triangles. The differences between the two 
measurements (COpp - COmEm vs. the mean of the two measurements [(COpp+ C0therm)'^ 2] for each 
measure, are represented graphically. The continuous thick horizontal line represents the line of origin of 
the x~axis, the thin continuous line indicate the means difference or bias and the broken lines, the limits of 
agreement (defined as mean ±2S.D.).
A
173
Figure 3.4c
4 -
3 -
2 -
d 1 -
;oo 0-1
feo 1 -o
- 2 -
3
□
Mean + 2SD 
□
Mean
Mean - 2SD
 1------------ r
2 3
( COp,+ CO THERM
 1------------ r
4 5
) 2 (L • )
Figure 3.4c: Comparison o f  cardiac output (CO) obtained using the impedance method (COpp) by the 
Bland and Altman method during all the physiological situations compared with that o f  the cardiac 
output obtained by the thermodilutional method (C O th e r m )  six individuals with connective tissue 
disease (CTD)(n=J2), are shown), the paired data o f  which are shown by a square. The differences 
between the two measurements (COpp - C O th e r m  the mean o f the two measurements [(COpp  ^
OOtherm)^2] fo r  each measi4re, are represented graphically. Ihe continuous thick horizontal line 
represents the line o f  origin o f  the x-axis, the thin continuous line indicate the means difference or bias 
and the broken lines, the limits o f agreement (defined as mean ±  2 S. D.).
The correlation coefficient squared of the two techniques in the 2  subjects with ILD was 
r^  =  0 . 9 8  (p = 0 . 0 0 1 )  when all the data was analyzed, and gave a regression equation of 
C O p F  =  1 . 2 0 3  +  C O t h e r m  •  1 . 0 2 4  (L*min'*), for all 5  sets of measurements, as shown in
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figure 3.4a. A comparison (by the Bland-Altman method, figure 3.4b) of the two 
techniques was made for the 5 measurements and the total mean difference 
(COpF -COtiierm) (± standard deviation) was found to be 1.30 (± 0.17) L#min"\ (giving 
95% confidence intervals of between 0.95 and 1.64 L*min'^). The total mean difference 
(COpF -COtheiuvi) (± standard deviation) as expressed as a percentage of mean of COpp 
and COtherm was found to be 22.4 (± 3.0)%.
An analysis was also undertaken reviewing the change occurring in the subjects, when 
taking the baseline to be supine subjects at rest, and comparing with the difference to 
values inhaling oxygen, nitric oxide/oxygen combined or during exercise. These 
differences were expressed in L min"\ change of physioflow derived cardiac output 
from baseline, ACOppBaseline, and change from baseline of thermodilutional derived 
cardiac output, ACOi’HERMBaseline). The correlation coefficient squared of the two 
techniques in the 21 subjects, 26 paired data, r^  = 0.71 (p < 0.001) when all the data was 
analyzed, and gave a regression equation of ACOppBaseline = 0.22 + 
ACOTUERMBaseline « 1.1 (L min"^), for all 26 sets of measurements, as shown in figure 
3.5a. A comparison (by the Bland-Altman method, figure 3.5b) of the two techniques 
was made for the 26 measurements and the total mean difference (ACOppBaseline - 
ACÜTHERMBaseline) (± standard deviation) was found to be 0.29 (± 1.05) L m in '\ 
(giving 95% confidence intervals of between -0.79 and 1.97 L min'^). The total mean 
difference (ACOppBaseline -ACOppiERMBaseline) (± standard deviation) as expressed as 
a percentage of mean of ACOppBaseline and ACOTPiERMBaseline was found to be 35 (± 
131)%.
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If, to avoid overrepresentation of individuals, only the measurements taken under 
individual physiological circumstances, we get the following results.
The correlation coefficient squared of the two techniques in the 7 subjects, receiving 
oxygen at rest, r^  = 0.40 (p = 0.13) when all the data was analyzed, and gave a 
regression equation of ACOppBaseline = 0.024 + ACOxHERiviBaselme » 1.71 (L miiT^), 
for the 7 sets of measurements. A comparison (by the Bland-Altman method) of the 
two techniques was made for the 7 measurements and the total mean difference 
(ACOppBaseline -ACOppiERMBaseline) (+ standard deviation) was found to be 0.00 (± 
0.55) L min"\ (giving 95% confidence intervals of between —1.10 and 1.10 L min'^). 
The total mean difference (ACOppBaseline -ACOppiERMBaseline) (± standard deviation) 
as expressed as a percentage of mean of ACOppBaseline and ACOppiERMBaseline was 
found to be 0 (± 385)%.
The correlation coefficient squared of the two techniques in the 14 subjects, receiving 
nitric oxide at rest, r^  = 0.24 (p = 0.14) when all the data was analyzed, and gave a 
regression equation of ACOppBaseline = 0.15 + ACOppiEiuviBaseline » 0.40 (L min'^), 
for the 14 sets of measurements. A comparison (by the Bland-Altman method) of the 
two techniques was made for the 14 measurements and the total mean difference 
(ACOppBaseline -ACOppiERMBaseline) (± standard deviation) was found to be 0.02 (± 
0.47) L m in '\ (giving 95% confidence intervals of between —0.92 and 0.96 L min'^). 
The total mean difference (ACOppBaseline -ACOppiERMBaseline) (± standard deviation) 
as expressed as a percentage of mean of ACOppBaseline and ACOppiERMBaseline was 
found to be 9 (± 207)%.
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The correlation coefficient squared of the two teclmiques in the 9 subjects, exercising, r^  
= 0.53 (p = 0.06) when all the data was analyzed, and gave a regression equation of 
ACOppBaseline = 1.14 + ACOppiERMBaseline • 0.84 (L min'^), for the 9 sets of 
measurements. A comparison (by the Bland-Altman method) of the two techniques was 
made for the 9 measurements and the total mean difference (ACOppBaseline - 
ACOpHERMBaseline) (± standard deviation) was found to be 1.04 (± 1.80) L min"\ 
(giving 95% confidence intervals of between -2.56 and 4.63 L min'^). The total mean 
difference (ACOppBaseline -ACOpiPERMBaseline) (± standard deviation) as expressed as 
a percentage of mean of ACOppBaseline and ACOpHERMBaseline was found to be 37 (± 
64)%.
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Figure 3.5a: Comparison change of physioflow derived cardiac output fi^om baseline, ACOppBaseline (L 
minf,  during all the physiological situations compared with that of the chcmge from baseline of 
thermodilutional derived cardiac output, ACÜTHEmBaseline (L min^), in the 21 individuals (n==26). The 
individual diseases with the paired data of normal subjects shown by an inverse pmple triangle, 
idiopathic pulmonary arterial hypertension (IPAH) by a red hexagon, Connective tissue disorders (CTD) 
by a green square. Chronic obstructive pulmonary disease (COPD) by a dark blue circle, interstitial lung 
disease shown with a tanned upright triangle and Chronic thromboembolic pulmonaty hypertension by a 
light blue star. The line of identity given by the broken black line, and the regression line for the 
combined paired data sets, by the continuous black line.
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Figure 3.5b
D
O jkL
O V
0 2 4
(ACOpp B a seliiie 4- A C O y^^^ B aseliiie)/2 (L miir^)
Figure 3.5b: Comparison change of physioflow derived cardiac output front baseline, ACOppBaseline (L 
mittf, during all the physiological situations compared with that of the change from baseline of 
thermodilutional derived cardiac output, ACOmEmrTaseline (L min^), in the 21 individuals (n^26) by the 
Bland and Altman method. The individual diseases with the paired data of a normal subjects shown by 
an inverse purple triangle, Idiopathic pulmonary arterial hypertension (IPAH) by a red hexagon, 
Connective tissue disorders (CTD) by a green square, Chronic obstructive pulmonary disease (COPD) by 
a dark blue circle, interstitial lung disease shown with a tanned upright triangle and Chronic 
thromboembolic pulmonary hypertension by a light blue star. The differences between the two 
measurements (COpp - C O th e r m  Vs. the mean of the two measurements [(COpp+ C0therm)^2] for each 
measure, are represented graphically. The continuous thick horizontal Ihie represents the line of origin of 
the x-axis, the thin continuous line indicate the means difference or bias and the broken lines, the limits of 
agreement (defined as mean ±2S.D.).
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Figure 3.5c
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Figure 3.5c: Comparison change o f  physioflow derived cardiac output from baseline, ACOppBaseline (L 
min'f, during all the physiological sitidations compared with that o f  the chattge from baseline o f  
thermodilutional derived cardiac output, ACÜTHEmfluseline (L mitF), in the 21 individuals (n=26). Ihe 
paired data fo r the individual physiological circumstances are shown, with inhalation by air shown by a 
dark blue circle, oxygen by a green triangle, nitric oxide by a red upright triangle, and during exercise 
with a purple hexagon. The litie o f identity given by the continuous black line, and the regression line fo r  
the combined paired data sets, by the broken black line.
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Figure 3.5d: Comparison change o f  physioflow derived cardiac output from baseline, ACOppBaseline (L 
min'^), during all the physiological sitt/ations compared with that o f the change from baseline o f  
thermodilutional derived cardiac output, ACOrHEmBaselme (L min'f, in the 21 individuals (n=26) by the 
Bland and Altman method. The paired data fo r  the individual physiological circumstances are shown, 
with inhalation by air shown by a dark blue circle, oxygen by a green triangle, nitric oxide by a red  
upright triangle, and during exercise with a purple hexagon. The differences between the two 
measurements (COpp - COtherm the mean o f  the two measurements f(COpp +- C 0 therm)''2] fo r  each 
measure, are represented graphically. The conthmous thick horizontal line represents the line o f origin of 
the x-axis, the thin contimums line indicate the means difference or bias and the broken lines, the limits o f  
agreement (defined as mean ±  2S. D.).
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An analysis was also undertaken reviewing the change in cardiac output which 
occurred in the subjects, from baseline, (the baseline taken to be the cardiac output of 
the subject, at rest, inhaling air), and comparing with the difference to values inhaling 
oxygen, nitric oxide/oxygen combined or during exercise. These differences were 
expressed as a percentage of the value at baseline (percentage change of physioflow 
derived cardiac output from baseline, %ACOppBaseline, and percentage change from 
baseline of thermodilutional derived cardiac output, % ACOTUERMBaseline). The 
correlation coefficient squared of the two techniques in the 21 subjects, 26 paired data, 
r^  = 0.81 (p < 0.001) when all the data was analyzed, and gave a regression equation of 
%ACOpFBaseline = 3.16 + % ACÜTHERMBaseline ® 0.916 (%), for all 26 sets of 
measurements, as shown in figure 3.6a. A comparison (by the Bland-Altman method, 
figure 3.6b) of the two techniques was made for the 26 measurements and the total 
mean difference (%ACOppBaseline -%ACOTHERMBaseline) (+ standard deviation) was 
found to be 2.08 % (± 12.5), (giving 95% confidence intervals of between -23.0 and
27.1 %). The total mean difference (%ACOppBaseline -%ACOTHERMBaseline) (± 
standard deviation) as expressed as a percentage of mean of %ACOppBaseline and 
%ACOTHERMBaseiine was found to be 14.7% (± 90.7).
If, to avoid overrepresentation of individuals, only the measurements taken under 
individual physiological circumstances, we get the following results.
The correlation coefficient squared of the two techniques in the 7 subjects, receiving 
oxygen at rest, was r^  = 0.45 (p = 0.101) when all the data was analyzed, and gave a 
regression equation of %ACOppBaseline = 0.25 + % ACÜTHERMBaseline * 0.84 (%), for
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tlie 7 sets of measurements. A comparison (by the Bland-Altman method) of the two 
techniques was made for the 7 measurements and the total mean difference 
(%ACOpFBaseline -%ACOTHERMBaseline) (± standard deviation) was found to be 0.728 
% (± 10.89), (giving 95% confidence intervals of between -22.1 and 22.5%). The total 
mean difference (%ACOpFBaseline -%ACOTHERMBaseline) (± standard deviation) as 
expressed as a percentage of mean of %ACOppBaseline and %ACOxHERMBaseline was 
found to be -27.8% (±415.0).
The correlation coefficient squared of the two techniques in the 12 subjects, receiving 
nitric oxide/oxygen at rest, was r^  = 0.02 (p = 0.63) when all the data was analyzed, and 
gave a regression equation of % ACOppBaseline = 4.87 + % ACÜTHERMBaseline # -0.07 
(%), for the 12 sets of measurements. A comparison (by the Bland-Altman method) of 
the two techniques was made for the 12 measurements and the total mean difference 
(%ACOppBaseline -%ACÜTHERMBaseline) (± standard deviation) was foimd to be -1.6 
% (± 12.8), (giving 95% confidence intervals of between -27.3 and 24.0%). The total 
mean difference (%ACOppBaseline -%ACÜTi-iEmBaseline) (± standard deviation) as 
expressed as a percentage of mean of %ACOppBaseline and %ACÜTHEi{MBaseline was 
found to be -31.1% (± 244.0).
The correlation coefficient squared of the two techniques in the 9 subjects, whilst 
exercising, was r^  = 0.82 (p = 0.005) when all the data was analyzed, and gave a 
regression equation of %ACOppBaseline = 17.89 + %ACOrHBRMBaseline • 0.766(%), 
for the 12 sets of measurements. A comparison (by the Bland-Altman method) of the 
two techniques was made for the 12 measmements and the total mean difference
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(%ACOppBaseline -%ACOppiERMBaseline) (± standard deviation) was found to be 8.26 
% (± 16.8) , (giving 95% confidence intervals of between -25.5 and 42.0%). The total 
mean difference (%ACOppBaseline -%ACOppiERMBaseline) (± standard deviation) as 
expressed as a percentage of mean of %ACOppBaseline and %ACOpHERMBaseline was 
found to be 18.2% (± 37.2).
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Figure 3.6a: Comparison change o f physioflow derived cardiac output from baseline, VoACOppBaseline, 
during all the phy.siological situations compared with that o f the change from baseline o f  
thermodilutional derived cardiac output, %ACÜTHEmSt^^line in the 21 individuals (n=26). Ihe 
individual diseases with the paired data o f  a  normal subjects shown by an inverse purple triangle. 
Idiopathic pulmonary arterial hypertension (IPAH) by a red hexagon. Connective tissue disorders (CTD) 
by a green square. Chronic obstructive pulmonary disease (COPD) by a dark blue circle, interstitial lung 
disease shown with a tamied ttpright triangle and Chrotiic thromboembolic pulmonary hypertension by a 
light blue star. The line o f identity given by the continuous black litie, atid the regression litie fo r the 
combined ordinate, by the broken black line.
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Figure 3.6b: Comparison change of physioflow derived cardiac ouiput from baseline, HACOppBaseline, 
during all the physiological situations compared with that of the change from baseline of 
thermodilutional derived cardiac ouiput, %ACOmERMBaseline, in the 21 individuals (n^26) by the Bland 
and Altman method. The individual diseases with the paired data of a normal subjects shown by an 
inverse purple triangle. Idiopathic pulmonary arterial hypertension (IPAH) by a red hexagon. Connective 
tissue disorders (CTD) by a gt'een square, Chronic obstructive pulmonary disease (COPD) by a dark blue 
circle, interstitial lung disease shown with a tanned upright triangle and Chronic thromboembolic 
pulmonaty hypertension by a light blue star. The differences between the two measurements (COpp - 
C O th e r m  the mean of the two measurements [(COpp + COtherm)'^ ]^ for each measure, are represented 
graphically. The continuous thick horizontal line represents the line of origin of the x-axis, the thin 
continuous line indicate the means difference or bias and the broken lines, the limits of agreement 
(defined, as mean ±2S.D.).
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Figure 3.6c
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Figure 3.6c: Comparison change o f physioflow derived cardiac output from baseline, %ACOppBaseline, 
during all the physiological situations compared with that o f the change from baseline o f  
thermodilutional derived cardiac output, %ACOTHERMSaseline, in the 21 individuals (n=26). The paired  
data fo r  the individual physiological circumstances are shown, with inhalation by air shown by a dark 
blue circle, oxygen by a green triangle, nitric oxide by a red upright triangle, and during exercise with a  
purple hexagon. The line o f identity given by the continuous black line, and the regression line fo r the 
combined ordinate, by the broken black line.
Figure 3.6d
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Figure 3.6d: Comparison change o f  physioflow derived cardiac output from baseline, %ACOppBaseline, 
during all the physiological situations compared with that o f  the change from baseline o f  
thermodilutional derived cardiac output, %ACOTHERKtBaseline, in the 21 individuals (n=26) by the Bland 
and Altman method. The paired data fo r  the individual physiological circumstances are .shown, with 
inhalation by oxygen by a green triangle, nitric oxide by a red upright triangle, and during exercise with 
a purple hexagon. Ihe differences between the two measurements (COpp - C O therm  the mean o f  the 
two measurements [(COpp^ C0therm)^2] fo r  each measure, are represented graphically. Ihe continuous 
thick horizontal line represents the line o f  origin o f  the x-axis, the thin continuotts line indicate the means 
difference or bias and the broken lines, the limits o f agreement (defined as mean ±2S.D.).
Stepwise regression analysis was performed on the mean difference of the two methods
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(COpF -C O th e r m ) to investigate whether other haemodynamic or lung function 
parameters may have been responsible for the difference in results between the two 
methods. This was only performed where the results were available, on 25 subjects with 
regards to mean pulmonary arterial pressure, (MPAP), systolic pulmonary arterial 
pressure (SPAP), diastolic pulmonary arterial pressure (DPAP), pulmonary arterial 
pulse pressure (SPAP-DPAP, PAlPP), pulmonary artery wedge pressure (PAWP), Right 
atrial pressure (RAP) and pulmonary vascular resistance, (PVR), and on 13 subjects 
with respect to forced expiratory volume in 1 second, (FEVi), forced vital capacity 
(FVC), percent of predicted FEVi, and FYC, ratio of FEVi/FVC, carbon dioxide 
transfer coefficient, (KCO ) and percent predicted KCO. No conelations were found.
The small number of subjects, the large number of covariates and the inter-correlation 
of some of the covariates, the stepwise regression analysis should have been biased 
towards positive results. The results of this analysis, being negative, suggests that none 
of these variables were related to the mean difference of the two methods (COpf - 
C O th e r m ). In  order to minimise errors, the stepwise regression analysis was repeated, 
with only MPAP, PAWP, RAP and PVR for 25 subjects and no coiTelation was still 
found.
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3,4. Discussion
The results of this study found that the physioflow bioimpedance (Physioflow, Type 
PF05L1, Manatee, France) device overestimates cardiac output when compared to 
thermodilutional results. When all the results were analysed, the overestimation was 
estimate to be on average 1.21 (± 1.85) L#min % and the total mean difference (C O p f - 
C O th e r m ) (± standard deviation), expressed as a percentage of mean of C O p f and 
C O th eiu vi was found to be 23.35 (± 35.9) %. This latter result is similar to results 
obtained when evaluating other methods of now validated clinical cardiac output 
devices in the statistical variation, except with a positive bias (Bein, B. et al 2004; 
Durkin, R. J. et al 1994; Hoeper, M. M. et al 1999). Positive and negative errors in 
measurement are often be seen under certain clinical conditions, in routinely used 
clinical devices, for instance the positive bias often seen with thermodilutional methods 
in the people with low output states (Kohanna, F. H. et al 1977; Nishikawa, T. et al 
1993) or negative bias in valvular heart disease (Cigarroa, R. G. et al 1989).
There are several areas of introducible errors in the measurement of cardiac output by 
thoracic bioimpedance in this study, which may explain the overestimate. These may 
include operator error and procedural differences, and that the other studies compared 
the bioimpedance cardiac output obtained against results obtained by Tick's method or 
by echocardiography rather than thermodilutional derived cardiac output. With regards 
to operator error, all results obtained dming the early period of the learning curve have 
been included. Further error may have been introduced in those subjects where the 
device was left unadjusted during the right heart catheterisation, even when signal 
difficulties may have developed. A further issue was that in those subjects in whom the
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physioflow (Physioflow, Type PF05L1, Manatee, France) device was left unattended, 
further blood pressure measurements, just prior to the thermodilutional measurements, 
were not inputted.
During the straight leg raising, the cardiac output derived by the thermodilutional 
method, measures cardiac output over on average 30 seconds. If repeated 3 times for 
accuracy, the cardiac output obtained would be an average over 1-2 minutes. This 
would be satisfactory, if cardiac output was constant, but in a clinical context, with ill 
subjects, the work load achieved, and thus the cardiac output would also vary. The 
physioflow (Physioflow, Type PF05L1, Manatee, France), however took measurements 
over 15 seconds, and so may be checking a different cardiac output timescale (value) as 
opposed to the thermodilutional cardiac output timescale. Furthermore, the accuracy of 
the results obtained by the thennodilutional method, when testing subjects with 
tricuspid regurgitation and thus pulmonary hypertension, has been questioned after a 
number of studies (Hoeper, M. M. et al 1999).
When sub-analysed by underlying disease condition, we found that the correlations for 
normals was better than previous studies, with a correlation coefficient squared of the 
two techniques of r^  = 0.96 (p < 0.001) and measurements and the total mean difference 
(C O pF  -C O t ite r m ) (± standard deviation) was found to be 0.45 (± 0.58) L»min"\ 
However in all the pulmonary hypertensive subgroups analyzed, the total mean 
difference between the methods had a positive bias, [IPAIT, 1.19 (± 2.00) L#min"\ 
CTEPH3.95 (± 2.01) L#m in\C TD  0.84 (± 0.72) L 'm in \IL D  1.30 (± 0.17) L#miiT^]. 
Unfortunately, the numbers of individual subjects in each group were small, and it may
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be that one or two individuals in each group may have biased the result.
With regards to the initial correlation of the combined data, COpf = 1.924 + COymRM • 
0.844 (L*miA^), the strong correlation is largely driven by the good correlation found in 
the normal subjects C O p f == 1.165 + C O th e r m  ® 0.909 (L*min‘ )^, as in most of the 
pulmonary hypertensive patients, the correlation was weaker.
The resting data whilst inlialing air was used in an attempt to comparing both 
techniques, without the pooling of variable amounts of data from individuals, leading to 
bias. This demonstrated that the correlation in the various subgroups of patients, was 
similar, but usually weaker, than when all the data was combined [in IPAH subjects, 
(COpF -COtierm) (± standard deviation) was found to be 1.19 (± 2.00) L#min'^ when all 
the data is used and 2.17 (± 2.17) L#min'^j as compared to only using measurements at 
rest on air. Wlien analysing percentage change in cardiac output data for either oxygen, 
nitric oxide/oxygen inhalations and exercising, the correlation was found to be 
particular poor in the pulmonary hypertensive disease subgroup data of inhaling nitric 
oxide and oxygen. The poor correlation may have been as a result of the data from 4 
individuals having the difference in percentage changes in cardiac output between the 
physioflow and thermodilutional methods being greater than 10%.
Critchley & Critchley (1998) found that in subjects with large lung fluid content, 
cardiac output measured by a thoracic impedance device underestimated CO. This is 
consistent with the results of subject 34 who had portopulmonaiy hypertension. This 
was felt to be secondary to the differential of the aorta’s change in impedance with
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respect to time (dZ/dt) being minored by the pulmonary’s dZ/dt (the lung resistance is 
usually higher, and conductivity lower, than mediastinal tissues, but this is reversed if 
there is a large fluid content in the lungs). Bougault et al (2005) found that in subjects 
with COPD during maximal exercise, tire results obtained by thoracic impedance, 
underestimated cardiac output, and speculated that for the opposite reasons in COPD, 
the values obtained by thoracic bioimpedance methods may overestimate the levels in 
their COPD subjects. In subjects with pulmonary hypertension due to arterial disease or 
emboli, it is likely that the lung water volume would be reduced, especially compared to 
normals during exercise, and that the lung impedance would increase as compared to 
aortic, so we can speculate that the findings are consistent with those found in other 
studies.
Bougault et al found in their study in 2005, that in subjects with mild to moderate 
COPD, during upright exercise, the physioflow overestimated SV and thus cardiac 
output when compared with Pick derived measurements. However, the trend of change 
in cardiac output followed changes in cardiac output trends.
The percentage changes from baseline seen with the physioflow (Physioflow, Type 
PF05L1, Manatee, France) device were better correlated then actual values and this may 
suggest that the physioflow 1 derived cardiac output may be adequate to observe 
changes in CO within individual subjects. The correlation coefficient squared of the two 
techniques in the 21 subjects, 26 paired data, r^  = 0.81 (p < 0.001) and gave a regression 
equation of % ACOppBaseline = 3.16 + %ACOTi-iEiuviBaseline » 0.916 (%), (figure 3.4a.) 
The Bland-Altman comparison (figure 3.4b) of the two techniques (%ACOppBaseline -
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%ACOTHERMBaseline) (± standard deviation) was foimd to be 2.08 (± 12.5) %, (giving 
95% confidence intervals of between -23.0 and 27.1 %). The total mean difference 
(%ACOpFBaseline -%ACOTtmRMBaseline) (± standard deviation) as expressed as a 
percentage of mean of %ACOppBaseline and %ACOTiERMBaseline was found to be 14.7 
(± 90.7) %. Unfortunately, unlike Bougault et al (2005), we do not have data on 
stepwise exercise, demonstrating the physioflow 1 (Physioflow, Type PF05L1, 
Manatee, France) follows the cardiac output changes seen by the Fick method, in 
subjects with pulmonary hypertension.
Our study demonstrates that the physioflow (Physioflow, Type PF05L1, Manatee, 
France) gave slightly more positive values as compared to thermodilutional values. 
Assuming that the thermodilutional methods are accurate, the Physioflow (Physioflow, 
Type PF05L1, Manatee, France) could not be recommended from this study as a 
method of getting accurate results for absolute CO in clinical situations. However, the 
thermodilutional method of cardiac output measurement has been reported to 
underestimate the cardiac output in comparison the Fick method, when subjects have 
tricuspid regurgitation (Hoeper, M. M. et al 1999). The results of this study, however, 
demonstrate that the physioflow device is probably accurate in measuring changes in 
trends in cardiac output within an individual. The degree of accuracy, under various 
physiological, pathological and pharmacological states may vary. This will allow the 
physioflow (Physioflow, Type PF05L1, Manatee, France) to be a useful device in 
measuring CO changes during exercise or pharmacological interventions.
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Chapter 4
Viability of Pulmonary Pressure Flow Plots During Routine Clinical Investigations 
of Subjects with Possible Pulmonary Hypertension
195
4,1 Introduction
Pulmonary hypertension is defined as a condition in which mean pulmonary arterial 
pressure at rest is elevated above 25mHg or 30mmHg. In its purest form, idiopathic 
pulmonary arterial hypertension, is a condition with a historically poor prognosis, but 
which more recently a number of new therapeutic options have been developed (British 
Cardiac Society Guidelines 2001).
Traditionally, haemodynamic assessment has been made whilst the subject is at rest and 
supine, with a change in 'pulmonary vascular resistance' (PVR) being one of the most 
important parameters measured. However, it has been shown that changes in PVR can 
be misleading as the pulmonary arterial pressure, although linearly related to cardiac 
output (CO) in the physiological range usually has a positive extrapolated intercept 
(McGregor, M. et al 1985; Snidennan, A. D. et al 1988). This means that if there is a 
passive increase in CO, there will be a corresponding increase in pulmonary arterial 
pressure, without any change in the rmderlying pulmonary vascular state. Therefore, the 
calculated PVR would seem to fall, without any real change in the resistance, 
compliance or dilatation of the blood vessels.
This can be resolved this by plotting pressiue flow cinves, created from paired data of 
mean pulmonary arterial pressure and cardiac output (McGregor, M. et al 1985; 
Snidennan, A. D. et al 1988). The change in cardiac output can be generated via 
exercise, or diverting blood through one lung (Naeije, R. 1996). This has been 
performed experimentally in animals, and in a few human studies, but only in very few 
subjects with pulmonaiy hypertension (Evans, P. et al 1971; Janicki, J. S. et al 1985; 
Leeman, M. et al 1990; McGregor, M. et al 1985; Naeije, R. et al 1994), and has not
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been used clinically. Changes in the slope of the plot, or the intercept reflect changes in 
the resistance of the pulmonary vasculature.
The object of this study was to assess the feasibility of producing pressure flow plots via 
exercise in a clinical context, and whether clinical effects phannacologically on the true 
pulmonary vasculature could be detected clinically on an individual basis.
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4.2 Methods
4.2.1. Patient group & Ethics
The study was approved by the ethics committee of the West Glasgow's NHS trust, and 
informed consent was obtained from all the patients. Thirty consecutive patients 
consented, but only twenty-four were successfully studied (11 males and 13 females) 
(Table 4.1). In six subjects, the study was unsuccessful, due to equipment failure, 2 due 
to the micromometer tipped pulmonary artery catheter and 4 due to problems with the 
thoracic bioimpedance device. The mean (±S.D.) age of the studied subjects was 56.6 
years (± 13.5), but ranged from 33 to 81. Three turned out to be normal subjects, five 
had idiopathic pulmonary arterial hypertension (IPAH), five pulmonary hypertension 
secondary to comiective tissue disorder (CTD), four had chronic tliromboembolic 
pulmonary hypertension (CTEPH), two pulmonary hypertension due to interstitial lung 
disease (ILD), two due to chronic obstructive pulmonaiy disease (COPD), one found to 
have portopulmonary hypertension and two as a consequence of left sided heart disease 
(PVH). Ten had more than a 20% drop in pulmonaiy vascular resistance (PVR) to 
nitric oxide (NO, a pulmonary vasodilator) nine did not, and 4 were not studied. Mean 
pulmonary artery pressure (MPAP) ranged from 15 mmHg to 99 mniHg, with a mean 
(±S.D.) of 48.9 (± 19.5) mmHg, right atrial pressure, 0 to 47 mmHg, mean 11.0 (± 9,4) 
mmHg, pulmonary artery wedge pressure 1 to 28 mmHg with a mean of 10.8 (± 7.5) 
mmHg and PVR ranging from 0.5 to 37 mmHg • L“^ m in , with a mean of 11.1 (± 
8.6) mmHg min . In total 86 studies were performed, 30 each whilst inhaling air or 
a nitric oxide/ oxygen combination, and 26 whilst inhaling oxygen.
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Table 4.1: Subject demographics and haemodynamic supine resting
Subject
Number
Study
Number Initials
MPAP SPAP
(
DPAP
mmHg
RAP PAWP CO PVR
( i n n i H g  /  
L . i n i n ’ )
Age Sex Diagnosis Vaso­dilator
Response
1 1 M,C 17 23 11 47 8.1 2 55 F normal N/A
2 2 i,c 8 14 2 1 14 3.7 0.0 40 F normal
3 3 B,Ri 15 24 3 12 9 5.6 0.5 37 F normal N /A
5 4 G,C 57 91 37 6 7 5.5 9 49 M IPAIi N
5 5 G,C 56 90 32 5 8 4.6 10.4 50 M IPAH N
5 6 G,C 55 85 34 11 10 4.2 10.7 50 M IP AH N
6 7 W,F 79 137 48 11 14 3.3 20 67 M IPAH Y
7 8 E,M 63 115 23 14 15 3.7 13 73 F IPAH Y
8 9 W ,0'H 51 82 28 4 2 3.0 16.3 61 ,M IPAH Y
8 10 W ,0 ’H 51 82 28 4 2 3.0 16.3 61 M IPAH Y
8 11 W ,0'H 51 82 28 4 2 3,0 16.3 61 M IPAH Y
9 12 s ,s 60 103 60 10 3 4.5 13 45 F IPAH N
13 13 R,C 49 77 27 8 5 3.6 12 54 F CTD Y
14 14 Y,McB 48 79 33 0 1 2.6 14 48 F CTD Y
15 15 I,P 36 62 17 6 5 4.4 7.3 46 F CTD Y
16 16 J,P 99 130 82 9 4 2.4 37.1 59 M CTD Y
17 17 K,S 36 61 22 2 3,9 4 62 F CTD N
17 18 K,S 37 62 23 3 3.9 5 63 F CTD N
17 19 K,S 38 63 24 4 3.9 6 64 F CTD N
20 20 TF 63 100 36 20 20 3.7 12 71 M CTEPH N
21 21 s ,o 46 79 27 8 5 11 74 M CTEPH N/A
26 22 G,S 66 107 40 14 23 4.1 10.6 50 M CTEPH N
27 23 G,W 56 98 33 9 7 3.3 14.9 37 M CTEPH N
2 8 2 4 W,F 39 54 28 18 12 2.6 5 71 M ILD Y
30 25 B,Ra 57 81 44 3 4 2.0 26.1 33 F ILD Y
31 26 R,McD 43 74 26 11 8 2.2 16 60 M COPD N
32 27 M,T 30 50 10 4 13 4.1 4 81 F COPD N
34 28 S,C 19 31 9 10 15 10.7 0,4 48 F portopulm N/A
36 29 F.B 43 60 26 9 22 4.9 4.2 65 F PVH N
1 37 30 J,B 52 86 32 19 28 5.4 4.2 73 M PVH Y
4.2.2. Equipment and Experiments
Initial haemodynamic evaluation was performed with the patient supine and breathing 
room air, according to our standard protocol as described in chapter 2.3. The inhaled gas 
was delivered to the patient, as described in chapter 2.5.1, and shown in Figures 2.14 a-
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c and Figure 4.1. The right heart catheter (Gaeltec, Dunvegan, Isle of Skye), its insertion 
storage and processing are described in chapter 2.1. Cardiac output was measured non- 
invasively by thoracic electrical bioimpedance (PhysioFlow 1, Manatee, France) as 
described in chapter 2.2 and the pulmonary pressuie and cardiac output data combined 
as in chapter 2.5. Between 4-18 sets, [mean (± S.D.) of 14 (± 3.2), on air mean (± S.D.)
12.1 (± 3.7), with oxygen 14.6 (±2.5), and with the nitric oxide oxygen combination, 
14.9 (± 2.6)] of paired of data were collected at rest and exercise respectively on each 
subject. The exercise consisted of a maximum of 3 minutes, or less if the subjects could 
not manage it, of alternate straight leg raising. All subjects had almost a full resting 
haemodynamics performed within 24 hours of the exercise test during routine right 
heart catheterization with a swan-gantz catheter, when MPAP, Svo2, PWCP and CO 
were initially measured.
The nitric oxide was supplied by a pure NO source cylinder (HOC, UK) and delivered 
via a mouth piece (figure 4.1). The mixture of 02/NO was sampled by a NO sampling 
device (NOXBOXII, Bedford scientific Ltd, Kent, England).
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Figure 4.1 : Inhalation gas delivery system
Magill-Mapelson A 1.6m with2L reservoir bag
- A .
Standard 2 4F
Elephant tubingSampling 
tubing to 
NOxBOx
APL 
V alveNitric Oxide supply tubing
Air/Oxygen 
supply-15 LAnin
2L reservoir bag
4.2.3. Analysis
Analysis of the data obtained was performed using the SPSS 13.0 package as described 
in chapter 2.7.
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4.3. Results
All the sets of paired data for all the studies underwent regression analysis with 
confidence intervals for slope and intercept (tables 4.2, and table 4.3). Scattergrams 
were reviewed for predicted- actual MPAP versus actual MPAP, and were all found to 
be reasonable. An anova test of non-linearity (table 4.3), the visual assessment of 
histograms of frequency of standardized residuals and normal probability plots of 
standardized residuals were reviewed, to assess the linearity or suitability for linear 
regression of the produced lines. An ancova test of parallelism (table 4.4) as well as 
comparing the confidence intervals of the slope and intercept were undertaken to assess 
if the slopes (or intercepts) were statistically different.
Figidre 4.2a
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Figures 4.2a & h: Examples o f  regression plots produced from individual subjects, using data derived 
dttring a 3 minute straight leg raising exercise test, and from a micromanometer tipped pulmonary artery 
catheter and thoracic bio-impedance (a) example ofpoor quality plots (b) example o f good quality plots.
Examples of the variable quality of plots produced are shown in figures 4.2a & b.
The combined number of subjects was 24, and they underwent sets 30 studies, 
producing 86 linear regression lines (a single line for each exercise test). Of these lines, 
only forty two were able to be tested for non-linearity and 3 were statistically found to 
be non-linear. The histograms of frequency of residuals and the normal probability plot
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of residuals, in more than 50% of the lines, were also visually poor, with either a poor 
normal distribution or deviation from the line of identity. The combination of these 
three tests despite all the scattergrams being reasonable, suggest that about a third of the 
plots could produce lines which were satisfactorily straight.
The analysis of differences in slope, performed by the ancova test of parallelism, 
(covariance) found only a significant difference in only 26 pairing of slopes, out of 86. 
The confidence intervals for slopes did not overlap in only 9 pairs of slopes.
The intercept had a standard error that was on average 51% of intercept, (± 109%) but 
with a median of 26.52% and range of 5.38%- 966.67%. Seven of the 86 intercepts had 
a standard error of greater than 100% of baseline, and if these were excluded the mean 
standard error would have been 30.1% of intercept, (± 21.0%) but with a median of 
25.7% and range of 5.38% to 99.07%. Only 32 of the 86 lines had a standard error of 
less than 20% of baseline. The slope had a standard error that was on average 105% of 
baseline, (± 359%) but with a median of 15.1% and range of 1.4 to 2767%. Ten of the 
86 slopes had a standard error of greater than 100% of baseline, and if these were 
excluded the mean standard error would have been 20.0% of baseline slope, (± 20.7%) 
but with a median of 14.27% and range of 1.4% to 98.6%. Only 49 of the 85 lines had a 
standard error of the slope less than 20% of baseline. In addition, only 65 of the of the 
linear regression analysis were significant (Table 4.3).
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STUDY GAS constant Sig.
95% Co lnter\ con. 
Lower
nfidence ta\ for stant 
Upper
1
AIR InterceptSlope
-6.57
5.74
0.215
<0.001
-17.394
3.635
4.255
7.854
OXYGEN InterceptSlope
-12.62
6.05
0.003
<0.001
-20.071
4.645
-5.176
7.455
N0&
OXYGEN
Intercept
Slope
-2.86
3.64
0.326
<0.001
-8.864
2.546
3.139
4.742
2
AIR InterceptSlope
-0.35
1.62
0.801
<0.001
-3.233
1.196
2.541
2.035
OXYGEN InterceptSlope
4.31
1.80
0.001
<0.001
2.019
1.441
6.599
2.150
NO & 
OXYGEN
Intercept
Slope
7.74
1.48
<0.001
<0.001
4.540
0.940
10.935
2.025
3
AIR InterceptSlope
18.07
1.96
<0.001
0.001
13.921
0.968
22.226
2.950
OXYGEN InterceptSlope
-2.51
7.33
0.738
0,002
-18.215
3.120
13.192
11.538
N0&
OXYGEN
Intercept
Slope
12.69
2.82
<0.001
<0.001
9.126
1.820
16.255
3.817
4
AIR InterceptSlope
60.32
3.45
0.001
0.237
33.079
-2.856
87.559
9.751
OXYGEN InterceptSlope
45.72
7.95
<0.001
<0.001
38.899
6.244
52.540
9.648
N0&
OXYGEN
Intercept
Slope
64.80
2.80
<0.001
0.018
56.045
0.552
73.547
5.039
5
AIR InterceptSlope
39.55
7.56
<0.001
<0.001
34.120
6.234
44.981
8.877
OXYGEN InterceptSlope
52.96
4.57
<0.001
<0.001
47.238
3.080
58.686
6.063
N0&
OXYGEN
Intercept
Slope
44.85
6.69
<0.001
<0.001
42.121
5.925
47.584
7.453
6
AIR InterceptSlope
28.86
10.89
0.002
<0.001
12.715
6.727
45.002
15.057
OXYGEN InterceptSlope
41.47
7.38
<0.001
<0.001
28.443
3.929
54.494
10.839
N 0&
OXYGEN
Intercept
Slope
45.87
5.96
<0.001
0.002
33.915
2.483
57.818
9.437
7
AIR InterceptSlope
72.72
3.38
<0.001
0.548
48.842
-8.891
96.595
15.657
OXYGEN InterceptSlope
62.46
6.85
<0.001
0.011
52.838
1.826
72.082
11,874
N 0&
OXYGEN
Intercept
Slope
53.90
5.06
<0.001
0.002
49.639
2.267
58.156
7.846
Table 4.2a: The value o f the constant for the Slope, intercept with the y-axis o f the linear regression equation
for each study, as well as the significance and the 95% confidence internal for each value, for studies 1-7
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STUDY GAS constant Sig.
95% Confidence 
Interval for 
constant
Lower
Bound
Upper
Bound
8
AIR Intercept 23.03 0.238 -18.575 64.635Slope 7.98 0,059 -0.390 16.346
OXYGEN Intercept 99.24 0.002 48.332 150.151Slope -8.55 0.119 -19.772 2.669
N 0&
OXYGEN
Intercept 31.13 0.055 -0,731 62.989
Slope 5.92 0.072 -0.613 12.457
9
AIR intercept 46.26 <0.001 40.079 52.433Slope 9.44 <0.001 7.432 11.445
OXYGEN Intercept 15.46 0.008 4.771 26.153Slope 17.00 <0.001 13.187 20.803
NO&
OXYGEN
Intercept 23.28 0.011 6.349 40.213
Slope 11.98 0.001 6.126 17.838
10
AIR Intercept 20.31 0.034 2.088 38.539Slope 15.44 0.001 8.882 21.993
NO & 
OXYGEN
Intercept -9.83 0.541 -43.472 23.817
Slope 22.87 0.001 10.973 34.776
11
AIR Intercept 40.43 0.010 13.182 67.677Slope 15.07 0.006 5.846 24.296
NO&
OXYGEN
Intercept 15.12 0.117 -4.282 34.520
Slope 16.07 <0.001 9.236 22.909
12
AIR Intercept 40.42 0.049 0.239 80.601Slope 8.55 0.078 -1.290 18.381
OXYGEN Intercept 39.84 0.038 2.773 76.907Slope 7.88 0.108 -2.153 17.922
NO & 
OXYGEN
Intercept 36.60 0.026 5.506 67.702
Slope 6.25 0.100 -1.503 14.012
13
AIR Intercept 65.20 <0.001 48.536 81.868Slope 3.40 0.176 -1.841 8.636
OXYGEN Intercept 43.28 <0.001 33.411 53.154Slope 8.26 <0.001 5.200 11.329
NO & 
OXYGEN
Intercept 30.67 <0.001 20.582 40.761
Slope 9.54 <0.001 6.081 13.001
14
AIR Intercept 37.31 0.003 17.174 57.455Slope 6.49 0.017 1.535 11.444
OXYGEN Intercept 44.70 0.001 23.592 65.813Slope 4.34 0.127 -1.470 10.141
N 0&
OXYGEN
Intercept 49.18 <0.001 41.161 57.207
Slope 2.53 0.028 0.335 4.720
Table 4.2b: The value o f the constant for the Slope, intercept with the y-axis o f the linear regression equation
for each study, as well as the significance and the 95% confidence interval for each value, for studies 8-14
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STUDY GAS CONSTANT Sig.
95% Co 
Interv 
Con 
Lower 
Bound
nfidence 
'al for 
stant 
Upper 
Bound
15
AIR Intercept 23.66 <0.001 14.951 32.366Slope 5.66 <0.001 3.447 7.873
OXYGEN Intercept 29.90 <0.001 25.193 34.609Slope 4.14 <0.001 2.875 5.408
NO & 
OXYGEN
Intercept 27.22 <0.001 23.638 30.795
Slope 3.89 <0.001 2.889 4.888
16
AIR InterceptSlope
94.79
2.13
<0.001
<0.001
91.860
1.327
97.721
2.934
OXYGEN InterceptSlope
80.00
5.92
<0.001
<0.001
74.136
4.206
85.868
7.638
NO & 
OXYGEN
Intercept
Slope
59.46
9.67
<0.001
<0.001
54.209
7.886
64.702
11.448
17
InterceptAIR Slope
35.69
4.35
0.001
0.067
22.712
-0.424
48.662
9.116
NO & Intercept 
OXYGEN Slope
41.37
1.42
<0.001
0.132
36.052
-0.516
46.680
3.350
18
Intercept
Slope
47.59
1.09
<0.001
0.367
39.922
-1.542
55.249
3.725
NO & Intercept 
OXYGEN Slope
43.82
1.23
<0.001
0.061
39.956
-0.068
47.685
2.523
19
AIR InterceptSlope
41.59
1.48
<0.001
0.199
33.839
-0.990
49.345
3.949
OXYGEN InterceptSlope
40.01
1.74
<0.001
0.021
35.912
0.343
44.109
3.146
NO&
OXYGEN
Intercept
Slope
43.80
-0.03
<0.001
0.912
41.804
-0.703
45.787
0.636
20
AIR Slope
13.97
15.43
0.415
0.018
-21.841
3.067
49.781
27.786
OXYGEN Slope
17.53
15.09
0.113
0.001
-4.734
6.970
39.801
23.214
NO & Intercept 
OXYGEN Slope
30.58
9.37
<0.001
<0.001
24.397
7.044
36.769
11.687
21
AIR InterceptSlope
-6.71
12.17
0.067
<0.001
-13.970
9.916
0.541
14.414
OXYGEN InterceptSlope
0.60
9.89
0.919
<0.001
-11.658
6.026
12.867
13.751
NO & 
OXYGEN
Intercept
Slope
2.39
7.40
0.749
0.008
-12.886
2.100
17.668
12.705
Table 4.2c: The value o f the constant for the Slope, intercept with the y~axis o f the linear regression equation
for each study, as well as the significance and the 95% confidence interval for each value, for studies 15-21
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STUDY GAS CONSTANT Sig.
95% Confidence 
Interval for 
constant
Lower
Bound
Upper
Bound
22
AIR InterceptSlope
86.98
4.18
<0.001
0.002
75.044
1.793
98.925
6.575
OXYGEN InterceptSlope
97.79
1.75
<0.001
<0.001
94.513
1.124
101.067
2.366
NO & 
OXYGEN
Intercept
Slope
104.09
0.46
<0.001
0.401
97.757
-0.684
110.423
1.603
23
AIR InterceptSlope
38.54
9.63
<0.001
0.005
21.748
3.636
55.325
15.629
OXYGEN InterceptSlope
45.31
5.56
<0.001
<0.001
41.848
4.231
48.766
6.895
NO & 
OXYGEN
Intercept
Slope
52.32
3.19
<0.001
0.004
47.124
1.262
57.514
5.116
24
AIR InterceptSlope
35.71
4.20
<0.001
0.021
27.835
0.860
43.577
7.538
OXYGEN InterceptSlope
45.23
0.49
<0.001
0.710
38.362
-2.461
52.102
3.448
NO & 
OXYGEN
Intercept
Slope
22.59
7.87
0.014
0.030
5.993
0.985
39.191
14.745
25
AIR InterceptSlope
21.26
17.59
0.088
0.002
-3.948
8.650
46.462
26.534
OXYGEN InterceptSlope
43.64
5.13
<0.001
0.074
29.876
-0.593
57.397
10.847
NO & 
OXYGEN
Intercept
Slope
27.14
10.57
<0.001
<0.001
18.600
6.692
35.675
14.451
26
AIR interceptSlope
60.68
-3.38
<0.001
0.258
43.662
-9.661
77.692
2.901
OXYGEN InterceptSlope
42.71
4.30
0.003
0.335
17.696
-5.086
67.727
13.681
NO & 
OXYGEN
Intercept
Slope
37.44
5.96
0.001
0.058
19,922
-0.241
54.955
12.163
27
AIR InterceptSlope
0.98
9.22
0.888
<0.001
-14.131
5.555
16.089
12.882
OXYGEN InterceptSlope
-0.31
9.82
0.972
0.003
-19.005
4.155
18.382
15.483
NO & 
OXYGEN
Intercept
Slope
4.32
7.78
0.244
<0.001
-3.293
5.588
11.940
9.978
Table 4.2d: The vaine o f  the constant fo r  the Slope, intercept with the y-axis o f  the linear regression ecpiation 
fo r  each study, as well as the significance and the 95% confidence interval fo r  each value, fo r  studies 22-27
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Study gas CONSTANT Sig.
95% Co 
Inten 
con
Lower
Bound
nfidence 
tal for 
3tant
Upper
Bound
AIR InterceptSlope
21.69
0.33
<0.001
0.520
16.351
-0.758
27.034
1.414
28 OXYGEN InterceptSlope
-4.22
10.15
0.656
0.011
-24.007
2.707
15.575
17.593
NO&
OXYGEN
Intercept
Slope
24.30
-0.80
0.001
0.667
11.743
-4.657
36.857
3.065
AIR InterceptSlope
28.88
5.42
<0.001
0.002
15.559
2.263
42.198
8.580
29 OXYGEN InterceptSlope
31.94
4.19
<0.001
0.001
22.395
1.918
41.495
6.458
NO & 
OXYGEN
Intercept
Slope
43.13
1.16
<0.001
0.205
35.710
-0.688
50.554
3.017
AIR InterceptSlope
23.56
12.84
0.102
0.039
-8.590
1.250
55.717
24.428
30 OXYGEN InterceptSlope
1.10
19.71
0.949
0.004
-35.344
7.224
37.554
32.203
NO&
OXYGEN
Intercept
Slope
35.74
4.65
<0.001
0,001
26.887
2.393
44.584
6.914
Table 4.2e: The value o f the constant fo r  the Slope, intercept with the y-axis o f the linear regression equation 
fo r  each study, as well as the significance and the 95% confidence interval fo r  each value, fo r  studies 28-30
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study gas
Line
F
3ar regresï 
statistics
Sig.
>ion
r 2
test of d 
from lii
F
eviation
learity
Sig.
1
AIR
OXYGEN
NO & 
OXYGEN
33.68
85.34
50.07
<0.001
<0.001
<0.001
0.692
0.859
0.769
16.78
1.28
8.03
0.19
0.61
0.27
2
AIR
OXYGEN
NO & 
OXYGEN
68.23
117.87
34.38
<0.001
<0.001
<0.001
0.830
0.894
0.711
0.99
5.28
0.55
0.33
3
AIR
OXYGEN
NO & 
OXYGEN
17.75
13.78
36.19
0.001
0.002
<0.001
0.542
0.479
0.707
1.81
4.40
4.49
0.30
0.20
0.20
4
AIR
OXYGEN
NO & 
OXYGEN
1.67
100.30
7.14
0.237
<0.001
0.018
0.193
0.878
0.338
1.51
17.17
0.55
0.02
5
AIR
OXYGEN
NO & 
OXYGEN
150.31
41.82
348.02
<0.001
<0.001
<0.001
0.915
0.711
0.959
5.96 0.31
6
AIR
OXYGEN
NO & 
OXYGEN
2.01
8.24
0.01
.199(a)
.021(a)
.912(a)
0.692
0.600
0.491
0.75
10.11
0.66
0.02
7
AIR
OXYGEN
NO & 
OXYGEN
4.52
3.28
3.46
0.078
0.108
0.100
0.041
0.400
0.519
2.01 0.49
8
AIR
OXYGEN
NO & 
OXYGEN
31.46
21.01
13.52
<0.001
<0.001
0.002
0.377
0.248
0.245
9
AIR
OXYGEN
N 0&
OXYGEN
0.39
8.68
15.11
0.548
0.011
0.002
0.926
0.858
0.579
12.95 0.21
10
AIR
NO&
OXYGEN
4.83
2.97
.059(a)
.119(a)
0.816
0.548
1.88 0 .3 9
11
AIR
NO & 
OXYGEN
3.90
113.21
.072(a)
<0.001
0.681
0.626
1.26 0.61
Table 4.3a: Linear regression statistics, and test o f linearity statistics, for studies I -11
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Study gas
Line
F
îar regresî 
statistics
Sig.
Sion
R^
test of d 
from li
F
eviation
learity
Sig.
12
AIR
OXYGEN
NO&
OXYGEN
90.50
19.26
31.01
<0.001
0.001
0.001
0.430
0.291
0.302
1.67 0.55
13
AIR
OXYGEN
NO & 
OXYGEN
16.99
14.92
25.11
0.001
0.006
<0.001
0.193
0.723
0.714
14
AIR
OXYGEN
N 0&
OXYGEN
2.15
33.94
34.99
0.176
<0.001
<0.001
0.578
0.217
0.430
15
AIR
OXYGEN
NO & 
OXYGEN
9.59
2.77
6.80
.017(a)
.127(a)
.028(a)
0.721
0.825
0.882 0.16 0.96
16
AIR
OXYGEN
NO & 
OXYGEN
31.06
51.80
75.09
<0.001
<0.001
<0.001
0.800
0.825
0.906
20.32
29.04
0 .17
0.03
17
AIR
NO & 
OXYGEN
35.95
56.54
<0.001
<0.001
0.453
0.234
18
AIR
NO & 
OXYGEN
135.58
4.97
<0.001
.067(a)
0.102
0.244
19
AIR
OXYGEN
NO & 
OXYGEN
2.75
0.91
4.19
.132(a)
.367(a)
.061(a)
0.223
0.507
0.002
1.72
0.09
2.89
0.42
0.99
0.28
20
AIR
OXYGEN
NO & 
OXYGEN
7.27
16.12
74.86
.018(a)
0.001
<0.001
0.359
0.553
0.842
4.85
1.95
0.34
0.51
21
AIR
OXYGEN
NO & 
OXYGEN
131.45
28.93
8.38
<0.001
<0.001
.008(a)
0.891
0.616
0.276
2.01
0.52
4.87
0.51
0.81
0.18
22
AIR
OXYGEN
N 0&
OXYGEN
14.29
36.82
0.75
.002(a)
<0.001
.401(a)
0.524
0.739
0.055
191.99
1229.92
21.30
0.06
0.02
0.17
Table 4.3b: Linear regression statistics, and test o f linearity statistics, for studies 12-22
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study gas
Line
F
sar regres; 
statistics
Sig.
sion
R=
test of d 
from li
F
aviation
learity
Sig.
23
AIR
OXYGEN
NO&
OXYGEN
12.81
80.21
13.01
.005(a)
<0.001
.004(a)
0.562
0.851
0.520
24
AIR
OXYGEN
NO&
OXYGEN
8.84
0.15
6.95
.021(a)
.710(a)
.030(a)
0.558
0.018
0.465
17.22 0.18
25
AIR
OXYGEN
NO&
OXYGEN
20.58
3.99
34.16
.002(a)
.074(a)
<0.001
0.720
0.285
0.709 6.83 0.28
26
AIR
OXYGEN
NO&
OXYGEN
1.44
1.02
4.59
.258(a)
.335(a)
.058(a)
0.126
0.085
0.314 0.38 0.86
27
AIR
OXYGEN
NO & 
OXYGEN
31.43
14.27
57.85
<0.001
.003(a)
<0.001
0.759
0.543
0.805
28
AIR
OXYGEN
NO&
OXYGEN
0.44
8.45
0.19
.520(a)
.011(a)
.667(a)
0.039
0.360
0.013
146.07
5.01
5.68
0.06
0.34
0.32
29
AIR
OXYGEN
NO&
OXYGEN
12.82
14.72
1.72
.002(a)
0.001
.205(a)
0.391
0.412
0.079
1.28
0.21
0.53
0.96
30
AIR
OXYGEN
NO&
OXYGEN
12.43
11.46
19.49
.039(a)
.004(a)
0.001
0.806
0.450
0.582
4.23
0.76
0.37
0.70
Table 4.3c: Linear regression statistics, and test o f linearity statistics, for studies 23-30
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study F (air vs 02)
Sig.(air vs 
02)
F (Air vs 
NO)
Sig. (air vs 
NO)
F (02  vs 
NO)
Sig. (02  vs 
NO)
1 0.062 0.805 3.855 0.059 8.146 0.008
2 0.495 0.488 0.168 0.685 1.031 0.319
3 8.062 0.008 1.387 0.248 6.785 0.014
4 3.991 0.059 0.068 0.797 15.633 <0.001
5 10.079 0.003 1.390 0.248 6.472 0.016
6 1.689 0.204 3.808 0.061 0.354 0.556
7 0.424 0.522 0.133 0.719 0.482 0.493
8 7.280 0.015 0.145 0.707 5.565 0.028
9 14.847 0.001 0.876 0.359 2.455 0.128
10 1.465 0.240
11 0.035 0.853
12 0.011 0.916 0.178 0.680 0.089 0.769
13 2.955 0.100 4.769 0.039 0.344 0.562
14 0.379 0.546 2.409 0.140 0.251 0.622
15 1.770 0.196 2.111 0.160 0.099 0.757
16 18.198 <0.001 66.598 <0.001 10.705 0.003
17 1.322 0,268
18 0.009 0.925
19 0.039 0.846 2.574 0.129 7.087 0.017
20 0.002 0.961 1.301 0.264 2.263 0.144
21 1.187 0.284 3.251 0.079 0.597 0.444
22 6.088 0.021 9.946 0.004 4.552 0.042
23 3.324 0.081 6.799 0.016 4.804 0.038
24 2.602 0.128 17.749 0.001 0.219 0.646
25 6.164 0.023 3.413 0.078 2.326 0.140
26 2.320 0.143 5.561 0.029 0.110 0.743
27 0.028 0.868 0.541 0.469 0.616 0.440
28 6.652 0.016 0.304 0.586 7.856 0.009
29 0.449 0.507 6.207 0.017 4.632 0.037
30 0.558 0.465 1.294 0.271 6.751 0.015
Table 4.4.: F values and significance for comparison o f slopes o f equations produced by 
linear regression analysis for individual studies whilst inhaling air, oxygen o f nitric 
oxide and oxygen.
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4.4. Discussion
The results of the study showed some variability. Of the 62 subjects asked to participate 
in the study, only 30 agreed. Of this cohort, due to equipment failure, only 24 
underwent successful studies (80%), 4 failed due to complete failure of the impedance 
cardiac output monitor (13% of those studied) and 2 (7%) due to a failure of the 
micromanometer tipped catheter to measure or record accurately the pulmonary artery 
pressures.
86 sets of paired data were successfully performed, whilst supine at rest and exercising, 
as part of 30 experiments. From the 86 sets of paired data, only 42 could be tested 
statistically for linearity and 3 failed the test of linearity, leaving only 45 % successful. 
Furthennore, the confidence intervals for the slope & the intercept were so wide, that 
only 32 of 86 obtained had slopes that had 95% confidence intervals that were within 
20% of the base levels, and 65 with intercepts that had 95% confidence intervals that 
were within 20% of the base levels.
These results indicate that at least on an individual basis, reliable Fressure-Flow (P~Q) 
plots generated by a combination of a micromanometer tipped catheter, thoracic 
bioimpedance, and supine straight leg raising exercise is not feasible in clinical practice 
in subjects investigated for pulmonary hypertension.
Experimentally, however, cumulative effects in individual patient groups may still be 
detectable, if the results from several individuals were pooled. This method may still be 
useful in the investigation of effects of diseases and phannaceuticals in human 
experiments.
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The thoracic bioimpedance Cardiac index seemed to be the less reliable of the two 
devices. If the cardiac index and the pulmonary arterial pressure values obtained during 
each episode of exercise were plotted against time, the measured mean pulmonary 
artery pressures followed more closely the exercise periods, with less variability than 
the increase in cardiac output measurements. It may be that another method of 
measurement for continuous cardiac output, like pulse contour continuous cardiac 
output (PiCCO) or continuous lithium dilutional cardiac output (LiDCO) (Warburton, 
D. E. et al 1999), or another exercise mechanism, like a supine cycle ergometer, may 
give better results. It is however worth noting that the LiDCO and PiCCO devices have 
not been validated for use during exercise. Simminou et al (2002), used a supine cycle 
ergometer to produce the exercise, and states that in all seven subjects the plots 
produced were recto-linear, but the statistical evidence to back up this statement was not 
produced.
It is also worth noting that although we aimed to collect a total of 15-17 sets of paired 
data, 4 during rest and 11/12 during 3 minutes exercise, a large percentage of subjects 
could not maintain this exercise regime. In only 46 out of 86 studies, were 15 or more 
sets of paired data collected, and of these only 9 out of 30 of the studies completed the 
full regime whilst inhaling air, during exercise. The fraction of incomplete studies, in 
which the full term of exercise was not completed, when divided into disease categories, 
was as follows, 6 of 26 studies in IPAH subjects, 8 out of 12 studies in subjects with 
CTEPH, 12 out of 19 studies in subjects with CTD, and 9 out of 10 studies in subjects 
with COPD or ILD. The average time exercising achieved in those who did not 
complete the exercise was 110 secs (100 seconds in the 19 air inhalation studies, and
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120 seconds in the 25 incomplete studies inhaling 0% or NO/O2).
The linear regression analysis of sets of paired data include 4 taken just prior to 
exercise, as it was assumed that the anticipation of exercise, would lead to a slight 
increase in cardiac output. This was not always seen. The importance of this is that the 
resting values may be too contiguous, and alter the weighting of the linear regression 
equation. Furthermore, with the large numbers of incomplete exercise studies, the 
influence would be even gieater.
Possible methods of increasing the number of sets of paired data would be to do 
repeated exercise tests or to continue monitoring pressure flow data after exercise. The 
problem with the former method is the fact that we were dealing with sick individuals. 
If an individual study is performed, without any problems, and with the pressme and 
flow values returning to baseline within the six-minute rest period, excluding set up 
time, the study lasted a minimum of 1/2 hr. In practice, the study would last at least an 
hour or more, from start to finish, and the individuals in whom repeated values are most 
required, were those who were unable to exercise for the full 3 minutes as they were 
fairly exhausted. Repeating the tests on the same day in such cases is clearly not feasible 
and other factors may change if the study was to be repeated on another occasion. With 
the latter possible method, to continue monitoring pressure flow data after exercise, the 
subjects in our study were detached from the gas delivery apparatus immediately post 
exercise, often at their own request, especially when inhaling air, and so the 
experimental conditions were altered. Furthermore, even if this had not been the case, 
the fact that the subject was not exercising, may also have altered the conditions.
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The importance of attempts to eontinue to develop a method of producing pressure flow 
plots clinically, can be demonstrated by the paper by Simminou et al (2002), as well as 
chapters 1.6. Simminou et al (2002) demonstrate that there are clear differences in 
subjects at baseline and at 3 months after prostacyclin treatment, without a significant 
difference in traditional haemodynamic outcomes, which may be the reason for 
improved exercise tolerance. Future research might demonstrate differences in response 
to treatments or prognosis.
Finally, a study investigating the use of dobutamine as a method of producing pressure 
flow plots clinically would be useful (Naeije, R. et al 1994)..
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Chapter 5
Analysis of the Pulmonary Pressure-Flow Response in Man during Exercise whilst 
inhaling Pharmacological Agents. & a Sub-analysis of the Response within Disease
Subsets
218 :
■I5.1 Introduction 1
As previously mentioned, the term and calculation of pulmonaiy vascular resistance, 
(PVR), which is the calculation in common usage in both the literature, and medical 
practice, is misleading. It is only correct where the pulmonary arterial wedge pressure 
(PAWP), which is a sunogate marker for left atrial pressure, is also the critical closing 
pressure. The critical closing pressure is the pressure at which blood flow ceases, and 
this may be at a higher pulmonary arterial pressure than left atrial pressure (McGregor, 
M. et al 1985). This may be due to alveolar pressure (on pulmonary capillaries (West, J. 
B. et al 1965)) or other factors external to the blood vessels, or due to elastic recoil of 
the blood vessel wall (Burton, A. C. 1951). However, by ignoring the critical pressure, 
an error is introduced in the analysis of any change in ‘resistance’, in that the 
‘resistance’ as taken by PVR, may seem to decrease as cardiac output increases, without 
any change in the vasomotor, compliance, elasticity or any other physical properties of 
the pulmonaiy vasculature (Chapter 1.6) (McGregor, M. et al 1985).
Several authors have now published data, demonstrating that pressure-flow plots, which 
demonstrate more accurately the state of the pulmonary vasculature, could be produced 
in both animals and humans, by various mechanisms (Evans, P. et al 1971; McGregor, 
M. et al 1985; Naeije, R. et al 1994; Naeije, R. 1996; Reeves, J. T. et al 1988).
In our previous studies, (Chapter 4), we have shown that it is possible to produce such 
pressure-flow plots, in humans, using a combination of a micromanometer tipped 
pulmonaiy arterial catheter, and a non-invasive, thoracic bioimpedance cardiac output, 
during straight leg raising exercise, under clinical conditions in ‘diseased’ humans, with
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a varying degree of suecess. An analysis of the pooled data of all the studied subjects, to 
review the response to the pressure-flow plots to receiving air, oxygen (O2) or a nitric 
oxide/oxygen combination (NO/O2), and a further sub-analysis of the data, was 
undertaken, to review whether differing disease subgroups responded in different ways.
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5.2 Methods
5.2.1. Patient group & Ethics
Recruitment and Ethics are described in Chapter 2. In total, twenty four were 
successfully studied (Table 4.1). The data was pooled for all the studies, and where 
there were sufficient numbers of subjects, in a patient disease group, and then further 
analyzed. For the subgroup analysis, only the normal subject group (n=3), the idiopathic 
pulmonary arterial hypertension (PAH) group (n=5), the pulmonary hypertension 
secondary to connective tissue disorder (CTD) group (n=5), and the chronic 
thromboembolic pulmonary hypertension (CTEPH) (n=4) (Table 5.1) were there 
sufficient subjects. In the 3 normal subjects, all 3 were females, the mean (± S.D.) age 
was 44 (± 9) years. The idiopathic pulmonary arterial hypertension (IPAH) group, 
consisted of 3 males and 2 females, 3 of which were vasodilator responders, and whose 
mean (± S.D.) age was 59 (± 11) years. The five pulmonary hypertension secondary to 
connective tissue disorder (CTD) group consisted of 4 females and 1 male, 4 vasodilator 
responders and 1 non responder, with an mean age of 54 ± 7 years. The four subjects in 
the chronic thromboembolic pulmonary hypertension (CTEPH) group, were all males, 3 
were vasodilator non-responders, and their mean (± S.D.) age was 58 (±18) years. The 
details are shown in table 5.1
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Subject
Number
Study
Number Liitials
MPAP SPAP
(n
DPAP
imHg)
RAP PAWP CO
{ L . n i i i i ‘ )
PVR
( m n i H g  /  
L . i n i n ' ^ )
Age Sex Diagnosis VasodilatorResponse
1 1 M,C 17 23 11 47 55 2 55 F normal N/A
2 2 1,0 8 14 2 1 14 40 0.0 40 F normal
3 3 B,Ri 15 24 3 12 9 37 0.5 37 F normal N/A
5 4 G,C 57 91 37 6 7 49 9 49 M IPAH N
6 7 W,F 79 137 48 11 14 67 20 67 M IPAH Y
7 8 E,M 63 115 23 14 15 73 13 73 F IPAH Y
8 9 W,0'H 51 82 28 4 2 61 16.3 61 M IPAH Y
9 12 s,s 60 103 60 10 3 45 13 45 F IPAH N
13 13 R,C 49 77 27 8 5 54 12 54 F CTD Y
14 14
Y,Mc
B 48 79 33 0 1 48 14 48 F CTD Y
15 15 I,P 36 62 17 6 5 46 7.3 46 F CTD Y
16 16 J,P 99 130 82 9 4 59 37.1 59 M CTD Y
17 17 K,S 36 61 22 2 62 4 62 F CTD N
2 0 2 0 J,F 63 100 36 20 20 71 12 71 M CTEPH N
21 21 S,0 46 79 27 8 74 11 74 M CTEPH N/A
26 2 2 G,S 66 107 40 14 23 SO 10.6 50 M CTEPH N
27 23 G,W 56 98 33 9 7 37 14.9 37 M CTEPH N
MEAN 54.9 89.7 34.4 8.9 8 . 8 55.5 13.0 55.5
S.D, 21.0 32.3 19.0 10.7 6.9 12.1 8.7 12.1
Table 5.1: List o f subjects and studies used to pool data for assessment o f individual 
disease subgroups.
5.2.2.Equipment and Experiments
Initial haemodynamic evaluation was performed with the patient supine and breathing 
room air, according to our standard protocol as described in chapter 2.3. The inhaled gas 
was delivered to the patient, as described in chapter 2.5.1, and shown in Figures 2.14 a- 
c and Figure 4.1. The right heart catheter (Gaeltec, Dunvegan, Isle of Skye), its insertion
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storage and processing are described in chapter 2.1. Cardiac output was measured non- 
invasively by thoracic electrical bioimpedance (PhysioFlow 1, Manatee, France) as 
described in chapter 2.2 and the pulmonary pressure and cardiac output data combined 
as in chapter 2.5. Between 4-18 sets, [combined mean (± S.D.) of 14 (± 3.2), on air 
mean (± S.D.) 12.1 (± 3.7), with oxygen 14.6 (± 2.5), and with the nitric oxide/oxygen 
combination 14.9 (± 2.6)] of paired of data were collected at rest and exercise on each 
subject. All subjects had almost a full resting haemodynamics performed within 24 
hours of the exercise test during routine right heart catheterization with a swan-gantz 
catheter, when MPAP, PWCP and CO were initially measured.
The nitric oxide was supplied as previously described (chapter 4.2, figure 4.1).
5.2.3. Analysis
Analysis of the data obtained was performed using the SPSS 13.0 package as described 
in chapter 2.7.
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5.3 Results
The combined data of all 24 subjects produced 308 sets of paired sets of data for 
inhaling oxygen, 357 for inhaling oxygen and 372 for inhaling the nitric oxide/oxygen 
combination. The data, the slope was significantly different for between all three 
inhaled gas groups, (p<0.001, p=0.001, p<0.001, for air compared to oxygen, air 
compared to nitric oxide/oxygen, and oxygen compared to nitric oxide and oxygen 
combined, respectively) (Tables 5.4, Figure 5.1).
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Figures 5.1: Shows the linear regression plot o f the data o f cardiac index (Cl, L min^ m' )^ and mean 
pulmonary artery pressure (MPAP, mmHg) produced during exercise, o f  the entire pooled data set. 
A blue circle indicates the air plots, a green triangle fo r the oxygen (Ot) plots and a red square for  
the nitric oxide and oxygen inhalation plots (NO O2). The continuous line is the line o f regression for  
the air plots, the evenly broken dashed line fo r the oxygen plots and the unevenly dashed line fo r the 
nitric oxide and oxygen plots.
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The linear regression equations for the combined exercise data of the all the subjects, 
for inhalation of air, oxygen (O2) and the nitric oxide/oxygen combination (NO/O2), 
were respectively [MPAP = 7.1 *CI + 30.2] mmHg, (R  ^= 0.98, p <0.001), [MPAP =7.5 
• Cl + 28.0] mmHg, (R  ^= 0.98, p <0.001), [MPAP = 6.6 • Cl + 28.0 ] mmHg, (R  ^ = 
0.99, p <0.001) (Tables 5.2 & 5.3).
In the normal group, subjects 1-3, the data, the slope was significantly different for 
between all three inhaled gas groups, (p<0.001, p=0.004, p<0.001, for air compared to 
oxygen, air compared to nitric oxide/oxygen, and oxygen compared to nitric oxide and 
oxygen combined, respectively) (Tables 5.4, Figure 5.2).
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Figures 5.2: Shows the linear regression plot o f the paired data o f cardiac index (Cl, L min'  ^ nf^) 
and mean imlmonary artery pressure (MPAP, mmHg) produced during exercise, o f the pool data 
o f  the study disease .stihgroup o f normals. A blue circle indicates the air plots, a green triangle for  
the oxygen (O t) plots and a red square fo r  the nitric oxide and oxygen inhalation plots (NO/Ot). 
The continuous line is the line o f regression fo r  the air plot.s, the evenly broken da.shed line fo r  the 
oxygen plots and the unevenly dashed line fo r  the nitric oxide and oxygen plot.s.
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The linear regression equations for the combined exercise data of the three nonual 
subjects, for inhalation of air, oxygen (O2) and the nitric oxide/oxygen combination 
(NO/O2), were respectively [MPAP ^3 . 1  #CI + 2.9] mmHg, (R  ^ = 0.95, p <0.001), 
[MPAP -4.0 • Cl -0.8] mmHg, (R  ^ -  0.92, p <0.001), [MPAP -  2.6 • Cl + 5.6 ] 
mmHg, (R  ^= 0.90, p <0.001) (Tables 5.2 & 5.3).
The slope of the NO/O2 group, was the shallowest (slope -  2.6 mmHg *min • n f  * L'^), 
indicating that in this group, true resistance increased the least with exercise in this 
group (table 5.4).
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disease: IPAH
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Figures 5.3: Shows the linear regression plots o f  the paired data o f cardiac index (Cl, L min'  ^m' 
and mean pulmonary artery pressure (MPAP, mmHg) produced during exercise, o f the pool 
data o f  the study disease siihgroup o f  Idiopathic pulmonary arterial hypertension (IPAH). A 
blue circle indicates the air plots, a  green triangle fo r  the oxygen (Ot) plots and a red square for 
the nitric oxide and oxygen inhalation plots (NO O2). The continuous Une is the Une o f  
regression for the air plots, the evenly broken dashed Une for the oxygen plots and the unevenly 
da.shed Une for the nitric oxide and oxygen plots.
The linear regression equations for the combined exercise data of the five IPAH 
subjects during the inhalation of air, oxygen (O2 ) and the nitric oxide/oxygen 
combination (NO/O2 ), were respectively [MPAP = 8.6 #CI + 47 ] mmHg, (R^  = 0.94, p
228
<0.001), [MPAP -  9.6 • CI + 42 ] mniHg, (R  ^= 0.96, p <0.001), and [MPAP = 9.0 #
Cl + 38 ] mmHg, (R  ^= 0.95, p <0.001) (Tables 5.2 & 5.3, Figure 5.3).
In the IPAH group, the data, the slope was significantly different for between only the 
air and the oxygen subgroup, (p= 0.01) (Table 5.4).
The linear regression equations for the combined exercise data of the five CTD subjects 
during the inhalation of air, oxygen (0%) and the nitric oxide/oxygen combination 
(NO/Oi), were respectively [MPAP = 6.2 «CI + 44] mmHg •min # m^* L*‘, (R  ^== 0.99, 
p <0.001), [MPAP = 6.5 • Cl + 42 ] mmHg, (R  ^= 0.99, p <0.001), and [MPAP = 6.4 #
Cl + 38 ] mmHg, (R  ^= 0.97, p <0.001) (Tables 5.2 & 5.3, Figure 5.4).
In the CTD group, the data, the slope was significantly different for between only the air 
and the oxygen subgroup, (p = 0.003) (Table 5.4).
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Figures 5.4: Shows the linear regression plot o f the paired data o f cardiac index (Cl, L min^ m ') 
and mean pulmonary artery pressure (MPAP, mmHg) produced during exercise, o f the pool data 
o f the study disease subgroup o f pulmonary arterial hypertension secondary to connective tissue 
disease (CTD). A blue circle indicates the air plots, a green triangle fo r the oxygen (O2) plots 
and a red square fo r the nitric oxide and oxygen inhalation plots (NO/O2). The continuous line is 
the line o f regression for the air plots, the evenly broken dashed line fo r the oxygen plots and the 
unevenly dashed line fo r  the nitric oxide and oxygen plot.s.
The linear regression equations for the combined exercise data of the four CTEPH 
subjects during the inhalation of air, oxygen (O2) and the nitric oxide/oxygen 
combination (NO/O2), were respectively [MPAP = 10.3 «C1 + 12] mmHg, (R^  = 0.98, p
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<0.001), [MPAP =11.7 « C l + 8.2] mmHg, (R^  = 0.97, p <0.001), and [MPAP = 7.5 
C l +18]  mmHg, (R^  = 0.96, p <0.001) (Table 5.2 & 5.3, Figure 5.5).
disease: CTEPH
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C ard iac  In d e x  (C l,
f  igures 5.5: Shows the linear regression plot o f the paired data o f cardiac index (Cl, L 
min' m' )^ and mean pulmonary artery pressure (MPAP, mmHg) produced during 
exercise, o f the pool data o f  the study disease subgroup o f  Chronic thrombo-emholic 
ptdmonary hypertension (CTEPH). A blue circle indicates the air plots, a green 
triangle fo r the oxygen (O2) plots and a red square fo r the nitric oxide and oxygen 
inhalation plots (NO/O2)- Ihe continuous line is the line o f regression fo r  the air plots, 
the evenly broken dashed line fo r  the oxygen plots and the unevenly dashed line fo r the 
nitric oxide and oxygen plot.s.
In the CTEPH group, the data, the slope was significantly different for between all three 
inhaled gas groups, (p = 0.001, p < 0.001, p < 0.001, for air compared to oxygen, air
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compared to nitric oxide/oxygen, and oxygen compared to nitric oxide and oxygen 
combined, respectively) (Table 5.4).
The slope of the NO/O2 group, was the shallowest ( slope = 1.5 mmHg «min • m^# L'^), 
indicating that in this group, true resistance increased the least with exercise in this 
group (Table 5.4).
study gas
Line
F
îar regres 
sig.
Sion
R Square
Tes
deviatic
lines
F
t of
)n from 
rity
Sig.
All
AIR
Oxygen 
NO + 0 2
4 ,037
5,011
8,622
<0.001
<0.001
<0.001
0.972
0.976
0.985
0.339
26.197
2.579
0.977
0.001
0.114
normal
AIR
Oxygen 
N O + 0 2
965
563
443
<0.001
<0.001
<0.001
0.952
0.923
0.902
3.622
1.604
0.398
0.566
IPAH
AIR
Oxygen 
NO + 0 2
965
1,770
1,573
<0.001
<0.001
<0.001
0.944
0.96
0.953
CTD
AIR
Oxygen 
NO + 0 2
5,705
4,980
2,023
<0.001
<0.001
<0.001
0.991
0.988
0.969
CTEPH
AIR 
Oxygen 
NO + 0 2
1,798
1,589
2,661
<0.001
<0.001
<0.001
0.968
0.96
0.975
0.105
42.91
1.564
1
0.001
0.364
Table 5.2: Linear regression statistics, standardised residual statistics and test o f  
linearity statistics, for pooled data o f individual disease subgroups
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DISEASE
Constants 
of slope or 
intercept Sig.
95% Confidence 
interval for B
Lower
Bound
Upper
Bound
AIR Intercept 24.67 <0.001 23.4 26.0Slope 10.17 <0,001 9.9 10.5
ALL Oxygen InterceptSlope
32.74
7.79
<0.001
<0.001
31.8
7.6
33.7
8.0
NO + 0 2 InterceptSlope
34.66
6.89
<0.001
<0.001
34.0
6.7
35.3
7.0
AIR InterceptSlope
2.90
3.17
<0.001
<0.001
1.7
3
4.1
3.4
normal Oxygen
Intercept
Slope
-0.81
4.05
0.373
<0.001
-2.6
3.7
1
4.4
NO + 0 2 Intercept 5.62
<0.001
4.3 6.9
Slope 2.65 <0.001 2.4 2.9
AIR
Intercept 46.83 <0.001 44.7 49
Slope 8.64 <0.001 8.1 9.2
IPAH Oxygen intercept 42.40
<0.001 40.8 44
Slope 9.56 <0.001 9.1 10
Intercept 38.65 <0.001 37.1 40.2
NO + 0 2
Slope 9.07 <0.001 8.6 9.5
AIR Intercept 44.62 <0.001 43.8 45.4
Slope 6.17 <0.001 6 6.3
CTD Oxygen InterceptSlope
42.13
6.54
<0.001
<0.001
41.2
6.4
43
6.7
NO + 0 2 Intercept 38.15
<0.001 36.9 39.4
Slope 6.44 <0.001 6.2 6.7
AIR Intercept 12.00 <0.001 10.3 13.7
Slope 10.31 <0.001 9.8 10.8
CTEPH Oxygen InterceptSlope
8.24
11.66
<0.001
<0.001
6.4
11.1
10.1
12.2
NO + 0 2 InterceptSlope
18.54
7.52
<0.001
<0.001
17.5
7.2
19.5
7.8
Table 5.3: Slope, intercept of ihe linear regression equation for each study, as well as the standard 
errors and significance and confidence interval for each value, for pooled data of individual disease 
subgiaups
233
study F (air vs 02)
Sig.(air vs 
02)
F (Air vs 
NO)
Sig. (air vs 
NO)
F (02  vs 
NO)
Sig. (02  
vs NO)
All Combined 
Normal 
IPAH 
CTD 
CTEPH
30.6
16.962
6.669
9.157
12.447
<0.001
<0.001
0.011
0.003
<0.001
59.3
8.833
1.411
2.928
102.437
<0.001
0.004
0.237
0.09
<0.001
199.6
44.771
2.308
0.35
172.915
<0.001
<0.001
0.131
0.555
<0,001
Table 5.4.: F  values and significance for comparison o f slopes o f equations 
produced by linear regression analysis for individual studies M>hilst inhaling air, 
oxygen (02), or nitric oxide and oxygen (NO), for pooled data o f individual 
disease subgroups.
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5.4 Discussion
Pooled data and sub analysis of individual disease groups turned up some interesting 
findings. The slopes produced in the group of ‘normal’ patients ranged from 2.6-4.1 
mmHg •min «m^* L '\  which is higher than that previously noted for normal individuals 
(previously noted at -1.5 mmHg*min»m^*L''). Other studies have found that the slope 
in normals was 1 mmHg • in fit young men (Reeves, J. T. et al 1988), and assuming 
an average B.S.A. of 1.9, this would give a slope of 2.85 mmHg •min •m^^ There 
are several possible explanations for any discrepancies between our result in normals 
and findings from previous studies.
Firstly, most of the studies looking at pulmonary pressure flow responses in man 
obstructed one of the main pulmonary arteries thereby doubling the flow of blood down 
the other artei*y. This avoided the possible error introduced of increasing left arterial 
pressure during exercise, which may alter the resultant slope. A second error is the 
action of straight leg raising exercise, which may alter the alveolar effects on the 
vasculature, as with this form of exercise, the abdominal muscles are often involved, 
increasing intra-abdominal pressure and thus splinting the diaphragm and altering 
thoracic pressure. As, the data in Chapter 3 demonstrated, the measurement of cardiac 
output by thoracic impedance may give reasonable trends, but the actual values of 
cardiac output derived from this method did not match accurately those derived from 
thermodilutional methods. Finally, in subject 1, the slope was significantly steeper than 
subjects 2 & 3 (Table 4.2a), and this may have biased the pooled result.
In the ‘normal’ subgroup, the NO/O2 combination seemed to reduce the slope, and thus 
the resistance by the most.
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In the IPAH subgi’oup, the slopes whilst inhaling air or O2 or NO/O2 combinations, 
were all similar, (8.6, 9.6, 9.0 imnHg #min • m^# L‘  ^ respectively), but analysis found a 
statistically difference between the air and the oxygen subgroups, with a suggestion that 
with high flow oxygen, the resistance actually increased. This is not what was expected. 
Both subjects 4 & 5 demonstrated a steeper individual slope for O2 as opposed to air. 
Although not statistically significant, the slope of the air group was less than the NO/O2 
group, but the latter had a lower critical closing pressure (47 mmHg with air as opposed 
to 38 mmHg with NO/O2).
Again in the CTD group of patients, all the slopes were similar (6.2 mmHg «min • m 
L'  ^for air, 6.5 mmHg •min • m^  ^ for O2 , 6.4 mmHg •min • m^^ L'  ^for the NO/O2 
group), but the slope was significantly different when comparing air with oxygen, 
(p=0.003). Again, both O2 and NO/O2 results seem to suggest that resistance is 
increased when inhaling these gases. The critical closing pressure however seems to be 
lower when giving the O2 or NO/O2 mixture (closing pressure of air was 45mHg, O2 
42mmHg, and NO/O2 38mmHg).
In the final subgroup, of four CTEPH patients, there was a significant drop in slope (or 
resistance) from the baseline when inhaling air (slope of 10.3 mmHg •min • m^^ L'^) to 
both O2 inhalation (slope 8.2 mmHg •min • nf* L '\  p= 0.001) and NO/O2 inhalation 
study (slope 7.5 mmHg •min • m^  ^ U \  p<0.001) and also between the O2 study and 
the NO/O2 study of pooled data (p<0.001), which is what was expected in all the patient 
subgroups.
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As mentioned earlier, the slope of the ‘normal’ subgroup was twice that which was 
expected. As previously demonstrated by other authors, the slope (or real resistance) of 
the IPAH group, was greater than the nonnal subgroup (Castelain, V. et al 2002; 
Janicki, J. S. et al 1985), but the slope produced here was less than noted in these other 
studies. The slope in the CTD group was also elevated but less compared to the IPAH 
group, and the CTEPH group was steeper, suggesting that the baseline resistance was 
greatest with CTEPH and least with CTD in the pulmonary hypertensive group. The 
reduction in resistance on giving NO/O2 was greatest for the CTEPH group but seemed 
to not occur in the other disease groups. In the idiopathic pulmonary arterial 
hypertensive group, although the test for parallelism (or lack of difference) between 
slopes was non-significant (Table 5.4), the confidence intervals between the air and the 
NO/O2 slopes overlap (8.1-9.2 an 8.6-9.5 respectively). In this group the NO/O2 slope 
had a lower intercept (or closing pressure, air 46.83 mmHg (± 2.17) compared to NO/O2 
38.65 mmHg (± 1.55).
One of the weaknesses of this study was that due to low numbers of subjects, the data 
could not be split further into vasodilator responders and non-vasodilator responders. 
Both the IPAH and CTD groups had a preponderance of vasodilator responders (3 out 
of 5 and 4 out of 5, and the CTEPH group, non-vasodilator responders (at least 3 out of 
4). It may be that there is a difference between the vasodilator responders and the non­
vasodilator responders, but a larger number of subjects would be required for to divide 
each of the disease subgroups into differing vasodilator properties.
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Chapter 6
Pulmonary hypertension^ vasodilator non-responders: Fact or Fiction
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6.1 Introduction
The majority of patients with pulmonary hypertension have a thickened non-responsive 
vasculatui'e. This was demonstrated by a non-reduction of pulmonary vascular 
resistance (PVR) or mean pulmonary arterial pressure (MPAP) to an acute trial of 
inhaled nitric oxide (NO), one of the most potent and specific pulmonary vasodilators 
(Peacock, AJ 1996; Zapol, W. M. et al 1994). If a subject was shown to have no 
response at rest, then it was felt that the pulmonary vasculature could not be affected 
pharmacologically. However as demonstrated by Castelain et al (2002), PVR 
measurements alone may not reflect the effects of pharmacological agents on the 
pulmonary circulation. This is because the extrapolated pressure -flow (P-Q) plot has a 
positive intercept in patients with primary pulmonary hypertension and other respiratory 
conditions (Castelain, V. et al 2002; Harris, P. et al 1968; Janicki, J. S. et al 1985). 
Consequently changes in PVR, which is (MPAP-Left Atrial Pressure [LAP])/CO), may 
not actually reflect changes to the underlying physiology of the pulmonaiy circulation 
but simply reflect changes in cardiac output, pushing the pressure up or down a static P- 
Q plot.
The haemodynamic response of a subject to a vasodilator, at rest, on first presentation, 
is used to divide all patients into vasodilator responders and non-responders, the former 
having a greater than 20% improvement in either MPAP or PVR (2001), which allows 
patients to be selected for long term vasodilator therapy or disease targeted therapy 
(Rubin, L. J. 1997).
The purpose of this study was to ascertain whether no response of pulmonary 
haemodynamics to a vasodilator at rest, (essentially PVR), meant that there was no
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change in the P-Q profile, and hence no change in the nature of the pulmonary 
vasculature. In addition, if any change in the pressm'e-flow profiles was found, was it 
found in both vasodilator responders and non-responders. The measurements were 
perfonned with inhaled air, oxygen and a nitric oxide/oxygen (NO/O2) combination.
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6.2 Methods
6.2.1. Patient group & Ethics
The ethics and recruitment are described in chapters 2,8 and 2.6 respectively. There 
were 9 subjects in the vasodilator non-responder subgroup, of which 6  were male, 3 
female, 2 had Idiopathic pulmonary hypertension (IPAH), one pulmonary hypertension 
secondary to connective tissue disorder (CTD), 4 secondary to chronic thromboembolic 
disease (CTEPH), and 2 due to chronic obstructive pulmonary disease (COPD), and the 
mean (± S.D.) age was 58 (± 15) years (Table 6.1a). The diagnosis of pulmonary 
hypertension was made from the criteria from the 2002-WHO symposium (Simonneau, 
G. et al 2004). Patients with right-to-left shunting were excluded.
Subject
Number Initials MPAP SPAP
(
DPAP
mmHg
RAP
)
PAWP CO
L.niiii''
PVR
nunlig / 
L.iiiin')
Age Sex Diagnosis
Vasodilator
Response
5 G,C 57 91 37 6 7 4.6 9 49 M IPA H N
9 S,S 60 103 60 10 3 4.5 13 45 F IPA H N
17 K ,S 36 61 22 2 3.9 4 62 F C T D N
20 J,F 63 100 36 20 20 3.7 12 71 M C T E PH N
21 s ,o 46 79 27 8 5 11 74 M C T E PH N
, 26 G,S 66 107 40 14 23 4.1 10.6 50 M C T E PH N
27 G,W 56 98 33 9 7 3.3 14.9 37 M C T E PH N
31 R ,M cD 43 74 26 11 8 2.2 16 60 M C O PD N
32 M ,T 30 50 10 4 13 4.1 4 81 F C O PD N
Mean 50.8 84.8 32.3 9.3 11.6 3.9 10.5 58.8
S.D. 12.6 27.6 13.1 5.9 6.9 1.2 4.0 21.0
Table 6.1a: List o f subjects and studies used to pool data for assessment vasodilator 
non responder subgroup.
There were 9 subjects in the vasodilator responder subgroup, of which 4 were male, 5 
female, 3 had Idiopathic pulmonary hypertension (IPAH), 4 pulmonary hypertension
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secondary to connective tissue disorder (CTD), 2 secondary to interstitial lung disease 
(ILD), and the mean (± S.D.) age was 57 (± 13) (Table 6.1b).
Subject
Number
Initials
MPAP SPAP DPAP
nmHg)
RAP PAWP
CO
L . i i i i n ' *
PVR
( i n i t i H g  /  
L . m i n ' )
Age Sex Diagnosis
Vasodilator
Response
6 W,F 79 137 48 11 14 3.3 20 67 M IPAH Y
7 E,M 63 115 23 14 15 3.7 13 73 F IPAH Y
8 W,OT-I 51 82 28 4 2 3 16.3 61 M IPAH Y
13 R,C 49 77 27 8 5 3 12 54 F CTD Y
14 Y,McB 48 79 33 0 1 3 14 48 F CTD Y
15 hP 36 62 17 6 5 3.6 7.3 46 F CTD Y
16 J,P 99 130 82 9 4 2.6 37.1 59 M CTD Y
28 W,F 39 54 28 18 12 4.4 5 71 M ILD Y
30 B,Ra 57 81 44 3 4 2.4 26.1 33 F ILD Y
Mean 57.9 90.8 36.7 8.1 6.9 3.2 16.8 56.9
S.D. 20.1 29.5 19.6 5.6 5.3 0.6 9.9 13.0
Table 6. lb: List ofsubjects and studies used to pool data for assessment vasodilator 
responder subgroup.
6.2.2. Study Protocol
Initial haemodynamic evaluation was performed with the patient supine and breathing 
room air, according to our standard protocol as described in chapter 2.3. The inhaled gas 
was delivered to the patient, as described in chapter 2.5.1, and shown in Figures 2.14 a-c 
and Figure 4.1. Cardiac output was measured non-invasively by thoracic electrical 
bioimpedance (PhysioFlow 1, Manatee, France) and Cardiac Index (Cl) calculated from 
CO divided by body surface area. This thoracic electrical bioimpedance device has 
previously been described (Chapter 1.11, 2.2 and 3) (Charloux, A. et al 2000). The 
results were transferred to Microsoft Excel, and then processed to produce 16-second 
averages compatible intime with the MPAP. Between 9-19 sets, [vasodilator combined
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mean (± S.D.) of 12.5 (± 2.5), on air mean (± S.D.) 10.7 (± 1.5), with oxygen 12.6 (± 
2.5), and with the nitric oxide oxygen combination, 14.4 (± 2.1), and non-vasodilator 
responder combined mean (± S.D.) of 13.3 (+ 3.5), on air mean (± S.D.) 12.6 (± 3.3), 
with oxygen 13.1 (± 4.3), and with the nitric oxide oxygen combination, 14.1 (± 3.1)] of 
paired of data were collected at rest and exercise respectively on each subject. The 
exercise consisted of a maximum of 3 minutes, or less if the subjects could not manage 
it, of alternate straight leg raising. All subjects had almost a full resting haemodynamics 
perfonned within 24 hours of the exercise test during routine right heart catheterization 
with a swan-gantz catheter, at which time MPAP, PWCP and CO were initially 
measured, except subject 2 1 , who had previously had a vasodilator study, in which he 
was not a responder, and in whom total pulmonary vascular resistance (MPAP/CO) also 
had a less than 2 0 % drop with the NO/O2 combination.
The nitric oxide was supplied as previously described (chapter 4.2, figure 4.1).
6.2.3. Analysis
Analysis of the data obtained was performed using the SPSS 13.0 package as described 
in chapter 2.7.
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6.3 Results
The haemodynamic variables and patient groups are shown in Table 6.1 a & b. In the 
vasodilator non-responder group, the air and NO/O2 recto-linear lines, did not 
significantly deviate from linearity. The oxygen recto-linear plot, statistically deviated 
from linearity (F = 262, p -= 0.001). However, on reviewing the scattergrams, 
histograms of residuals, and normal probability plots of the residuals, all three lines 
seem to meet the criteria for linearity.
The regression lines for vasodilator responders, were not able to be tested statistically 
for linearity, due to small study numbers, however on reviewing the scattergrams, 
histograms of residuals, and normal probability plots of the residuals, all three lines 
seem to meet the criteria for linearity.
4 data points, in the 64 seconds prior to exercise and 5-13 data points, during exercise, 
were recorded on each patient, producing reasonable visually recto-linear plots in the 
majority of studies.
The slope of the MPAP/CI plot tended to decrease but was not statistically significant in 
all patients on the NO/O2 mixture as compared to the slope on air. When the data points 
from the nine patients who were non-vasodilator responders, were pooled the relations 
between MPAP and Cl were rectilinear (Figure 6.1) with the following equations 
produced, on air MPAP = lO.HCI + 24.1, = 0.97, p< 0.001, with oxygen, MPAP =
7.8.C1 +32.7, R  ^ = 0.97, p< 0.001 and NO/O2 mixture, MPAP -  6.9.C1+ 34.6, R  ^ = 
0.98, p<0.001). The slope of the MPAP/CI plot was significantly decreased from air to
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oxygen and the to the NO/O2 mixture (Figure 6.1, Table 6.2 & 6.3) (10.1 vs. 7.8 vs. 6.9 
mmHg/L/min/m2; p<0.001) suggesting that in these non-vasodilator responder subjects, 
there is a decrease in true resistance after inhaling oxygen and a further decrease with 
the addition of nitric oxide.
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Figures 6.1: Shows ihe linear regression plots o f ihe paired data o f cardiac index (Cl, L 
min ‘ m' )^ and mean pulmonary artery pre.ssure (MPAP, mmHg) produced during exercise, 
o f  ihe pool data o f ihe study non-vasodilator responder subgroup. A blue circle indicates 
the air plots, a green triangle fo r the oxygen (O2) plots and a red square fo r the nitric oxide 
and oxygen inhalation plots (NO/O2). Ihe blues line is the line o f regres.sion fo r  the air 
plots, green line fo r the oxygen plots red fo r the nitric oxide and oxygen plots.
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When the data points from the nine patients who were vasodilator responders, were
pooled the relations between MPAP and Cl were rectilinear (Figure 6.2) with the
following equations produced, on air MPAP =8.5*CI + 40.4, -  0.97, p< 0.001, with
oxygen, MPAP = 7.8#CI +40.1, == 0.97, p< 0.001 and NO/O2 mixture, MPAP =
8 .9 .CI+ 30.1, R  ^ = 0.97, p<0.001). The slope of the MPAP/CI plot on testing by
ANCOVA was significantly decreased from air to oxygen, and increased form the air to
the NO/O2 mixture, and oxygen to the NO/O2 mixture (Figure 6.2, Table 6 . 2  & 6.3) (8.5
vs. 7.8 vs. 8.9 mmFlg/L/min/m2; p = 0.001, p= 0.044, p<0.001).
However the 95% confidence intei'vals for the slopes of the air and the NO/O2 groups 
overlapped, which may actually suggest that there is no significant decrease in 
resistance in vasodilator responders.
246
100 -
8 0 -
60 —
cm
0 2 84 6
Cardiac Lidex (CI, )
F iltres  6.2: Shows the linear regression plot o f  the paired data o f cardiac index (Cl, L 
m in’ m' )^ and mean pulmonary artery pressure (MPAP, mmHg) produced during exercise, 
o f  the piw led data o f the study va.sodilator subgroup. A blue circle indicates the air plots, a 
green triangle fo r the oxygen (Od plots and a red square fo r the nitric oxide and oxygen 
inhalation plots (NO/Ot)- The blues line is the line o f regression fo r  the air plots, green line 
fo r  the oxygen plots red fo r the nitric oxide and oxygen plots.
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VASODILA­
TION Gas
Linea
F
r regres 
Sig.
sion Test of deviation from linearity
F Sig.
Non
Responder
AIR 
Oxygen 
NO + 02
4036.73
5011.19
8621.66
<0.001
<0.001
<0.001
0.97
0.97
0.99
0.34 0.977 
26.20 0.001 
2.58 0.114
Responder
AIR 
Oxygen 
NO+ 02
3302.97
4201.17
4481.89
<0.001
<0.001
<0.001
0.97
0.97
0.97
Table 6.2: Linear regre.s,sion statisfias, standardised residual statistics and test of linearity .statistics, 
for pooled data of vasodilator responder and non~responder subgroups
Vasodilator
responder Gas
Constants 
of slope or 
intercept
Sig.
95% Cot 
Intervs 
Lower 
Bound
ifidence 
1 for B 
Upper 
Bound
Non
R esponder
AIR
Intercept
S lope
24.672
10.174
<0.001
<0.001
23.345
9.856
25.999
10,491
Oxygen
Intercept
Slope
32.737
7,786
<0.001
<0.001
31.789
7,568
33,685
8.004
NO + 0 2
Intercept
Slope
34.660
6.890
<0.001
<0.001
33,997
6.744
35.324
7.037
R esp ond er
AIR 
Oxygen 
NO + 0 2
Intercept
Slope
40.41631
8,506524
<0,001
<0.001
39.26813
8,212599
41.56449
8.800448
Intercept
Slope
40.01696
7.850533
<0.001
<0.001
39.09567
7.610573
40.93826
8.090492
Intercept
Slope
30.77414
8.910249
<0.001
<0.001
29.87121
8.646919
31.67708
9.173579
Table 6.3: Slope, intercept of the linear regression equation for each study, as well as the standard 
errors and significance and confidence interval for each value, for pooled data of va,sodilator 
responder and non-responder subgroups
VASODILATION
F (air vs. 
0 2)
SIg. (air vs. 
0 2)
F (Air vs. 
NO)
SIg. (air vs. 
NO)
F (02  vs. 
NO)
Sig. (02  
vs, NO)
NON RESPONDER 155.302 <0.001 47.316 <0.001 47.316 <0.001
RESPONDER 11.984 0.001 4.114 0.044 32.977 <0.001
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Table 6,4.: F values and significance for comparison of slopes of equal ions produced by linear 
regression analysis for individual studies whilst inhaling air, oxygen (02) or nitric oxide and 
oxygen (NO), for pooled data of va,sodilator responder and. non-responder subgroups
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6.2 D iscussion
Puimonaiy vascular tone in animals and humans is commonly evaluated by PVR 
calculated as MPAP minus PAOP (assumed equal to left atrial pressure) divided by CO. 
This approach is misleading in many clinical and experimental circumstances (Ahmed, 
T. et al 1983; Graham, R. et al 1983; Lodato.R.T et al 1985; McGregor, M. et al 1985) 
and does not change 'with changes in the patients clinical condition (Castelain, V. et al 
2002). In both isolated lung and in vivo the MPAP/ flow relationship is rectilinear over 
the physiological range of flow (Castelain, V. et al 2002; Janicki, J. S. et al 1985). In 
young normal himians this MPAP-LAP/CO line when extrapolated towards the y axis, 
may cross through the origin (Ekelund, L. G. et al 1967). However disease processes or 
pharmacological inteiwentions can alter both the intercepts, making it either positive or 
negative, across the pressure axis, or to alter the slope, (Castelain, V. et al 2002; Harris, 
P. et al 1968; Janicki, J. S. et al 1985; Leeman, M. et al 1988; Murray, P. A. et al 1986; 
Naeije, R. et al 1987). When closing pressure is greater than PCWP and flow varies, the 
discrimination of passive (or flow dependant) and active changes to PAP cannot be 
determined from single PVR calculations. The correct approach would be to determine 
P-Q over several levels of flow (McGregor, M. et al 1985).
The extrapolated intercept is felt by most to represent the mean closing pressure of the 
pulmonary vessels. The slope is felt to represent the average cross sectional area of the 
opened vessels, (Dawson, C. A. et al 1988; Mitzner, W. et al 1987).
We felt it important that the techniques used in this study could be easily replicated in a 
normal clinical setting. However, the method of increasing cardiac output does present 
problems and inaccuracies in the study. Straight leg raising is a difficult exercise to
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perform and many subjects were unable to complete the exercise period. Secondly, 
straight leg raising uses abdominal muscles, leading to increased intra abdominal and 
intra thoracic pressures. It was hoped that the averaging of the pressures and cardiac 
outputs over 16 seconds would eradicate any swing in pressures form this source. A 
future study, repeating the studies using a supine cycle ergometer may reduce this error.
The changes in the slopes of the recto-linear plots produced on linear regression 
analysis of the individual inhalational studies suggest that in the subjects reported to be 
vasodilator ‘non-responders’, that the NO/O2 combination, far from having no effect on 
the pulmonary vasculature, may decrease the actual resistance or effect the distensibility 
and compliance of the pulmonaiy vessels, (slope of the air plot 10.1 [95% confidence 
interval 9.8-10.5] compared with NO/O2 slope of 6.9 [95% confidence interval 6.7- 
7.0]). It was noted that 4 out of the 9 subjects in this gi’oup had CTEPH, but this fall in 
slope remained true, even when data from the remaining 5 subjects was pooled and 
analyzed separately.
More surprisingly, although statistically the recto-linear plots of the ‘vasodilator 
responsive’ pooled subjects were all different under ANCOVA analysis, and indeed the 
slope of the NO/O2 plot was greater than the air plot, it was noted that visually, the air 
and the NO/O2 inhalational plots seemed to run parallel. Indeed the 95% confidence 
interval of the air and the NO/O2 groups for their individual slopes, overlapped (95% 
confidence interval for the slope of the air plot, 8 .2 -8 . 8  and for the NO/O2 plot, 8.6-9.1). 
In only the oxygen gi'oup, was the slope decreased, compared to baseline on air. What 
was startlingly obvious was the overlap of the intercept between the air and the oxygen 
group, but the reduction of the intercept in the NO/O2 group (for air, 40.4, 95%
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confidence interval 39.3-41.6, for oxygen, 40.0, 95% confidence interval 39.1-40.9, and 
for NO/O2 30.1, 95% confidence interval 29.9-31.7). As the ANCOVA analysis of the 
plots suggested a change in the slopes, further analysis of the intercepts was not 
undertaken, but this study suggests that in ‘vasodilator responsive’ subjects, the effect of 
the vasodilator is to the reduce the mean opening pressure of the vessels, but to leave 
the resistance of the vessels intact.
The method of measuring cardiac output by thoracic bioimpedance has been validated 
in subjects with several respiratory conditions, but the accuracy in subjects with 
pulmonary hypertension during exercise had not been previously investigated. This 
analysis (chapter 3) suggests that although the actual values of cardiac output in an 
individual were not as accurate when compared to the thermodilutional method, but the 
percentage change in cardiac output, in an individual, were statistically comparable.
Another problem has been that the subjects received between 40-80 ppm of NO in the 
NO/ 02 mixture. It has been shown that at 20 ppm, NO exclusively affects small 
arterioles. At 50 ppm and above, venules and small veins may be affected. This 
however should not be a major problem in this patient group as the expected main site 
of resistance would be before the venous system (Shirai, M. et al 1996).
Hypoxia during exercise in subjects with cardiorespiratoiy disease may account for the 
increased steepness of the air P-Q plots. A reduction in the slopes the pressure-flow 
plots was seen in both the non-vasodilator and vasodilator groups, when inhaling 
oxygen alone. It was noted that the slope of the plots with oxygen in both groups was
7.8.
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A further problem may be that the change to the P-Q plot is secondary to either changes 
in LAP, intrathoracic pressure, or lung volumes. Although no attempt was made to 
assess lung volumes or intrathoracic pressures, by averaging over 16s (several 
respiratoiy cycles) we hoped to eradicate any changes, which would be due to changes 
in the respiratory rate or depth. It is hoped that in the near future, thoracic bioelectrical 
impedance will be able to give an accurate estimation of LAP.
Due to the heterogeneous nature of the subjects studied, subjects with pulmonary 
venous hypertension were excluded. It would be useful, if further studies were 
performed, to repeat this sub analysis of vasodilator responsive and non-responsive 
subjects, within individual disease subgroups. A separate study, looking at the effects of 
various concentrations of NO, with and without oxygen would also be useful.
Apart from the limitations of this study, there may be several reasons, other than actual 
direct vasodilating effects of vasodilators, to why the NO/O2 group had a reduced P-Q 
slope. During exercise, the subject may become hypoxic. The addition of oxygen may 
reduce this effect and thus reduce hypoxic vasoconstriction. In addition, during exercise 
there is adrenergic stimulation. Research has previously shown in dogs that blockade of 
P receptors leads to a parallel shift of the P-Q plot up and a blockade leads to a parallel 
shift down (Murray, P. A. et al 1986). It is known that NO affects the receptors, and 
may be possible that some NO diffuses to nerve endings. This infiltration of nerve 
endings may have differing effects in our vasodilator responsive and non-responsive 
groups.
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Finally, the point of action of the vasodilator may not necessarily be at the point of 
maximum resistance. It has been postulated that the change of slope reflects change in 
Starling resistance and that resistance is mostly upstream from the point of obstruction. 
Thus, the vasodilatation may all be upstream from the pathological regions of 
obstruction.
More research is required to see if the individual variations within subjects in their 
slopes or intercepts of their P-Q plots correlate with patient’s morbidity, mortality or 
other haemodynamic or clinical values.
In conclusion, giving nitric oxide and oxygen to subjects who have no vasodilatory 
response at rest, does have an effect on the P-Q slopes, leading to a reduction in the 
slope and indicates that the vasculature is still responsive to vasodilators. In vasodilator 
responders, the effect of nitric oxide seems to be to reduce the critical closing pressure. 
To our knowledge, this is the first time that these differences have been found. This 
demonstrates that it is important to measure P-Q plots and responses to vasodilators at 
baseline. Differences in the extent of response in P-Q plots may be found in the future 
to be responsible for differences in morbidity and mortality, or demonstrate affects of 
vasodilator responses.
In light of the results of this study, it would have been interesting to see whether in the 
Castilian et al (2002) study of the effects of prostacyclin at 3 months in non-vasodilator 
responders, whether these subjects had a reduction in resistance with NO or prostacyclin 
at the commencement of the study, and whether the resistance actually altered with long 
term treatment with prostacyclin. Another study of interest would be to assess the
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vasodilator responders, who seem to reduce their critical closing pressure, and to follow 
them to discover if their pressure-flow plot response changes, in non-responders, on 
treatment, become more like responders.
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Chapter 7
Postural Effects on Pressure Flow gradients measured by Micromanoineter tipped 
Pulmonary Artery Catheter and Thoracic Impedance Cardiac output in subjects 
being inyestigated for Pulmonary hypertension
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7.1 Introduction
It has been demonstrated that changes in pulmonary vascular resistance (PVR) as 
defined by the difference between mean pulmonary arteiy pressure (MPAP) and left 
atrial pressure (LAP) divided by cardiac output (CO), may not truly reflect any changes 
in the vasomotor tone of the pulmonary vasculature. The production of pressure flow 
plots of MPAP vs CO, leads to a more accurate way of following changes in vasomotor 
tone (Castelain, V. et al 2002; Llarris, P. et al 1968; Janicki, J. S. et al 1985).
We have performed a series of studies looking at the usefulness of producing pressure 
flow plots in clinical practice of subjects being investigated for possible pulmonary 
hypertension (Chapters 4-6). It was the intention of this part of the study that as part of 
the investigations the subjects would be offered cardiopulmonary exercise testing 
(CPET), whilst measuring their pressure flow gradients. The intention was to investigate 
whether any of the CPET measurements were related to the pressure-flow slope or the 
intercept and could be used as surrogates. Unfortunately, there was a poor level of 
consent and recruitment amongst potential subjects, hence this was not possible to 
perform.
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7.2 Methods
7.2.1. Patient group & Ethics
Recruitment and Ethics are described in Chapter 2. Six patients consented, but only four 
were successfully studied (2 males and 2 females) (Table 7.1). In two subjects, the study 
was unsuccessful due to problems with the thoracic bioimpedance device. The mean age 
(± S.D.) of the studied subjects was 55.5 years (± 17.9), but ranged from 33 to 74. The 
disease groups very heterogeneous, with one normal, one with chronic thromboembolic 
pulmonary hypertension, one with pulmonary hypertension secondary to interstitial 
disease and one secondary to chronic obstructive pulmonary disease.
Subject Number
Initials
MPAP SPAP
(1
DPAP
iniiHg)
RAP PAWP PVR
(mmHg / 
L.min )
Age Sex CO
(L ,mill )
Diagnosis VasodilatorResponse
1 M,C 17 23 11 47 2 55 F 8.1 normal N/A
21 S,0 46 79 27 8 11 74 M 5.0 CTEPH N/A
31 R,McD 43 74 26 11 8 16 60 M 2.2 COPD N
36 F.B 43 60 26 9 22 4.2 65 F 4.9 PVH N
Mean
S.D.
37.3
15.9
59.0
27.6
22.5
8.5
18.8
15.9
15,0
7.7
8.3
6.0
63.5
26.7
5.1
2.4
Table 7.1: List of individual subjects with demographics and baseline haemodynamic results
7.2.2.Equipment and Experiments
Initial haemodynamic evaluation was perfonned with the patient supine and breathing 
room air, according to our standard protocol as described in chapter 2.3. The inhaled gas 
was delivered to the patient, as described in chapter 2.5.1, and shown in Figures 2.14 a- 
c and Figure 4.1. The right heart catheter (Gaeltec, Dunvegan, Isle of Skye), was as 
described in Chapter 2.1. Cardiac output was measured non-invasively by thoracic 
electrical bio impedance (PhysioFlow 1, Manatee, France) as described previously
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(Chapter 1.11, 2.2 and 3) (Charloux, A. et al 2000). The results were transferred to 
Microsoft Excel, and then processed to produce 16 second averages compatible in time 
with the MPAP as described in chapter 2.5.
Between 12-19 sets, [mean (± S.D.) of 16,2 (± 2.9)], of paired data were measured in 
these subjects whilst supine, breathing air performing straight leg raising exercises 
(chapter 4), and between 18-40 sets of paired data [mean (± S.D.) 30.8 (± 11.0)] were 
taken one minute prior, and during the cardiopulmonary exercise test. The 
cardiopulmonary exercise test was a standard ramp test, with an estimation of 
incremental work sufficient to allow 6-7 minutes before maximal exercise. All subjects 
had almost a full resting haemodynamics performed within 24 hours of the exercise test 
during routine right heart catheterization with a Swan-Gantz catheter, where MPAP, 
Svo2, PWCP and CO were initially measured.
All subjects were exercised using the “Sensormatics V-max system” (Sensormatics, 
Yorba Linda, CA, USA) wearing an adult face mask (Hans Rudolph, inc. 72000, 
Kansas City, USA).
7.2.3. Analysis
Analysis of the data obtained was performed using the SPSS 13.0 package as described 
in chapter 2.7.
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7.3 Results
The linear regression plots for the pooled data was MPAP = 7.6#CI - 1.46 mmHg, for 
the semi-erect study, and MPAP = 9.0»CI + 5.7 mmHg, for the supine study, and the 
slopes were significantly different (F=9.0, =0.003).
80 —
6 0 -
2 0 -
0 2 64 8 10 12
Cai'diac Lidex (CT, )
Figures 7.1: Shows /he linear regression plot o f  the paired data o f cardiac index (Cl, L ntin‘ 
m^) and mean pulmonary artery pressure (MPAP, mmHg) produced during exercise, o f the 
p(H)led data o f differing posture. A blue circle indicates the air plots taken whilst supine and, 
an orange pentagram fo r  the air plots taken whilst semi-erect. The continuous Une is the Une 
o f regression for the air plot.s, whilst supine the evenly broken dashed Une whilst semi-erect.
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The equations for the individual subjects were as follows. Subject 1, 
MPAP = 5.2 • C l  -  8 . 8  mmHg, for the semi-erect study, and MPAP = 5.7 • Cl -6 . 6  
mmHg, for the supine study. Subject 21, MPAP = 12 * 0 1 - 5 . 7  mmHg, for the 
semi-erect study, and MPAP = 6 . 8  • Cl -8.7 mmHg, for the supine study. Subject 31, 
MPAP = 9.4 • Cl + 27.4 mmHg, for the semi-erect study, and MPAP = -3.4 • Cl + 60.1 
mmHg, for the supine study. Subject 36, MPAP = 2.4 • Cl + 35.8 mmHg, for the semi- 
erect study, and MPAP = 5.4 * Cl +28.9 mmHg, for the supine study. Subjects 21 and 
36 had slopes that statistically differed (F = 17.4, p<0.001, F = 10.3, p=0.003), whereas 
the slopes of subject 1 and 31 did not differ.
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Caidiar Index (Cl, L* )
Figure 7.2a: Shows the linear regression plot ofpaired data of cardiac index 
(Cl, L min  ^ m'^ ) and mean pulmonary artery pressure (MPAP, mmHg) 
produced during exercise, of subject 1 of differing posture. A blue circle 
indicates the air plots taken whilst supine and, an orange pentagram for the 
air plots taken whilst semi-erect. The continuous line is the line of regression 
for the air plots, whilst supine the evenly broken dashed line whilst semi- 
erect.
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Figure 7.2b: Shows the linear regression plot ofpaired data of cardiac index 
(Cl, L min^ m^) and mean pulmonary artery pressure (MPAP, mmHg) 
produced during exercise, of subject 21 of differing posture. A blue circle 
indicates the air plots taken whilst supine and, an orange pentagram for the 
air plots taken whilst semi-erect. The continuous line is the line of regression 
for the air plots, whilst supine the evenly broken dashed line whilst semi- 
erect.
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Figure 7.2c: Shows the linear regression plot ofpaired data of cardiac index 
(Cl, L min^ m^) and mean pulmonary artery pressure (MPAP, mmHg) 
produced during exercise, of subject 31 of differing posture. A blue circle 
indicates the air plots taken whilst supine and, an orange pentagram for the 
air plots taken whilst semi-erect. The continuous line is the line of regression 
for the air plots, whilst supine the evenly broken dashed line whilst semi- 
erect.
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Figure 7.2d: Shows the linear regression plot ofpaired data of cardiac index 
(Cl, L min^ m'^ ) and mean pulmonary artery pressure (MPAP, mmHg) 
produced during exercise, of subject 36 o f dijfering posture. A blue circle 
indicates the air plots taken whilst supine and, an orange pentagram for the 
air plots taken whilst semi-erect. The continuous line is the line of regression 
for the air plots, whilst supine the evenly broken dashed line whilst semi- 
erect.
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SUBJECT
POSTURE
Constants 
of slope or 
intercept
Sig.
95% Confidence 
Interval for B
Lower
Bound
Upper
Bound
POOLED
SUPINE Slope 
SEMI- Intercept 
ERECT Slope
5.361
9.026
-1.457
7.606
0.002
<0.001
0.313
<0.001
2.016
8.195
-4.301
7.11
8.706
9.857
1.388
8.103
1
SUPINE Slope 
SEMI- Intercept 
ERECT Slope
-6.569
5.745
-8.782
5.168
0.215
<0.001
0,053
<0.001
-17.394
3.635
-17.694
4.029
4.255
7.854
0.129
6.308
21
SUPINE Slope 
SEMI- Intercept 
ERECT Slope
-6.714
12.165
-8.782
6.830
0.067
<0.001
0.053
<0.001
-13.970
9.916
-17.694
5.324
0.541
14.414
0.129
8.336
31
SUPINE Slope 
SEMI- Intercept 
ERECT Slope
60.677
-3.380
27.400
9.339
<0.001
0.258
0.008
0.002
43.662
-9.661
8.437
4.121
77.692
2.901
46.363
14.558
36
SUPINE '"‘"^ “ P'Slope
SEMI- Intercept 
ERECT Slope
28.879
5.422
35.819
2.413
<0.001
0.002
<0.001
0.002
15.559
2.263
24.575
0.942
42.198
8.580
47.063
3.883
Table 7.2: Slope, intercept o f the linear regression equation for each 
study, as well as the standard errors and significance and confidence 
interval for each value, supine and erect, for pooled data o f and 
individual subjects
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SUBJECT POSTURE
Line
F
ar regre 
Sig.
ssion
p 2
test of c 
from II
F
evlation
nearity
Sig.
POOLED SUPINE
ERECT
470.066 
921.037
<0.001
<0.001
0.689
0,689
1.406
5.523
0.413
0.031
1 SUPINE
ERECT
33.683
84.270
<0.001
<0.001
0.692
0.689
7.427
2.474
0.281
0.329
21 SUPINE
ERECT
131.446
84.270
<0.001
<0.001
0.891
0.689
2.439 0.253
31 SUPINE
ERECT
1.438
14.550
0.258
0.002
0.126
0.492 2.439 0.253
36 SUPINE
ERECT
12.818
11.471
0.002
0.002
0.391
0.323 1.130 0.570
Table 7.3: Linear regression statistics, standardised residual statistics and test 
o f linearity statistics, supine and erect, for pooled data o f and individual 
subjects
Study
F (supine vs 
semi-erect)
Sig.(supine vs 
semi-erect)
POOLED 9.062 0.003
1 0.175 0.677
21 17.44 <0.001
31 10.33 0.003
36 3.767 0.059
Table 7.4. : F  values and significance for comparison o f slopes o f  
equations produced by linear regression analysis supine and erect, for 
pooled data o f and individual subjects
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7.4. Discussion
In all but one of the subjects, as well as in the pooled result, the slope pulmonary 
pressure flow response supine was gieater than the slope erect. However the critical 
closing pressure (the slopes’ intercept) was reduced in the semi-erect position. The latter 
change was expected, as when a human subject is erect, the left atrial pressure, initially 
is lower than then the supine pressure (Reeves, J. T. et al 1988). However, in an analysis 
of pooled data of other studies performed by Reeves et al (1988), found that although 
the pulmonary artery pressure starts at a lower level when at rest semi-erect, the rate of 
increase thereafter (the slope of the P-Q plot or the true resistance) in young healthy 
subjects is actually equal in both the supine and semi-erect exercise (Reeves, J. T. et al 
1988). The subjects for which the semi-erect data was analysed were not all fit and 
young subjects (Bevegard, S. et al 1963; Groves, B. M. et al 1987; Reeves, J. T. et al 
1987). In this study, of the 4 subjects tested, the results were not as expected. A possible 
explanation for this is that the type of supine exercise perfonned was different to that 
performed in other studies (straight leg raising, as opposed to supine bicycle 
ergometry), and that the inhalation of air at rest in this study was through a gas delivery 
system. Both of these changes may have combined to increase intrathoracic pressure. If 
this increase in intrathoracic pressure resulted in a steady increase in alveolar pressure, 
the result might be a continual rise in the outflow pressure, and a continual rise in the 
total or mean pulmonary artery pressure.
Another source of error may have been the method used to monitor cardiac output, 
namely the Physioflow (Manatee, France) thoracic impedance device. This however has 
been validated in both COPD, and normal subjects at rest and in chapter 3,
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demonstrating changes in cardiac output in an individual with pulmonary hypertension 
adequately. Another possible explanation is the heterogeneity of the disease group, and 
degrees of pulmonary hypertension. The slope of the only normal subject, was as 
expected, but that of the other 3 subjects, with COPD, CTEPH, and PVH, varied, with 
the former having a more shallow slope whilst supine and the latter two subjects, having 
more shallow slopes whilst semi-erect.
The purposes of performing this study, namely comparing the differences in slope 
produced with varying posture in different disease groups, and comparing the slope and 
intercept of these produced pressure and flow plots, with variables obtained from 
cardiopulmonary exercise testing, was not able to be investigated, due to the relatively 
low number of studies achieved. This was because this study was the final investigation 
of a week of clinical and research procedures in subjects who were already feeling tired 
and ill. It may be possible however, by removing other parts of the studies perfonned on 
each of these subjects, to recruit greater numbers in the future, and complete this study 
in the future.
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Chapter 8
Pressure -Flow plots:
Use of Dobutamine as a Surrogate for Exercise.
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8.1. Introduction
Traditionally, the main method of assessing haemodynamically the success of any 
treatment in subjects with pulmonary hypertension was to review the changes to 
pulmonary vascular resistance, mean pulmonary artery pressure, and cardiac output. 
This is satisfactoiy if all three components improve, but may be misleading under other 
circumstances. As previously discussed, an increase in cardiac output, may lead to a 
small passive increase in mean pulmonary artery pressure, and an apparent decrease in 
pulmonary vascular resistance as traditionally calculated. This would erroneously then 
suggest that a pharmacological agent had led to some vasodilation of the pulmonary 
vascular circulation, when in effect its only real effect was to increase cardiac output, 
(McGregor, M. et al 1985).
A more soimd way of assessing the effects on the pulmonary circulation, would be to 
plot the pressure -flow plots of a series of paired data of mean pulmonary artery 
pressure and cardiac output (or index) produced by altering the flow tlii’ough the lungs 
(Castelain, V. et al 2002; Harris, P. et al 1968; Janicki, J. S. et al 1985).
There are several possible methods to achieve this. Traditionally, extra-corporal 
membrane oxygenation (ECMO) by-pass has been used in children in a clinical context. 
This is no longer in regular clinical use. Another method would be to measure the 
pressure and flow before and after obstructing one of the two main branches of the 
pulmonaiy arteries (right or left) and effectively doubling the flow through the other 
artery (Lategola, M. T. 1958). With regards to subjects with pulmonary hypertension, 
such a sudden rise in pulmonary artery pressure may be dangerous, and might have 
. catastrophic haemodynamic consequences.
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The final two options used are to increase cardiac output from the heart, either 
pharmacologically or via exercise (Kafi, S. A. et ai 1998). The latter has seen numerous 
experimental studies in humans (Castelain, V. et al 2002; Janicki, J. S. et al 1985; 
Reeves, J. T. et al 1988), but as shown earlier in chapter 4, is unlikely to be useful in an 
individual basis for the majority of patients.
Dobutamine has been used in a number of experimental animal and human studies 
(Ducas, J. et al 1992; Furman, W. R. et al 1982; Hyman, A. L. et al 1985; Lejeune, P. et 
al 1987b; Lejeune, P. et al 1987a; Light, R. B. et al 1988; Naeije, R. et al 1994; 
Pagnamenta, A. et al 2003). It is the intention of this study, to examine the feasibility of 
dobutamine as an alternative to exercise, to produce pressure flow plots in a clinical 
context, and to examine any differences to pressure flow plots produced by this method, 
and by exercise.
272
8.2. Method
8.2.1. Patient group & Ethics
The study was approved by the ethics committee of the West Glasgow’s NHS trust, and 
informed consent was obtained from all the patients. Subjects were recruited from all 
patients attending the Scottish Pulmonary Vascular Unit (SPVU) between January 2003 
and July 2003, for invasive investigations. Five consecutive patients consented (2 males 
and 3 females) (Table 8.1). The mean age (± S.D.) of the studied subjects was 55,2 
years (± 12.6), but the age ranged from 40 to 73. One turned out to be a normal subject, 
three had idiopathic pulmonaiy arterial hypertension (IPAH) and one pulmonary 
hypertension secondaiy to connective tissue disorder (CTD). Three had more than a 
20% drop in pulmonary vascular resistance (PVR) to nitric oxide (NO, a pulmonary 
vasodilator), one did not, and one was not studied. Mean pulmonary artery pressure 
(MPAP) ranged from 8  mmHg to 79 mmHg, with a mean (± S.D.) of 48.6 (± 24.5) 
mmHg. The range, mean and 95% confidence intervals for the other measured values 
were, right atrial pressure, 1 to 14 mmHg, mean 7,6 (± 4.5) mmHg, pulmonary artery 
wedge pressme 5 to 15 mmHg with a mean of 11.0 ±4.1 mmHg and PVR, ranging from 
0.5 to 20 mmHg • min* L"^  with a mean of 9.9 ± 6 .6 .
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Subject
Number
Initials
MPAP SPAP
(
DPAP
mmHg'
RAP PAWP CO
L . n i i n ‘
PVR
m n i l - I g  /  
L . m i n ' )
Age Sex D iagnosis
Vasodilator
Response
2 i ,c 8 14 2 1 14 3.7 0 40 F normal
5 G,C 57 91 37 6 7 4.6 9 50 M IPAH N
6 W,F 79 137 48 11 14 3.3 20 67 M IP AH Y
7 B,M 63 115 23 14 15 3.7 13 73 F IPAH Y
15 I,P 36 62 17 6 5 4.4 7 46 F CTD Y
Mean 58.8 101.3 31.3 9.3 10.3 3.9 12.3 55.2
S.D. 24,6 43.2 15.8 4.5 4.5 1.0 8.2 16.0
Table S. I: List o f  subjects who received a  10 mhmte dobutamine infusion, at a  rate o f  5 micrograms p e r  
kg weight p e r  minute for 5 minutes, and then at a rate o f  10 micrograms p e r  kg weight p e r  minute fo r  5 
minutes whilst inhaling air or a  nitric oxide/ oxygen combination through a  gas delivery system.
8.2.2. Equipment and Experiments
Initial haemodynamic evaluation was performed with the patient supine and breathing 
room air, according to our standard protocol as described in chapter 2.3. The inhaled gas 
was delivered to the patient, as described in chapter 2.5.1, and shown in Figures 2.14 a-c 
and Figure 4.1. The right heart catheter (Gaeltec, Dunvegan, Isle of Skye), its insertion 
storage and processing are described in chapter 2.1. Cardiac output was measured non- 
invasively by thoracic electrical bio impedance (PhysioFlow 1, Manatee, France) as 
described in chapter 2 . 2  and the pulmonary pressure and cardiac output data combined 
as in chapter 2.5. Between 41-45 sets, [mean (± S.D.) of 43 (± 1.6), on air and with the 
nitric oxide oxygen combination, mean (± S.D.) 42.6 (± 0.55)] of paired of data were 
collected at rest (4 sets) and during the dobutamine intravenous infusion, on each 
subject. The infusion lasted for a maximum of 10 minutes. All subjects had almost full 
resting haemodynamics performed within 24 hours of the exercise test during routine 
right heart catheterization with a swan-gantz catheter, when MPAP, PWCP and CO 
were initially measured.
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The exercise protocol was performed as described in chapter 2.3 The number of data 
plots collected for the exercise part of the study ranged between 10-16 sets, [mean (± 
S.D.) of 13.4 (± 2.8), on air and with the nitric oxide oxygen combination, mean (± 
S.D.) of 14.8 (± 1.8)]. The nitric oxide was supplied as previously described (chapter 
4.2, figure 4.1).
8.2.3. Analysis
Analysis of the data obtained was performed using the SPSS 13.0 package as described 
in chapter 2.7.
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8.3 Results
The results of the study, was variable in individual subjects. In the pooled data, the 
slope of the regression line was greatest in the study, if inhaling air (6.23 with 95% 
confidence intervals of 6.0-6.42). As expected, the slope of the NO/O2 pooled study
40
Cai diac Index (CT, L* )
Figures 8.1: Shows the linear regression plot o f  all the pooled paired data o f cardiac index (Cl, 7  
min^ m^) and mean pulmonary artery pressure (MPAP, mmHg) produced during exercise, or 
during a 10 minute intravefwus dobutamine infusion (of 5-10 micrograms/kg/min). A blue circle 
indicates the exercise inhaling air plots, a red square fo r the exercise inhaling nitric oxide and 
oxygen inhalation plots (NO/Oi, 40-80 ppm and 15L respectively), with an unbroken line, and a long 
and short broken line with wide gaps, representing the lines o f regression respectively. A green 
cross indicates a plot o f dobutamine whilst inhaling air, and an orange plus, dobutamine whilst 
inhaling the NO O2  combination, with lines o f regression respectively given by a broken line and by 
a line with long and short breaks and small gaps.
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during exercise was shallower (lower resistance), with a value of 4.97 (95% confidence 
interval of 4.84-5.09). However, the slopes of the dobutamine pressure-flow lines were 
not as expected. The air inhalation pooled data had a slope of 4.54 (95% confidence 
interval of 4.47-4.62), which indicated that it had the lowest resistance of all the studies. 
The slope of the NO/O2 inhalation dobutamine group was 5.42 (95% confidence 
interval of 5.35-5.50) (Figure 8.1, Tables 8.2). Comparison of the slopes by ANCOVA 
analysis found that there was a significant difference between the slopes of the air 
studies (exercise versus dobutamine, F 290, P<0.001), the NO/O2 studies (exercise 
versus dobutamine, F = 38, P <0.001), and between the studies of dobutamine (air 
versus NO/O2 slope, F = 218, P<0.001)(Table 8.2). Other analyses were not performed.
The results of the individual subjects were more variable (Figures 8.2 a-e, and Table 
8.2). In four subjects, the slopes of the dobutamine infusion studies were lower than the 
exercise study, (Table 8.2, figures 8.2a, b, d, e) (statistically true by ANCOVA analysis 
in 6  out of these 8  comparisons. Table 8.3). In two subjects, 5 & 11 (Figures 8.2c & e), 
the pressure -  flow slope was found to be negative for the inhalation of air whilst 
receiving dobutamine. Conversely, in subject 5, the NO/O2 & dobutamine pressure- 
flow slope was significantly steeper (11.42, with a 95% confidence interval of 5.08- 
17.76) compared to the other studies in that subject (Table 8.2).
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SUBJECT: 2
Caidiac Lidex (Cl, L ':nh& \n^)
Figures 8.2a: Shows the linear regression plot of the paired data of 
cardiac index (Cl, L min^ m'^ ) and mean pulmonary artery pressure 
(MPAP, mmHg) produced during exercise, or during a 10 minute 
intravenous dobutamine infusion (of 5-10 micrograms kg/min), in subject 
2. A blue circle indicates the exercise inhaling air plots, a red square for 
the exercise inhaling nitric oxide and oxygen inhalation plots (NO/O2, -10- 
80 ppm and 15L respectively), with an unbroken line, and a long and short 
broken line with wide gaps, representing the lines o f regression 
respectively. A green cro.ss indicates a plot of dobutamine whilst inhaling 
air, and an orange plus, dobutamine whilst inhaling the NO/O2 
combination, with lines o f regression respectively given by a broken line 
and by a line with long and short breaks and small gaps.
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Figures 8.2b: Shows (he linear regression plot of the paired data of 
cardiac index (Cl, L min^ rti )^ and mean pulmonary artery pressure 
(MPAP, mmHg) produced during exercise, or during a 10 minute 
intravenous dobutamine infusion (of 5-10 micrograms kg/min), in subject 
5. A blue circle indicates the exercise inhaling air plots, a red square for 
the exercise inhaling nitric oxide and oxygen inhalation plots (NO/O2. 40- 
80 ppm and 15L respectively), with an unbroken line, and a long and short 
broken line with wide gaps, representing the lines of regression 
respectively. A green cross indicates a plot of dobutamine whilst inhaling 
air, and an orange plus, dobutamine whilst inhaling the NO/O2  
combination, with lines of regression respectively given by a broken line 
and by a line with long and short breaks and small gaps.
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Canliac Liclex (Cl, L*miii**m )^
Figures 8.2c: Shows the linear regression plot of paired data of cardiac 
index (Cl, L min^ tn )^ and mean pulmonary artery pressure (MFAF, 
mmHg) produced during exercise, or during a 10 minute intravenous 
dobutamine infusion (of 5-10 micrograms kg min), in subject 6. A blue 
circle indicates the exercise inhaling air plots, a red square for the 
exercise inhaling nitric oxide and oxygen inhalation plots (NO/O2, ‘10-80 
ppm and 15L respectively), with an unbroken line, and a long and short 
broken line with wide gaps, representing the lines of regression 
respect ively. A green cross indicates a plot of dobutamine whilst inhaling 
air, and an orange plus, dobutamine whilst inhaling the NO/O2  
combination, with lines of regression respectively given by a broken line 
and by a line with long and short breaks and small gaps.
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Figures 8.2d: Shows the linear regression plot of the paired data of 
cardiac index (Cl, L min^ tn )^ and mean pulmonary artery pressure 
(MPAP, mmHg) produced during exercise, or during a 10 minute 
intravenous dobutamine infusion (of 5-10 micrograms kg min), in subject 
7. A blue circle indicates the exercise inhaling air plots, a red square for 
the exercise inhaling nitric oxide and oxygen inhalation plots (NO/O2, 40- 
80 ppm and 15L respectively), with an unbroken line, and a long and short 
broken line with wide gaps, representing the lines of regression 
respectively. A green cross indicates a plot of dobutamine whilst inhaling 
air, and an orange plus, dobutamine whilst inhaling the NO/O2 
combination, with lines of regression respectively given by a broken line 
and by a line with long and short breaks and small gaps.
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Figures 8.2e: Shows the linear regression plot of the paired data of 
cardiac index (Cl, L min^ m^) and mean pulmonary artery pressure 
(MPAP, mmHg) produced during exercise, or during a 10 minute 
intravenous dobutamine infusion (of 5-10 micrograms kg min), in subject 
15. A blue circle indicates the exercise inhaling air plots, a red square for 
the exercise inhaling nitric oxide and oxygen inhalation plots (NO/O2, 40- 
80 ppm and 15L respectively), with an unbroken line, and a long and short 
broken line with wide gaps, representing the lines of regression 
respectively. A green cross indicates a plot of dobutamine whilst inhaling 
air, and an orange plus, dobutamine whilst inhaling the NO/O2 
combination, with lines of regression respectively given by a broken line 
and by a line with long and short breaks and small gaps.
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Tt can be seen from figure 8.3, that the cardiac output increase for the individual 
subjects, whilst receiving dobutamine, was variable. In subjects 15 (whilst inhaling air) 
and 7 (whilst inhaling NO/O2) it may have actually decreased in the minute 
following the commencement of the dobutamine infusion, before subsequently 
increasing (figure 8.3). Taking the last minute of the dobutamine infusion to represent 
the maximal increase in Cardiac index (Cl), the mean (± S.D.) increase in, as a 
percentage of baseline was 137 (± 19) % for air (range 116-161) and 135 (± 14) % for 
NO/O2 (range 118-154). More startling, was the relatively little increase in mean 
pulmonary artery pressure (MPAP), the mean (± S.D.) for dobutamine whilst inhaling 
air was 106 (± 14) %, (range 90-123), and whilst inhaling NO/O2 107 (± 7) %, (range 
103-115). There was no statistically difference between the percentage increases in the 
air and the nitric oxide/ oxygen for neither Cl nor MPAP. There was also no statistical 
difference between the percentage MPAP pressure increase and baseline MPAP. The 
response to dobutamine in the individual subjects with respect to MPAP was again 
variable. Subject 15 has an apparent decrease in MPAP initially in both studies, 
followed in the NO/O2 with a late increase. Subject 5, seemed to initially have an 
increase in MPAP, but later, this was followed by a decrease. Subject 4 had an early and 
large increase in MPAP under both studies. Subject 2 has either a steady or late increase 
in MPAP under both studies, and in subject 7, the MPAP seemed relatively static. 
(Figure 8.3)
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SUBJECT PHARMACOLOGY
Constants 
of slope or 
Intercept
Sig.
95% Confidence 
Interval for B
Lower
Bound
Upper
Bound
POOLED
Intercept 
AIR Slope 
Intercept 
N 0 /0 2  Slope
25.97 
6.23  
30.35
4.97
<0.001
<0.001
<0.001
<0.001
24.90
6.04
28.67
4.84
27.04
6.42
31.02
5.09
DOBUTAMINE Intercept 
& AIR Slope
DOBUTAMINE Intercept 
& NO/02 Slope
37.15
4.54
28.67
5.42
<0.001
<0.001
<0.001
<0.001
36.63
4.47
28.27
5.35
37.68
4.62
29.07
5.50
2
Intercept 
AIR Slope 
Intercept 
N 0 /0 2  Slope
-0.35
1.62
7.74
1.48
0.801
<0.001
<0.001
<0.001
-3.23
1.20
4.54
0.94
2.54
2.03 
10.93
2.03
DOBUTAMINE intercept 
& AIR Slope
DOBUTAMINE Intercept 
& N 0 /0 2  Slope
10.67
1.05
9.50
1.07
<0.001
<0.001
<0.001
<0.001
9.01
0.77
7.83
0.61
12.33
I.34
II.17  
1.52
5
Intercept 
AIR Slope 
Intercept 
N 0 /0 2  Slope
39.55
7.56
44.85
6.69
<0.001
<0.001
<0.001
<0.001
34.12 
6.23
42.12 
5.92
44.98
8.88
47.58
7.45
DOBUTAMINE Intercept 
& AIR Slope
DOBUTAMINE Intercept 
& N 0 /0 2  Slope
48.62
6.55 
48.40
5.55
<0.001
<0.001
<0.001
<0.001
42.98
5.30
44.27
4.52
54.27
7.80
52.54
6.58
Table 8.2a: Slope, intercept o f  the linear regression equation fo r  each subject and study, as well as the 
standard errors and significance and confidence interval fo r  each value, supine, fo r  poo led  data o f  and  
individual subjects during exercise, or during a  10 minute intravenous dobutamine infusion (of 5-10 
microgiams/lcg/min), whilst inhaling a ir or the nitric oxide/oxygen combination
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SUBJECT PHARMACOLOGY
Constants 
of slope or 
intercept
Sig.
95% Confidence 
Interval for B
Lower
Bound
Upper
Bound
Intercept 72.72 <0.001 48.84 96.60
AIR Slope 3.38 0.548 -8.89 15.66
Intercept 53.90 <0.001 49.64 58.16
6 N 0/02 Slope 5.06 0.002 2.27 7.85
DOBUTAMINE Intercept 92.19 <0.001 80.02 104.35
&AIR Slope -1.43 0.034 -2.76 -0.11
DOBUTAMINE Intercept 45.79 <0.001 38.20 53.39
& N 0/02 Slope 11.42 0.001 5.08 17.76
Intercept 23.03 0.072 -2.24 48.30
AIR Slope 7.98 0.004 2.90 13.06
Intercept 31.13 0.004 10.71 51.55
7 N 0/02 Slope 5.92 0.007 1.73 10.11
DOBUTAMINE Intercept 58.91 <0.001 54.55 63.27
& AIR Slope 1.18 0.003 0.42 1.93
DOBUTAMINE Intercept 48.66 <0.001 43.95 53.37
& N 0/02 Slope 1.62 0.001 0.72 2.53
Intercept 23.66 <0.001 14.95 32.37
AIR Slope 5.66 <0.001 3.45 7.87
Intercept 27.22 <0.001 23.64 30.79
15 N 0/02 Slope 3.89 <0.001 2.89 4.89
DOBUTAMINE Intercept 53.75 <0.001 49.22 58.28
& AIR Slope -2.05 0.001 -3.17 -0.93
DOBUTAMINE Intercept 36.18 <0.001 32.62 39.74
& N 0 /02 Slope 0.77 0.114 -0.19 1.73
Table 8.2b: Slope, intercept o f  the linear regression equation fo r  each subject and study, as well as the 
standard errors and significance and confidence interval fo r  each value, supine, fo r  poo led  data o f  and  
individual subjects during exercise, or during a  10 minute intravenous dobutamine infusion (o f 5-10  
micrograms/kg/min), whilst inhaling a ir or the nitric oxide/ oxygen combination
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STUDY F (AIR;Exercise vs dobutamine)
Sig.(AIR;Exercise 
vs dobutamine)
F
(N0/02:Exercise 
vs dobutamine)
Sig.(N0/02:Exercise 
vs dobutamine)
F
(Dobutamine: 
air vs NO/02)
Sig.
(Dobutamine: a 
ir vs NO/02)
Pooled 290.50 <0.001 38.30 <0.001 218.40 <0.001
2 5.30 0.025 1.60 0.211 <0.001 0.966
5 8.97 0.004 3.35 0.073 1.50 0.225
6 6.86 0.011 2.86 0.096 18.80 <0.001
7 7.79 0.008 11.83 0.001 0.54 0.465
15 54.64 <0.001 14.98 <0.001 14.40 <0.001
Table 8.3. : F  values and significance fo r  comparison o f  slopes o f  equations produced by linear regression  
analysis, for p o o led  data o f  and individual subjects in the dobutamine study
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Figures 8.3a: Shows the p lo t o f  the mean pulm onary artery pressure (MPAP, %) and  
cardiac index (Cl, Vo) from  baseline (64 seconds resting values or pre-injusion values) 
against time, produ ced  during a dobutam ine infusion (5-10 m icrogram s kg min), o f  the 
individual subjects whilst inhaling air. The blue line represents fo r  subject 2, the green  
line subject 5, orange line subject 6, purple line subject 7 and the red  line subject 15.
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Figures 8.3b: Shows the p lo t o f  the mean pulm onary artery pressure (MPAP, %) and  
cardiac index (Cl, %) from  baseline (64 seconds resting values or pre-infusion values) 
against time, produ ced  during a dobutam ine infusion (5-10 m icrogram s kg min), o f  the 
individual subjects whilst inhaling N O  O 2 (40-80 ppm  15L respectively) on the right. The 
blue line is fo r  subject 2, the green line fo r  subject 5, orange line fo r  subject 6, purple line 
fo r  subject 7 and the red  line fo r  subject 15.
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8.4. D iscussion
Over the past two decades, the inadequacies of our current clinical investigation of the 
pulmonary circulation have become apparent. The in-vivo investigation that would give 
the most information with regards to the pulmonary vasculature would be investigations 
to determine pulmonaiy impedance. As this requires surgically implanted devices, it is 
difficult to determine in humans, and is impractical in a clinical context. Thus, the next 
level of information would be to obtain more about the non-pulsatile component of the 
pulmonary circulation.
It has been shown that pressure-flow plots avoid the errors generated in reviewing PVR 
and other static haemodynamic parameters, in assessing the state of dilatation and 
compliance of the pulmonary vasculature. Castelain et al (2002) found that in IPAH, 
those patients in whom there was no improvement in conventional haemodynamic 
measurements 3 month after commencement of intravenous prostacyclin, showed 
changes in pressure-flow gradients. This, they speculated, may account for the improved 
exercise tolerance found in this group. As demonstrated in chapter 6 , the pressure flow 
response to vasodilators may be different in responders as opposed to non-responders.
The majority of pressure flow plots produced in recent years in man, were produced by 
exercise or by the artery occlusion technique. They have investigated subjects with heart 
failure, ischaemic heart disease, idiopathic pulmonaiy hypertension, connective tissue 
disorders, pulmonary embolic disease and normals (Castelain, V. et al 2002; Janicki, J. 
S. et al 1985; Reeves, J. T. et al 1988). They also pooled data obtained from several 
subjects to obtain their conclusions. However, studies have not been performed to 
discover changes in individual subjects. Our study of 24 subjects who were being
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investigated for pulmonary hypertension, demonstrated that for individuals, pressure- 
flow plots produced by exercise are impractical, due to the poor success of achieving 
linearity and the wide confidence intervals for slopes and intercepts. Although changes 
in the exercise protocol and in the cardiac output measuring system might improve this, 
many of the subjects had significantly reduced exercise ability and this would lead to 
inadequate clinical test for these individuals.
Dobutamine is an ionotropic agent that has been in use since the 70's. It has combined 
alpha and beta adrenoreceptor activity. Alpha receptors and B receptors are found in the 
peripheral systemic vasculature, and it seems that at standard doses the effects of 
dobutamine on the systemic vasculature seems to cancel itself out. Its main effect is on 
the beta-1 receptors in the myocardium (Leier, C. V. et al 1983) and leads to increase 
myocardial contractility (Vatner, S. F. et al 1972; Vatner, S. F. et al 1974). It is often 
used in cardiac patients in order to increase cardiac output. With regards to the 
pulmonary circulation, receptors are present, but are not thought to have any clinical 
relevance.
This study used dobutamine as an alternative mechanism for producing pressure-flow 
plots. As with other studies in animals using dobutamine (Pagnamenta, A. et al 2003), 
we found that the steepness of the slopes of the recto-linear plots produced by the use 
of dobutamine rather than exercise, varied significantly between subjects. However, 
where there was a change in slope seen after inhaling a N 0/02 combination during 
exercise, this was only replicated in only two of the five subjects, during the dobutamine 
infusion.
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The differences in the slopes produced from dobutamine as compared to exercise may 
be due to several reasons. It may be that during exercise autonomic stimulation actually 
has an effect on the pulmonary circulation. There is some evidence to back this up, in 
that following prolonged exercise, pulmonary vascular resistance may actually fall to 
below pre- exercise levels (Ekelund, L. G. 1967; Reeves, J. T. et al 1988). Furthermore, 
during exercise the respiratory rate and flow increases six fold. This increases the 
alveolar pressure and the intrathoracic pressure in normal humans and results in an 
increase in the critical closing pressure. In some of our subjects, with underlying lung 
disease the effect may be exaggerated.
It was interesting to note the varying effects on MPAP despite a universal increase in 
cardiac index (Cl). Pagnamenta et al (2003) noted that in dogs with experimentally 
induced pulmonaiy hypertension, at doses higher than 1 0  pg kg"^  min'^ the effect of 
dobutamine on the pressure-flow curves depended on the resting tone. It may be in 
humans, depending on the underlying cause of pulmonary hypertension, the 
concentration of dobutamine required to be affective by resting tone may actually 
decrease. Other possible explanations for the reduction in MPAP noted, is that the 
dobutamine part of the study was performed 20 minutes after 3 sets of 3 minute straight 
leg raising exercises were perfonned (over a 33 minute period). Although the exercise 
was mild, in chronically ill subjects with pulmonary hypertension who are 
haemodynamically restricted, this exercise may have led to an alteration of basal tone, 
which changed during the dobutamine study. Performing the dobutamine study several 
hours after the exercise study may resolve this possibility.
It was also noted that the Cl only increased by a third in this study. It was decided to not
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exceed 10 pg kg'  ^ min'^ in this initial study for safety concerns. It would be useful to 
repeat this study using the routine cardiac protocol for dobutamine stress tests. This 
would involve increasing the dobutamine concentration in 5 pg kg"* min"* increments 
every few minutes, until the desired result, or a 40 pg kg"* min"* maximal threshold is 
achieved (Mishra, M. B. et al 1997). Mislira et al (1997) found that only 25% of 
subjects with possible ischaemic heart disease reached their maximal stroke volume on 
a 10 pg kg'* min"* infusion of dobutamine. In the pulmonaiy hypertensive subjects, a 
doubling of the Cl might be appropriate.
A further pressure-flow study with dobutamine should be performed looldng at the 
effects of dobutamine, at various concentrations, on Cl and MPAP in humans with 
various diseases.
From the results of this current study, dobutamine, at least under the cunent protocol 
cannot be recommended as a method for producing pressure flow plots in humans for 
routine clinical evaluation. Fuither studies, into its effect on humans, with pulmonary 
hypertension from a variety of causes need to be performed.
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Chapter 9 
General Discussion
293
9.1 Summary of results
Although this thesis has been limited by subject recruitment, and equipment failures, it 
has added infonnation in several areas, but also brought up several new questions that 
require further studies. In some of the studies we performed, it would be useful to 
continue collecting subjects in order to get sufficient numbers to assess statistically.
9.1.1. Non invasive cardiac output measurements in subjects with pulmonary 
hypertension
The gold standard measurement of cardiac output is by the Pick method. In clinical 
practice, the thermodilutional method is the main method of obtaining cardiac output, 
but its accuracy with respect to pulmonary hypertension is questionable for several 
reasons, and the blood flow results are not instantaneous (Cigarroa, R. G. et al 1989; 
Kohanna, F. H. et al 1977).
The physioflow 1, (© Manatee, France), in several previous studies seemed to have a 
higher accuracy then other thoracic impedance systems at measuring cardiac output, and 
it avoided the need for measuring plasma viscosity or distance between electrodes, it 
also benefited from an easy calibration system (Charloux, A. et al 2000). This device 
was potentially useful in subjects with pulmonary hypertension, but had not been 
previously validated in subjects with pulmonary hypertension.
Our study, the results of which are in chapter 3, demonstrate that with regards to the use 
of the physioflow 1 (© Manatee, France), in subjects with pulmonary hypertension, in 
general clinical practice, it did not produce results consistent with results produced by 
the thermodilutional method. The correlation with the thermodilutional results was r^  =
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0.463, with a regression equation of C O pf = 1.924 + C O th erm  • 0.844 (L#min'*). 
Assessment by the Bland- Altman method demonstrated that the physioflow 
overestimated cardiac output by 1.21 (± 1.85) L#min * when comparing the values with 
thermodilutional values, giving a mean difference (± S.D.) of 23.35 (± 35.9) %. A 
similar result was obtained during exercise. An overestimation could be expected, as 
previous findings have found excessive thoracic fluid, leads to a drop in estimated 
pressures, and in subjects with COPD and pulmonary hypertension, using other 
impedance devices, an overestimate was noted (Bougault, V. et al 2005). There is 
evidence that thermodilutional results in subjects with tricuspid regurgitation (and thus 
pulmonary hypertension), may be an underestimation (Hoeper, M. M. et al 1999).
With regards to changes of cardiac output within an individual, the physioflow was 
much more promising. In an analyses of 21 subjects, whilst either exercising or 
receiving oxygen or nitric oxide, the percentage change from baseline gave a 
correlation, r^  = 0.81 (p < 0 .0 0 1 ), with a regression equation of,
%ACOppBaselme = 3.16 + %ACOTUERMBaseline # 0.916 (%). 
Assessment by the Bland Altman method found that the change was a small 
overestimation of 2.08 (± 12.5) %, (giving 95% confidence intervals of between -23.0 
and 27.1 %). Of the 21 subjects analysed, 3 did not have pulmonary hypertension, and 9 
were pulmonary arterial hypertensive (WHO group I) subjects. The study, when sub­
analysed, to avoid over-representing individual subjects, found a much poorer 
correlation for the oxygen and the nitric oxide group. In the nitric oxide group the 
percentage change from baseline gave a correlation, r^  = 0.02 (p = 0.63), with a 
regression equation of.
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%ACOpFBaseline == 4,87 + %ACOTHERMBaseline • -0.07(%).
The number of subjects studied was small, and if more subjects were obtained, better 
results may have been obtained.
Our study had several areas of weaknesses. The first was the lack of any data of 
reproducibility of measurements on an individual when measurements are days apart. 
This was due to the limitation regarding ethics, but with this device potentially being an 
important tool in the future, a study looking into this would be useful.
Another weakness was that the method being used to compare the physioflow with was 
the thermodilutional technique, which in itself has been suggested to be inaccurate, 
especially in the context of pulmonary hypertension or severe tricuspid regurgitation. 
Unfortunately, echocardiogiaphic data for severe tricuspid regurgitation was only 
retrospectively available in 13 of the 25 individuals. The Tick technique, at least 
amongst the pulmonary hypertensive subjects, would be a more fair technique to make a 
comparison, to evaluate the physioflow’s usefulness in a clinical situation.
Two other weaknesses in the study were the small number of subjects in individual 
disease subgroups, making an individual disease sub-analysis difficult. In the exercise 
comparison, straight leg raising involves the intra-abdominal muscles more than other 
types of exercise, and is more likely to produce a poor signal for the physioflow than 
other methods of increasing cardiac output.
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9.1.2. Pressure flow plots
With regards to the production of pressure-flow plots, several areas were explored. Our 
aim for the project was to develop an easy and repeatable way of producing such plots 
in individual subjects in clinical practice. In order to do this, a combination of a micro­
manometer tipped pulmonary artery catheter placed in the right pulmonary artery and 
the use of a continuous cardiac output monitor, in the guise of the physioflow 1 thoracic 
impedance device was used in order to measure pulmonary artery pressure and cardiac 
output respectively. The first method used to change the individual subjects cardiac 
output was straight leg raising exercise. The first problem that arose, was the high level 
of equipment failure with either the catheter failing to be placed adequately, 
measurement recordings failing to be stored, or the failure to get adequate signals from 
the physioflow. The failure rate was in 20% of subjects.
The second problem, as found in chapter 3, was the discrepancy in cardiac output 
measurements taken by the physioflow 1 and by thermodilutional methods. Although in 
an individual, the changes in percentage from baseline were accurate, the lack of 
accurate quantitation mean that the slopes and intercepts produced in an individual 
subject would not be able to be compared with other individuals. Another problem is 
that no studies have been perfonned using the physioflow I to demonstrate 
reproducibility within an individual with pulmonary hypertension in terms of either 
cardiac output or pressure flow plots, over time.
With regards to the successful production of linear pressure-flow plots, 8 6  sets of paired 
data were produced in these studies, whilst supine and performing straight leg exercises. 
The results of chapter 4 found that of the 8 6  plots of paired data, all had an acceptable
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scattergram, but only 56 of the 8 6  (65%) had adequate histograms of ftequency versus 
regression standardized residuals and plots of cumulative probability of regression 
standardised plots. With regards for the ANOVA test of non-linearity, only 3 failed that 
test, but the test could not be performed on over half the linear regression plots, giving 
only 39 of 8 6  lines, achieved statistical linearity. When reviewing the confidence 
intervals of the slopes, only 38% of the slopes and 20% of the intercepts had confidence 
intervals which were within 2 0 % of the linear equation slope or intercept, making 
comparisons of small differences in the slopes or intercepts difficult.
When the data was sub-analysed, by pooling subject data into their respective disease 
groupings, there was very little difference in the slope between inhaled gases, except in 
the subjects with chronic thromboembolic hypertension (CTEPH) (and normals). 
Excluding the chronic thromboembolic and normal subjects, the slopes in the disease 
subgroups all seemed to show a parallel shift in the pressure flow plots. In the chronic 
thromboembolic group, there was a significant reduction in the slope from air to nitric 
oxide. In both the IPAH and CTEPH group, oxygen seemed to increase resistance.
An unexpected but interesting finding, which may explain the differences seen in 
chapter 5, was that non- vasodilator responders had a reduction in the slope of the 
pressure flow plot when given nitric oxide and oxygen combined, whereas vasodilator 
responders had a shift in their critical closing pressure (intercept) rather than a fall in 
their resistance. It may be that the effect of a high concentration of nitric oxide led to 
vasodilation of the pulmonary venules, and this may somehow altered the mean closing 
pressure.
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Our attempt to use dobutamine for the production of pressure flow plots (chapter 8) was 
not successful It was found that despite a gradually increasing cardiac output in all 5 
subjects throughout the study, the mean pulmonary arteiy pressme either increased 
within the first few minutes of the study and then reached a plateau, or in the case of 
one subject actually decreased. Its possible that the exercise perfoimed at least 20 
minutes earlier (chapter 4), resulted in an alteration of the basal tone of the pulmonary 
vasculature (Ekelund, L. G. 1967; Reeves, J. T. et al 1988). This may also be due to the 
effect of dobutamine on either the alpha or beta receptors in blood vessels in the 
pulmonary vasculature. In the systemic circulation, these effects on the blood vessels 
nonnally cancel each other out, (Leier, C. V. et al 1983) but this may not necessarily be 
the case in the pulmonary circulation. It had also been previously noted that the effects 
of dobutamine on the pulmonary vasculature in dogs, at concentrations higher than used 
in our study, depended on the imderlying resting tone (Pagnamenta, A. et al 2003).
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9.2. Future Work
There are several areas, in which the results of this thesis indicate future studies may be 
useful. With regards to the physioflow device, it would be useful to study whether a 
given cardiac output at rest, and changes of cardiac output from baseline, by exercise or 
dobutamine, are reproducible when measured within individuals, when the 
measurements are separated by a gap of several days. The pressure flow gradients 
produced, should also be repeated after several days to assess whether the results in an 
individual subject remains constant, which would mean the device would be able to be 
used to track changes in individuals.
When the studies were initiated, the nitric oxide group was given additional oxygen, 
irrespective of whether they were hypoxic at rest. This was in order to maximise the 
vasodilatory effects. However, as was noted in chapter 5, oxygen inlialation in the 
idiopathic pulmonary hypertensive subjects, seem to increase the slope and thus 
vascular resistance in some patients. During these studies, a direct comparison made 
between nitric oxide alone and nitric oxide/oxygen combination was not performed. It 
was noted that in chapter 5, in the IP AH subgroup, the slope of the pressure-flow plot 
actually increased with oxygen, and in the CTD group increased to 6.4 with the NO/O2 
combination, and 6.5 with oxygen alone. It may be the effects of oxygen on the 
pulmonary vasculatui'e may differ depending on whether a subject is exercising. This 
would be a future avenue to pursue. Furthermore, Shirai et al (1996) found that nitric 
oxide at concentrations of 20ppm were sufficient to dilate pulmonary arterioles. At 
concentrations above 40ppm, the pulmonary venules start to be affected. A study 
comparing various dosages of nitric oxide and its effect on pressure-flow plots in 
individuals would be useful. This would be particularly interesting to see if by altering
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the nitric oxide concentration, the effect on critical closing pressure alters, as the 
pulmonary venules vasodilate and outflow pressure alters. Using the pressure decay 
curve following pulmonary artery occlusion (Kafi, S. A. et al 1998), might help to 
partition the pulmonary vascular resistance. Finally, once the reproducibility of cardiac 
output measurements over time in an individual with pulmonary hypertension when 
measured by the physioflow 1 device is established long term studies, looking for 
changes in the response to vasodilators in subjects treated with disease modifying drugs, 
may be of interest.
Additionally a pilot study, using other methods of exercise, for instance a supine bicycle 
ergometer, is needed, to see whether the plots produced are more linear. A study 
comparing the effects of breathing air with or without the use nitric oxide delivery 
system would also be useful.
The use of dobutamine in these subjects, in order to produce pressure-flow plots, needs 
to be further investigated and ideally on separate days to any exercise studies. Further 
studies, using varying dosing regimes, also need to be performed, (either steady state or 
incremental up to 40 pg kg“^ min"*), to discover the optimum regime.
An unpublished review of high fidelity pulmonary artery pressure data, obtained over 
the past several years at the Scottish Pulmonary Vascular Unit, suggest that there is a 
linear relationship between systolic, diastolic, mean and pulse pressure, in the sense that 
knowing one pressure will allow the calculations of other pressures, through several 
derived equations. However, with regards to pulse pressure, the equation obtained, 
PAPP = 1.1 + 0.79 SAPP (mmHg), had the greatest variance, giving a standard
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deviation of 6.61 mmHg. A further study of unpublished data, found that pulmonary 
artery pulse pressure was related to survival, in all cause pulmonaiy hypertension. The 2 
year survival probability was 95 % for a pulse pressure of <55mmHg, but only 60% for 
a pulse pressure >70mmHg. Pulse pressure differences may be a reflection of 
differences in compliance or distensibility of the pulmonary vasculature. This is because 
pulse pressure is basically affected by four components. Compliance of the vessels that 
the blood is flowing through, the point of wave reflection (branch points), the volume of 
blood passed into the vasculature (stroke volume), and the frequency of flow pulsation 
(heart rate). It would be hoped, but not necessarily true, that when comparing the effects 
of pharmacological agents on a subject, the wave reflection sites would remain static. 
Thus further analysis of the pulmonary artery pressure data collected via the high 
fidelity pulmonary artery catheters and corresponding stroke volume and heart rate data 
from the physioflow 1 thoracic impedance device would be useful to investigate 
changes in compliance in individual disease groups. This would be especially be true 
when looking at changes in posture and in respect of vasodilator responses to oxygen or 
nitric oxide. (Data chapters 5-6).
All the evidence suggests that the pulsatile nature of the pulmonary circulation is 
important in determining the amoimt of stress placed on the right ventricle, as the 
hypertrophy of the right ventricle is a major contributor to death. The ideal situation 
would be to look at pulmonaiy vascular impedance, but in humans, under normal 
clinical conditions, this would be impractical. Studying the pulmonary artery pulse 
pressure alone and in conjunction with stroke volume or heart rate would go some way 
in looking at this pulsatile component to blood flow.
302
9.3 Conclusions
As a consequence of these studies, we have come to several conclusions, but the study 
has resulted in many more questions needing to be answered. It has been known for 
some years, that our current haemodynamic measurements of the pulmonary circulation 
are inadequate. This thesis attempted to look into several aspects of pulmonary 
circulation in order to improve our basic clinical investigations of all subjects.
The thesis relates to the validation of the non-invasive cardiac output device, the 
physioflow 1, and its use in the production of pressure flow plots in subjects with 
pulmonaiy hypertension. With regards to this, we found, at least when compared with 
thermodilution cardiac output, the physioflow overestimated cardiac output by IL, and 
had a wide confidence intervals. It did, however, follow trends in cardiac output much 
more readily. Thus, it may be useful experimentally with the pooling of data, but it 
cannot currently be a clinical substitute for invasive measurement. If further 
reproducibility studies are performed and found to be accurate within an individual, it 
may then become a method of following changes in cardiac output in an individual over 
a period of time.
The pressure-flow response to nitric oxide, varies from ‘vasodilator’ responders and 
non-responders, in an unexpected manner, and may also vary between disease 
aetiologies. Further investigations to understand this difference, may open up novel 
therapeutic options.
Studies in both nonnal and pulmonaiy hypertensive humans with regards to the 
pulmonary circulations response to dobutamine are also necessary. Understanding this 
may help in allowing dobutamine to be used as a surrogate for exercise.
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